<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Neuropharmacol</journal-id><journal-id journal-id-type="publisher-id">CN</journal-id><journal-title>Current Neuropharmacology</journal-title><issn pub-type="ppub">1570-159X</issn><issn pub-type="epub">1875-6190</issn><publisher><publisher-name>Bentham Science Publishers Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19305793</article-id><article-id pub-id-type="pmc">2647150</article-id><article-id pub-id-type="publisher-id">CN-6-125</article-id><article-id pub-id-type="doi">10.2174/157015908784533842</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Effects of Maternally Administered Methadone, Buprenorphine and Naltrexone on Offspring: Review of Human and Animal Data</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Farid</surname><given-names>W.O</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Dunlop</surname><given-names>S.A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Tait</surname><given-names>R.J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hulse</surname><given-names>G.K</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>School of Animal Biology, The University of Western Australia, Nedlands, WA 6009, Australia</aff><aff id="aff2"><label>2</label>Western Australian Institute for Medical Research, The University of Western Australia, Nedlands, WA 6009, Australia</aff><aff id="aff3"><label>3</label>School of Psychiatry and Clinical Neurosciences, The University of Western Australia, Nedlands, WA 6009, Australia</aff><author-notes><corresp id="cor1"><label>*</label>Address correspondence to this author at School of Animal Biology, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, USA; Tel: +618 6488 1403; Fax: +618 6488 7527; E-mail: <email xlink:href="sarah@cyllene.uwa.edu.au">sarah@cyllene.uwa.edu.au</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2008</year></pub-date><volume>6</volume><issue>2</issue><fpage>125</fpage><lpage>150</lpage><history><date date-type="received"><day>16</day><month>3</month><year>2007</year></date><date date-type="rev-recd"><day>20</day><month>11</month><year>2007</year></date><date date-type="accepted"><day>11</day><month>12</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; 2008 Bentham Science Publishers Ltd</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<uri xlink:type="simple" xlink:href="http://creativecommons.org/licenses/by/2.5/">http://creativecommons.org/licenses/by/2.5/</uri>) which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Most women using heroin are of reproductive age with major risks for their infants. We review clinical and experimental data on fetal, neonatal and postnatal complications associated with methadone, the current &#x0201c;gold standard&#x0201d;, and compare these with more recent, but limited, data on developmental effects of buprenorphine, and naltrexone. Methadone is a &#x000b5;-opioid receptor agonist and is commonly recommended for treatment of opioid dependence during pregnancy. However, it has undesired outcomes including neonatal abstinence syndrome (NAS). Animal studies also indicate detrimental effects on growth, behaviour, neuroanatomy and biochemistry, and increased perinatal mortality. Buprenorphine is a partial &#x000b5;-opioid receptor agonist and a &#x003ba;-opioid receptor antagonist. Clinical observations suggest that buprenorphine during pregnancy is similar to methadone on developmental measures but is potentially superior in reducing the incidence and prognosis of NAS. However, small animal studies demonstrate that low doses of buprenorphine during pregnancy and lactation lead to changes in offspring behaviour, neuroanatomy and biochemistry. Naltrexone is a non-selective opioid receptor antagonist. Although data are limited, humans treated with oral or sustained-release implantable naltrexone suggest outcomes potentially superior to those with methadone or buprenorphine. However, animal studies using oral or injectable naltrexone have shown developmental changes following exposure during pregnancy and lactation, raising concerns about its use in humans. Animal studies using chronic exposure, equivalent to clinical depot formulations, are required to evaluate safety. While each treatment is likely to have maternal advantages and disadvantages, studies are urgently required to determine which is optimal for offspring in the short and long term.</p></abstract><kwd-group><title>Key Words</title><kwd>Methadone</kwd><kwd>buprenorphine</kwd><kwd>naltrexone</kwd><kwd>pregnancy</kwd><kwd>fetal</kwd><kwd>neonatal</kwd><kwd>offspring</kwd><kwd>development.</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><label>1</label><title>INTRODUCTION</title><p>The global average prevalence of heroin abuse in 2002-4 was 0.3%. However, there is considerable regional variation with, for example, an estimated prevalence of 0.1% in the United States, 0.2% in Africa, 0.7% in Russia, 0.8% in Europe, and as high as 4.4% in Iran [<xref ref-type="bibr" rid="R367">367</xref>]. Females make up a large proportion of heroin users. For example, based on estimates from the 2001 National Drug Strategy Household Survey in Australia, there are over 36,000 females (0.18% of the population) who use opiates either daily or weekly [<xref ref-type="bibr" rid="R277">277</xref>]. Approximately 80-90% of all women using intravenous heroin are of reproductive age [<xref ref-type="bibr" rid="R276">276</xref>,<xref ref-type="bibr" rid="R291"> 291</xref>] and, although heroin can cause menstrual irregularities such as amenorrhea, oligomenorrhea and suppression of ovulation [<xref ref-type="bibr" rid="R108">108</xref>], pregnancy is not uncommon [<xref ref-type="bibr" rid="R313">313</xref>]. Indeed, a recent study showed that ~1/3<sup>rd</sup> of patients presenting at a high risk clinic were positive for opioid use at some stage during their pregnancy [<xref ref-type="bibr" rid="R295">295</xref>]. In many countries, including the United States and Australia, oral methadone is the currently preferred maintenance pharmacotherapy for the pregnant heroin user [<xref ref-type="bibr" rid="R136">136</xref>,<xref ref-type="bibr" rid="R190"> 190</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>]. However, recently, there have been a number of documented cases in which opioid-dependent women have undergone maintenance with oral naltrexone or sublingual buprenorphine for a portion, and in some cases the entire duration, of their pregnancy [<xref ref-type="bibr" rid="R158">158</xref>, <xref ref-type="bibr" rid="R228"> 228</xref>, <xref ref-type="bibr" rid="R248"> 248</xref>]. Moreover, with the advent of long-lasting, sustained-release naltrexone depot preparations and their potential use in treating heroin and alcohol dependence in women, an increasing number of fetuses are likely to be inadvertently exposed to naltrexone [<xref ref-type="bibr" rid="R149">149</xref>].</p><p>Although research on the developmental effects of methadone, naltrexone or buprenorphine already exists, it is inconclusive as to which treatment compromises fetal and postnatal development the least. The primary aim of this review is to provide a comprehensive overview of the developmental outcomes from exposure to methadone, buprenorphine or naltrexone during pregnancy and lactation in humans. Factors in addition to direct pharmacological actions of these drugs are also identified. To provide further insight into the independent effects of these pharmacotherapies, we review studies using pregnant animal models with discussion on mechanisms involved with opioid modulation of development.</p><sec><label>1.1</label><title> Role of the Opioid System in Development </title><p>Increasing evidence highlights the importance of the opioid system in mediating developmental events. Opioid receptor expression is regulated by signals from growth factors, proto-oncogenes and neurotransmitters [<xref ref-type="bibr" rid="R316">316</xref>]. Endogenous opioids and receptors are also present in the developing mammalian fetus. For example, endorphins are found in fetal plasma, and the classical opioid receptors, namely mu (&#x003bc;), delta (&#x003b4;) and kappa (&#x003ba;), have been identified in the brain and other organs [<xref ref-type="bibr" rid="R134">134</xref>,<xref ref-type="bibr" rid="R239"> 239</xref>,<xref ref-type="bibr" rid="R360"> 360</xref>,<xref ref-type="bibr" rid="R422"> 422</xref>,<xref ref-type="bibr" rid="R423"> 423</xref>,<xref ref-type="bibr" rid="R429"> 429</xref>]. Furthermore, opioid receptor expression [<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R229"> 229</xref>] and endogenous opioid concentration [<xref ref-type="bibr" rid="R11">11</xref>] in the fetus and neonate differ from that in adults. For example, the zeta (&#x003b6;) receptor (opioid growth factor receptor or OGFr), which belongs to the nuclear receptor superfamily, is ubiquitous in the developing rat brain, but unlike the classical receptors, it is not found in adults [<xref ref-type="bibr" rid="R174">174</xref>,<xref ref-type="bibr" rid="R405"> 405</xref>,<xref ref-type="bibr" rid="R434"> 434</xref>]. In addition, exogenously administered opiates such as methadone, have been localised in the brain of young rats, binding to &#x003bc;-opioid receptors [<xref ref-type="bibr" rid="R299">299</xref>]. Moreover, higher methadone binding occurs in the fetal brain (2-14 times greater) compared to maternal neurons [<xref ref-type="bibr" rid="R299">299</xref>].</p><p>In a variety of species including mouse, rat, guinea pig and human, opioid levels and opioid receptor concentration fluctuate during development [<xref ref-type="bibr" rid="R11">11</xref>,<xref ref-type="bibr" rid="R316"> 316</xref>]: universal opioid receptor binding is high during early embryogenesis, decreases towards birth, then gradually increases to adult levels [<xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R22"> 22</xref>,<xref ref-type="bibr" rid="R316"> 316</xref>]. Specifically, &#x003bc;- and &#x003ba;-receptors appear in the embryonic brain, whereas (-receptors appear later [<xref ref-type="bibr" rid="R432">432</xref>] with a similar time course being seen in humans and rats [<xref ref-type="bibr" rid="R244">244</xref>]. Furthermore, the receptor increases are associated with increases in endogenous opioid levels [<xref ref-type="bibr" rid="R11">11</xref>].</p><p>Endogenous opioids serve as natural inhibitory trophic factors [<xref ref-type="bibr" rid="R405">405</xref>], inhibiting mitosis and DNA synthesis in the developing brain [<xref ref-type="bibr" rid="R293">293</xref>,<xref ref-type="bibr" rid="R429"> 429</xref>]. Whilst the role of &#x003ba;-receptors is not clearly understood, selective &#x003bc;-receptor activation has been demonstrated to inhibit proliferation, whereas selective &#x003b4;-receptor agonists inhibit neuronal differentiation [<xref ref-type="bibr" rid="R132">132</xref>]. Cell viability and death are also controlled by opioid-mediated signalling [<xref ref-type="bibr" rid="R359">359</xref>], of which opioids have a tendency to suppress viability and increase cell death, perhaps the underlying cause for smaller opioid-exposed newborns [<xref ref-type="bibr" rid="R152">152</xref>,<xref ref-type="bibr" rid="R341"> 341</xref>].</p><p>The &#x003b6;-receptor has been shown to play a prominent role in the mediation of fetal cell proliferation [<xref ref-type="bibr" rid="R442">442</xref>], the biology of which has received thorough review [<xref ref-type="bibr" rid="R440">440</xref>]. Receptor function is regulated by its endogenous ligand, [Met<sup>5</sup>]-enkephalin (opioid growth factor or OGF), which has an inhibitory effect on transcription [<xref ref-type="bibr" rid="R433">433</xref>]. In human and rat, it is expressed during development in the cerebrum and cerebellum, and in somatic regions, for example heart, muscle and bone [<xref ref-type="bibr" rid="R440">440</xref>]. Developmental delays observed after fetal exposure to agonists, such as heroin or methadone, are postulated to result from their direct interaction with OGFr, retarding &#x0201c;normal&#x0201d; fetal development. On the other hand, fetal exposure to an opioid antagonist, (e.g. naltrexone) may prevent [Met<sup>5</sup>]-enkephalin from binding to the opioid growth factor receptor, thereby blocking the growth-inhibitory effects of the OGF-OGFr complex [<xref ref-type="bibr" rid="R405">405</xref>,<xref ref-type="bibr" rid="R435"> 435</xref>,<xref ref-type="bibr" rid="R440"> 440</xref>,<xref ref-type="bibr" rid="R441"> 441</xref>]; in other words, the brake is removed and growth is accelerated. Other studies have confirmed that OGFr localisation is associated with proliferating cells in the brain [<xref ref-type="bibr" rid="R174">174</xref>,<xref ref-type="bibr" rid="R404"> 404</xref>,<xref ref-type="bibr" rid="R442"> 442</xref>]. Furthermore, this receptor also up-regulates in response to decreased agonist release and receptor binding during cell proliferation and growth [<xref ref-type="bibr" rid="R431">431</xref>].</p></sec></sec><sec><label>2</label><title>TREATMENT FOR THE PREGNANT HEROIN USER</title><p>Heroin (diacetylmorphine) is an analogue of morphine which efficiently crosses the blood-brain barrier (BBB) [<xref ref-type="bibr" rid="R27">27</xref>] and its active metabolic products elicit morphine-like effects <italic>via</italic> agonist activity at the &#x003bc;-opioid receptor [<xref ref-type="bibr" rid="R309">309</xref>]. The abuse liability of intravenous heroin is attributable to its potency, rapid crossing of the BBB and induction of effects. The elimination half-life of heroin and its active metabolites is short (15-30 mins) [<xref ref-type="bibr" rid="R27">27</xref>]; tolerant users are therefore likely to use heroin several times each day to prevent aversive withdrawal symptoms [<xref ref-type="bibr" rid="R168">168</xref>,<xref ref-type="bibr" rid="R213"> 213</xref>]. Whilst pregnancy can be a powerful motivator for ceasing drug abuse, many pregnant women revert back to dependent heroin use, albeit commonly at a reduced level, and relapse post birth is common [<xref ref-type="bibr" rid="R104">104</xref>,<xref ref-type="bibr" rid="R127"> 127</xref>,<xref ref-type="bibr" rid="R203"> 203</xref>,<xref ref-type="bibr" rid="R272"> 272</xref>,<xref ref-type="bibr" rid="R295"> 295</xref>]. Heroin readily crosses the placenta [<xref ref-type="bibr" rid="R232">232</xref>] and, consequently, maternal heroin use during pregnancy is associated with an increased risk for a number of adverse neonatal outcomes, including low birthweight, antepartum haemorrhage and increased neonatal mortality [<xref ref-type="bibr" rid="R194">194</xref>,<xref ref-type="bibr" rid="R222"> 222</xref>,<xref ref-type="bibr" rid="R237"> 237</xref>,<xref ref-type="bibr" rid="R373"> 373</xref>,<xref ref-type="bibr" rid="R391"> 391</xref>], many of which have been confirmed in animal studies [<xref ref-type="bibr" rid="R109">109</xref>,<xref ref-type="bibr" rid="R223"> 223</xref>,<xref ref-type="bibr" rid="R401"> 401</xref>,<xref ref-type="bibr" rid="R419"> 419</xref>,<xref ref-type="bibr" rid="R444"> 444</xref>]. Meta-analyses on neonatal outcomes and maternal heroin use have produced crude odds ratios for antepartum haemorrhage (2.33; 95% CI 1.32-4.30) [<xref ref-type="bibr" rid="R153">153</xref>], low birthweight (4.61; 95% CI 2.78-7.65) [<xref ref-type="bibr" rid="R152">152</xref>] and neonatal mortality (3.27; 95% CI 0.95-9.60) [<xref ref-type="bibr" rid="R154">154</xref>]. In addition, compared to non-users, women who continue to use heroin during pregnancy have a significantly increased risk of exposure to infection and negative lifestyle factors associated with acquiring and injecting heroin, as well as a significantly poorer attendance at antenatal or other health care services [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R222"> 222</xref>,<xref ref-type="bibr" rid="R237"> 237</xref>]. </p><sec><label>2.1</label><title>Methadone</title><sec><label>2.1.1</label><title>Pharmacology and Role of Methadone in Treatment of Dependence</title><p>Methadone (6-dimethylamino-4,4-diphenyl-3-heptone) is a synthetically derived agonist which selectively binds to the &#x003bc;-opioid receptor, thereby exerting morphine-like effects. Currently, methadone maintenance treatment (MMT) is the most commonly used pharmacotherapy for opioid-dependence [<xref ref-type="bibr" rid="R325">325</xref>]. Methadone has a high bioavailability of 40-99% [<xref ref-type="bibr" rid="R101">101</xref>,<xref ref-type="bibr" rid="R214"> 214</xref>,<xref ref-type="bibr" rid="R260"> 260</xref>,<xref ref-type="bibr" rid="R284"> 284</xref>,<xref ref-type="bibr" rid="R285"> 285</xref>,<xref ref-type="bibr" rid="R325"> 325</xref>,<xref ref-type="bibr" rid="R330"> 330</xref>], and a relatively long elimination half-life of approximately 24 hours [<xref ref-type="bibr" rid="R164">164</xref>,<xref ref-type="bibr" rid="R168"> 168</xref>,<xref ref-type="bibr" rid="R171"> 171</xref>,<xref ref-type="bibr" rid="R397"> 397</xref>]. It therefore prevents opioid-withdrawal syndrome in opioid-dependent patients when they are maintained on a single daily oral dose of 60-100 mg [<xref ref-type="bibr" rid="R56">56</xref>,<xref ref-type="bibr" rid="R79"> 79</xref>,<xref ref-type="bibr" rid="R84"> 84</xref>,<xref ref-type="bibr" rid="R86"> 86</xref>,<xref ref-type="bibr" rid="R168"> 168</xref>,<xref ref-type="bibr" rid="R384"> 384</xref>] MMT falls within the realm of harm minimisation, and its use results in reductions in illicit drug use, crime, morbidity and mortality [<xref ref-type="bibr" rid="R213">213</xref>,<xref ref-type="bibr" rid="R370"> 370</xref>,<xref ref-type="bibr" rid="R385"> 385</xref>,<xref ref-type="bibr" rid="R386"> 386</xref>,<xref ref-type="bibr" rid="R388"> 388</xref>]. However, as methadone is an agonist, use of other opiates can still elicit morphine-like effects, with fatal overdose as a potential outcome [<xref ref-type="bibr" rid="R24">24</xref>,<xref ref-type="bibr" rid="R247"> 247</xref>,<xref ref-type="bibr" rid="R368"> 368</xref>]. For example, although sufficient methadone reduces or eliminates drug craving [<xref ref-type="bibr" rid="R213">213</xref>,<xref ref-type="bibr" rid="R384"> 384</xref>,<xref ref-type="bibr" rid="R393"> 393</xref>], in patients who fail to remain abstinent, methadone may attenuate the effects of, for example, heroin through cross-tolerance and increased competition for binding at &#x003bc;-opioid receptor sites [<xref ref-type="bibr" rid="R76">76</xref>,<xref ref-type="bibr" rid="R107"> 107</xref>,<xref ref-type="bibr" rid="R311"> 311</xref>,<xref ref-type="bibr" rid="R384"> 384</xref>]. Another limitation with this pharmacotherapy is that the duration of withdrawal is protracted compared to withdrawal from heroin; consequently, detoxification from methadone has lower success rates compared to detoxification from other opioids [<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R69"> 69</xref>,<xref ref-type="bibr" rid="R75"> 75</xref>,<xref ref-type="bibr" rid="R117"> 117</xref>,<xref ref-type="bibr" rid="R118"> 118</xref>,<xref ref-type="bibr" rid="R311"> 311</xref>].</p></sec><sec><label>2.1.2</label><title>Role of Methadone in Treatment of Dependence During Pregnancy</title><p>In many countries, including Britain, the United States and Australia, MMT is the currently accepted management for the pregnant heroin user. Patient compliance to MMT during pregnancy is generally high compared to non-pharmacotherapeutic interventions. Furthermore, higher methadone doses are associated with improved compliance, particularly during the last trimester of pregnancy [<xref ref-type="bibr" rid="R67">67</xref>,<xref ref-type="bibr" rid="R95"> 95</xref>,<xref ref-type="bibr" rid="R187"> 187</xref>,<xref ref-type="bibr" rid="R220"> 220</xref>,<xref ref-type="bibr" rid="R356"> 356</xref>]. As MMT involves daily dispensing only by licensed personnel, continual contact with the patient is accomplished and is associated with improved antenatal care [<xref ref-type="bibr" rid="R221">221</xref>]. In addition, toxicological screening for illicit drugs in pregnant patients undergoing MMT indicate that increasing methadone doses are associated with decreased drug abuse [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R251"> 251</xref>]. Thus, MMT upholds the policy of harm minimisation by reducing heroin use and other associated negative life-style factors, both of which improve neonatal outcomes. However, caution is required in selecting the maintenance dose for managing opioid-dependent pregnant women as methadone crosses the human placenta [<xref ref-type="bibr" rid="R329">329</xref>] and is currently registered by the Food and Drug Administration (FDA) in the United States as a Category C drug, a classification which is similar to that adopted by the Therapeutic Goods Administration (TGA) in Australia (also Category C) (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). </p></sec><sec><label>2.1.3</label><title>Pharmacokinetics of Methadone During Pregnancy</title><p>In addition to the benefits derived from MMT, methadone exposure also directly affects the fetus and newborn, the impact of which is dictated by pharmacokinetics during pregnancy and the extent of transfer to offspring. Metabolic inactivation of methadone to its primary metabolite, 2-ethyl-idene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) involves N-demethylation, mainly by hepatic cytochrome P<sub>450</sub>3A4 (CYP3A4) [<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R269"> 269</xref>,<xref ref-type="bibr" rid="R325"> 325</xref>]. To a lesser extent, the microsomal enzymes, CYP-2D6, -1A2, -2B6, -2C9, and -2C19 [<xref ref-type="bibr" rid="R86">86</xref>,<xref ref-type="bibr" rid="R100"> 100</xref>,<xref ref-type="bibr" rid="R111"> 111</xref>], also contribute to methadone inactivation. Furthermore, human intestinal microsomes have an additional metabolic role, transforming methadone sequentially to EDDP and 2-ethyl-5-methy-3,3-diphenyl-pyrroline (EMDP) [<xref ref-type="bibr" rid="R289">289</xref>]. As pregnancy progresses, methadone metabolism becomes enhanced, manifesting as increased clearance [<xref ref-type="bibr" rid="R178">178</xref>,<xref ref-type="bibr" rid="R396"> 396</xref>], with a reduced elimination half-life of 8-20 hours compared to the 24 hour half-life in a non-pregnant patient [<xref ref-type="bibr" rid="R105">105</xref>,<xref ref-type="bibr" rid="R306"> 306</xref>,<xref ref-type="bibr" rid="R357"> 357</xref>]. Thus, as pregnancy progresses, lower methadone plasma concentrations result despite an unchanged dose [<xref ref-type="bibr" rid="R178">178</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>,<xref ref-type="bibr" rid="R306"> 306</xref>,<xref ref-type="bibr" rid="R357"> 357</xref>,<xref ref-type="bibr" rid="R396"> 396</xref>]. The reduction in methadone blood levels as pregnancy progresses may also be attributable to the slight increase in the volume of distribution, lowered plasma protein binding and decreased oral absorption [<xref ref-type="bibr" rid="R105">105</xref>,<xref ref-type="bibr" rid="R178"> 178</xref>,<xref ref-type="bibr" rid="R306"> 306</xref>]. </p><p>Methadone blood levels late in pregnancy also require consideration. Dosing is highly variable, being 15-100 mg per day [<xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R61"> 61</xref>,<xref ref-type="bibr" rid="R74"> 74</xref>,<xref ref-type="bibr" rid="R85"> 85</xref>,<xref ref-type="bibr" rid="R112"> 112</xref>,<xref ref-type="bibr" rid="R115"> 115</xref>,<xref ref-type="bibr" rid="R192"> 192</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>,<xref ref-type="bibr" rid="R246"> 246</xref>,<xref ref-type="bibr" rid="R249"> 249</xref>,<xref ref-type="bibr" rid="R251"> 251</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>,<xref ref-type="bibr" rid="R339"> 339</xref>,<xref ref-type="bibr" rid="R398"> 398</xref>]. Methadone at 240 ng/ml or greater in the maternal circulation was recently identified as the required level for preventing maternal withdrawal during the third trimester, and is achieved by an oral dose of 50-150 mg [<xref ref-type="bibr" rid="R78">78</xref>]. Lower levels are associated with increased reporting of withdrawal symptoms which, if not addressed by the clinician, can lead to patient relapse to illicit opiate use, which in turn is detrimental to the well-being of the individual and their developing offspring [<xref ref-type="bibr" rid="R78">78</xref>,<xref ref-type="bibr" rid="R178"> 178</xref>,<xref ref-type="bibr" rid="R306"> 306</xref>]. </p><p>Drug transfer from the maternal to the fetal circulation is accomplished <italic>via</italic> the placenta which also acts as a barrier. Placental permeability is determined by the number of tissue layers between the fetal and maternal blood, the relative relationship of fetal to maternal blood flow, and the recruitment of specialised transport processes, such as facilitated and active diffusion. Methadone is also retained by the placenta and does not have adverse effects on its viability and function [<xref ref-type="bibr" rid="R281">281</xref>]. Furthermore, the placenta can metabolically alter many drugs during transfer. Methadone crosses the human placenta [<xref ref-type="bibr" rid="R329">329</xref>] and is dependent upon three processes: metabolism, simple diffusion, and carrier-mediated uptake/efflux [<xref ref-type="bibr" rid="R274">274</xref>]. </p><p>Metabolic inactivation of methadone to EDDP is mediated by the placental enzyme, aromatase (CYP19) [<xref ref-type="bibr" rid="R138">138</xref>], but EMDP has not been detected in trophoblast tissue, indicating that sequential demethylation does not occur [<xref ref-type="bibr" rid="R275">275</xref>]. Placental metabolism allows tonic regulation of methadone transfer to the fetus, although inactivation by the placenta is significantly less than that of the maternal liver or intestine [<xref ref-type="bibr" rid="R28">28</xref>,<xref ref-type="bibr" rid="R100"> 100</xref>,<xref ref-type="bibr" rid="R275"> 275</xref>,<xref ref-type="bibr" rid="R289"> 289</xref>]. During gestation, the placenta also undergoes continual structural and functional changes, which may lead to modulated activity and expression of metabolic enzymes. Whilst affinity of placental aromatase for methadone is unchanged between 17- and 34-weeks gestation (2<sup>nd</sup> to mid-3<sup>rd</sup> trimester), aromatase concentrations increase 4-fold and catalytic activity doubles at term (37 weeks) [<xref ref-type="bibr" rid="R138">138</xref>,<xref ref-type="bibr" rid="R275"> 275</xref>], in part accounting for lower methadone blood levels as pregnancy progresses. Another factor contributing to the difficulty in selecting appropriate doses is the 4- to 6-fold individual variation in the rate of methadone metabolism by the placenta at term [<xref ref-type="bibr" rid="R275">275</xref>].</p><p>Methadone transfer is also bi-directional due to dual perfusion of the placental lobule. The transfer and clearance index for methadone is greater in the returning fetal to maternal circuit compared to the maternal to fetal direction due to unidirectional activity of the efflux transporter, P-glyco-protein, localised in the brush-border of trophoblast cells [<xref ref-type="bibr" rid="R274">274</xref>,<xref ref-type="bibr" rid="R281"> 281</xref>].</p><p>There have been a limited number of studies which have compared methadone levels in the fetus and neonate and its association with the period of pregnancy, maternal levels, and maternal dose [<xref ref-type="bibr" rid="R105">105</xref>]. The studies support extensive materno-fetal transfer of methadone with considerable levels in cord blood [<xref ref-type="bibr" rid="R281">281</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>], although these are approximately 5-fold less than the maternal plasma concentration [<xref ref-type="bibr" rid="R128">128</xref>]. Once in the fetus, methadone undergoes hepatic metabolism, the capacity of which depends on fetal maturation, with CYP-3A4 and -2D6 being present by week 20 [<xref ref-type="bibr" rid="R125">125</xref>,<xref ref-type="bibr" rid="R219"> 219</xref>]. However, fetal metabolic capacity is considerably less than in the mother, due to the absence of other cytochrome enzymes, including CYP-2C9, -1A2 and -2B6 [<xref ref-type="bibr" rid="R125">125</xref>,<xref ref-type="bibr" rid="R310"> 310</xref>]. As pregnancy progresses, fetal metabolic capacity increases but at birth decreases dramatically [<xref ref-type="bibr" rid="R250">250</xref>,<xref ref-type="bibr" rid="R314"> 314</xref>,<xref ref-type="bibr" rid="R396"> 396</xref>]. In addition, methadone has been identified in amniotic fluid, suggesting oral and cloacal uptake, although such exposure is presumably minimal compared to that received across the placenta [<xref ref-type="bibr" rid="R128">128</xref>,<xref ref-type="bibr" rid="R211"> 211</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>,<xref ref-type="bibr" rid="R326"> 326</xref>]. </p><p>Methadone is also transferred into breast milk, thereby exposing infants postnatally. The pharmacokinetic parameters involved with methadone transfer into breast milk have been reviewed elsewhere [<xref ref-type="bibr" rid="R176">176</xref>,<xref ref-type="bibr" rid="R252"> 252</xref>]. Milk-to-plasma ratios vary considerably between studies, ranging from 0.05 to 1.89 [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>]. With an average breast milk intake of 475 ml/day and a large maternal dose range (10-180 mg/day), the estimated neonatal/infant intake of methadone <italic>via</italic> the breast milk ranges widely (0.01-0.1 mg/day). [<xref ref-type="bibr" rid="R25">25</xref>,<xref ref-type="bibr" rid="R110"> 110</xref>,<xref ref-type="bibr" rid="R212"> 212</xref>,<xref ref-type="bibr" rid="R252"> 252</xref>]. The elimination half-life in neonates is longer (32.5 h) than in adults (24 h) [<xref ref-type="bibr" rid="R212">212</xref>], contributing to higher levels on a mg per kg basis [<xref ref-type="bibr" rid="R105">105</xref>,<xref ref-type="bibr" rid="R281"> 281</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>]. Nevertheless, the relative infant dose has been estimated as 2.8% of the maternal one [<xref ref-type="bibr" rid="R16">16</xref>]. Despite the relatively low level of infant exposure to methadone, caution is required for lactating women undergoing MMT as animal studies have demonstrated altered postnatal development [<xref ref-type="bibr" rid="R256">256</xref>,<xref ref-type="bibr" rid="R257"> 257</xref>,<xref ref-type="bibr" rid="R409"> 409</xref>-<xref ref-type="bibr" rid="R411">411</xref>,<xref ref-type="bibr" rid="R418"> 418</xref>,<xref ref-type="bibr" rid="R420"> 420</xref>]. </p></sec><sec><label>2.1.4</label><title>Methadone and Developmental Effects</title><sec><label>2.1.4.1</label><title>Methadone and Fetal Outcomes</title><p>Methadone has undoubtedly improved the management of pregnancy and neonatal outcome in heroin addicts [<xref ref-type="bibr" rid="R196">196</xref>]. For example, high methadone doses in the third trimester are related to improved fetal growth compared to pregnancies of non-treated heroin addicts [<xref ref-type="bibr" rid="R124">124</xref>]. Importantly, no serious fetal toxicity has been associated with methadone [<xref ref-type="bibr" rid="R81">81</xref>,<xref ref-type="bibr" rid="R222"> 222</xref>]. However, human studies have identified adverse effects associated with methadone use during pregnancy, although many of these findings are inconsistent and have not established a causal link to methadone use. Poor outcomes include a higher incidence of prematurity [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R85"> 85</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>], intrauterine growth retardation [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R74"> 74</xref>,<xref ref-type="bibr" rid="R195"> 195</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>] and increased fetal mortality [<xref ref-type="bibr" rid="R198">198</xref>,<xref ref-type="bibr" rid="R242"> 242</xref>]. Clinical observations <italic>in utero</italic> have also shown that fetal activity, respiration and heart rate are depressed in mothers taking daily oral methadone compared to those not dependent on opioids [<xref ref-type="bibr" rid="R175">175</xref>,<xref ref-type="bibr" rid="R307"> 307</xref>,<xref ref-type="bibr" rid="R398"> 398</xref>].</p></sec><sec><label>2.1.4.2</label><title>Methadone and Neonatal Outcomes</title><p>Methadone maintenance treatmentin the stabilised patient, when combined with antenatal care and supervision of illicit drugs, produces a considerable improvement in birthweight and decreases the risk of neonatal morbidity, when compared to the outcomes of neonates from non-treated pregnant heroin users [<xref ref-type="bibr" rid="R88">88</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R198"> 198</xref>,<xref ref-type="bibr" rid="R350"> 350</xref>,<xref ref-type="bibr" rid="R373"> 373</xref>]. However, MMT during pregnancy is still associated with poorer neonatal outcome compared to drug-free controls. For example, the proportion of infants of low birthweight ranges from 29-62% (mean: 45%; n=730) for heroin [<xref ref-type="bibr" rid="R88">88</xref>,<xref ref-type="bibr" rid="R102"> 102</xref>,<xref ref-type="bibr" rid="R312"> 312</xref>,<xref ref-type="bibr" rid="R350"> 350</xref>,<xref ref-type="bibr" rid="R351"> 351</xref>,<xref ref-type="bibr" rid="R443"> 443</xref>], 18-47% (mean: 29%; n=845) for methadone [<xref ref-type="bibr" rid="R88">88</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>,<xref ref-type="bibr" rid="R180"> 180</xref>,<xref ref-type="bibr" rid="R283"> 283</xref>,<xref ref-type="bibr" rid="R350"> 350</xref>,<xref ref-type="bibr" rid="R443"> 443</xref>], and 3-15% (mean: 15%; n=42019) for drug-free controls [<xref ref-type="bibr" rid="R88">88</xref>,<xref ref-type="bibr" rid="R102"> 102</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>,<xref ref-type="bibr" rid="R180"> 180</xref>,<xref ref-type="bibr" rid="R351"> 351</xref>]; these studies, however, did not consistently control for confounding factors, such as other drug use. Additionally, when compared to drug-free controls, MMT during pregnancy is associated with reduced head circumference [<xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R74"> 74</xref>,<xref ref-type="bibr" rid="R231"> 231</xref>] as well as slight increases in neonatal mortality [<xref ref-type="bibr" rid="R54">54</xref>,<xref ref-type="bibr" rid="R154"> 154</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>], morbidity and the incidence of neonatal abstinence syndrome [<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R61"> 61</xref>,<xref ref-type="bibr" rid="R80"> 80</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>]. </p><p>In comparison to low dose MMT, birthweight and head circumference is improved by higher methadone dosing during the early and late phases of pregnancy [<xref ref-type="bibr" rid="R74">74</xref>,<xref ref-type="bibr" rid="R124"> 124</xref>,<xref ref-type="bibr" rid="R195"> 195</xref>]. Such improvements in neonates are presumed to be a consequence of better lifestyle factors (e.g. nutritional intake) and reduced drug abuse. Indeed, human studies using lower methadone doses, which were insufficient to alleviate withdrawal symptoms, were associated with increased abuse of other drugs [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R251"> 251</xref>]. Furthermore, a recent investigation on human development following <italic>in utero</italic> exposure to methadone demonstrated dose-related growth effects contrary to that previously reported, whereby, neonates from patients administered methadone during pregnancy for the management of opioid-dependence were compared with newborns of patients who received methadone for the management of pain [<xref ref-type="bibr" rid="R339">339</xref>]. The dosing regimens differed in that patients being managed for pain received lower doses of methadone (40 mg/day) and for a shorter duration of time (5 weeks toward end of pregnancy) in comparison to heroin users undergoing MMT, who received 60 mg per day for a duration of 36 weeks [<xref ref-type="bibr" rid="R339">339</xref>]. As pain-managed patients were not opioid-dependent prior to receiving methadone, they were less likely to use other drugs of abuse than the cohort of opioid-dependent patients, when methadone reached trough levels. This effect is in part due to their lower levels of tolerance from an abstinent history of opioid use. Thus, it may be proposed that these data reflect the true pharmacological actions of methadone, whereby higher doses are associated with a greater suppressant effect on growth.</p><sec><label>2.1.4.2.1</label><title>Methadone and Neonatal Abstinence Syndrome</title><p>Neonatal abstinence syndrome (NAS) is characterised by high-pitched crying, hyperactive reflexes, tremors, hypertonicity, convulsions, frantic suckling of fists, poor feeding, regurgitation, diarrhoea, dehydration, yawning, sneezing, nasal stuffiness, sweating, skin mottling, fever, rapid respiration and skin abrasion, as assessed by the Finnegan scale [<xref ref-type="bibr" rid="R91">91</xref>,<xref ref-type="bibr" rid="R128"> 128</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>]. Although symptoms can lead to prolonged hospital stays for the new born [<xref ref-type="bibr" rid="R183">183</xref>], behavioural abnormalities do not persist. However, withdrawal following MMT is likely to be more prolonged than that from heroin [<xref ref-type="bibr" rid="R177">177</xref>] and, if NAS is left untreated, there is an increased risk of mortality [<xref ref-type="bibr" rid="R88">88</xref>,<xref ref-type="bibr" rid="R304"> 304</xref>]. Consequently, some physicians are reluctant to increase the daily methadone dose as pregnancy progresses, despite the increased clearance and volume of distribution and, therefore, reduced plasma concentrations and declining patient satiety. Moreover, some highly motivated patients are encouraged to endure gradual dose reductions to accomplish complete detoxification prior to parturition [<xref ref-type="bibr" rid="R60">60</xref>,<xref ref-type="bibr" rid="R215"> 215</xref>,<xref ref-type="bibr" rid="R246"> 246</xref>,<xref ref-type="bibr" rid="R294"> 294</xref>]. However, this approach is generally avoided as the post-detoxification risk of relapse [<xref ref-type="bibr" rid="R92">92</xref>] is likely to involve fluctuating opiate levels, leading to numerous complications, such as fetal distress, meconium aspiration, fetal hypoxia and death [<xref ref-type="bibr" rid="R90">90</xref>,<xref ref-type="bibr" rid="R177"> 177</xref>,<xref ref-type="bibr" rid="R190"> 190</xref>,<xref ref-type="bibr" rid="R447"> 447</xref>]. As NAS can be managed pharmacologically, stabilisation onto methadone, involving sufficient dosing and employment for the duration of gestation, is the preferred management for the pregnant opioid-dependent woman [<xref ref-type="bibr" rid="R190">190</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>,<xref ref-type="bibr" rid="R294"> 294</xref>].</p><p>The incidence of NAS when pregnant opioid-dependent women receive MMT is typically 60-90% of newborns [<xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>,<xref ref-type="bibr" rid="R189"> 189</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>,<xref ref-type="bibr" rid="R228"> 228</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>]; a large proportion of which (45-80%) endure severe withdrawal, necessitating pharmacotherapeutic intervention to alleviate the symptoms [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R23"> 23</xref>,<xref ref-type="bibr" rid="R80"> 80</xref>,<xref ref-type="bibr" rid="R195"> 195</xref>,<xref ref-type="bibr" rid="R246"> 246</xref>,<xref ref-type="bibr" rid="R339"> 339</xref>]. The issue of maternal methadone dose versus the prognosis of NAS remain unresolved; whilst a number of studies show a positive correlation between dose and the prevalence, duration and severity of NAS [<xref ref-type="bibr" rid="R61">61</xref>,<xref ref-type="bibr" rid="R73"> 73</xref>,<xref ref-type="bibr" rid="R246"> 246</xref>,<xref ref-type="bibr" rid="R294"> 294</xref>,<xref ref-type="bibr" rid="R339"> 339</xref>], others report the absence of this association [<xref ref-type="bibr" rid="R23">23</xref>,<xref ref-type="bibr" rid="R33"> 33</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>,<xref ref-type="bibr" rid="R243"> 243</xref>,<xref ref-type="bibr" rid="R283"> 283</xref>,<xref ref-type="bibr" rid="R324"> 324</xref>]. The inconsistency is presumably from the inability to appropriately control for numerous confounding factors, such as poor antenatal care, smoking, poverty, personal neglect, and poor health status [<xref ref-type="bibr" rid="R364">364</xref>]. For example, a recent study demonstrated that the onset and severity of NAS was greater in neonates from patients smoking more than 20 cigarettes per day versus less than 10 per day [<xref ref-type="bibr" rid="R46">46</xref>]. Other studies do not sufficiently control for cigarette smoking [<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R129"> 129</xref>,<xref ref-type="bibr" rid="R246"> 246</xref>,<xref ref-type="bibr" rid="R249"> 249</xref>], or other drugs which can influence the prognosis of NAS [<xref ref-type="bibr" rid="R112">112</xref>,<xref ref-type="bibr" rid="R191"> 191</xref>,<xref ref-type="bibr" rid="R339"> 339</xref>]. Another study showed that higher methadone doses in third trimester were associated with increased gestational age, and after adjustments were made for maternal dose and gestational age, a correlation was found between NAS, gestational age and race, with non-black infants exhibiting higher NAS scores than black infants [<xref ref-type="bibr" rid="R124">124</xref>]. </p><p>The rate of decline in neonatal methadone plasma concentration is positively correlated with the severity of NAS during the first four days after birth [<xref ref-type="bibr" rid="R73">73</xref>]. Another study which examined neonatal plasma concentration and NAS reported that neonatal withdrawal was not observed if their methadone plasma concentration was greater than 60 ng/ml [<xref ref-type="bibr" rid="R324">324</xref>]. This finding is consistent with recent data whereby maternal withdrawal is avoided when methadone plasma levels are greater than 240 ng/ml [<xref ref-type="bibr" rid="R78">78</xref>]. Indeed, it has been shown that maternal and fetal withdrawal occur simultaneously [<xref ref-type="bibr" rid="R2">2</xref>], even though perinatal methadone blood levels are approximately 5-fold less than maternal ones [<xref ref-type="bibr" rid="R128">128</xref>]. The findings provide a plausible explanation for observed decreases in the severity of NAS after exposing the newborn to methadone <italic>via</italic> the breast milk [<xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R9"> 9</xref>,<xref ref-type="bibr" rid="R245"> 245</xref>,<xref ref-type="bibr" rid="R252"> 252</xref>]. This approach may therefore be useful in the management of the newborn displaying symptoms of withdrawal.</p><p>Improved management of the pregnant opioid-dependent person may be achieved by MMT with split dosing, whereby half the standard methadone dose is administered twice-daily [<xref ref-type="bibr" rid="R196">196</xref>,<xref ref-type="bibr" rid="R252"> 252</xref>,<xref ref-type="bibr" rid="R357"> 357</xref>]. Compared to single-daily dosing, split-dosing more closely resembles a steady state plasma concentrations over a 24 hour period [<xref ref-type="bibr" rid="R395">395</xref>]. Furthermore, methadone is sustained at a higher concentration and for longer from a split rather than a once-daily dose [<xref ref-type="bibr" rid="R110">110</xref>,<xref ref-type="bibr" rid="R196"> 196</xref>,<xref ref-type="bibr" rid="R357"> 357</xref>]. In addition, compared to single-dosing, split-dosing during the third trimester of pregnancy is associated with reduced cocaine abuse and improved compliance [<xref ref-type="bibr" rid="R67">67</xref>]. It is therefore suggested that split-dosing will improve compliance and treatment by producing fewer withdrawal symptoms [<xref ref-type="bibr" rid="R357">357</xref>], reducing depression of fetal body movements and breathing rate [<xref ref-type="bibr" rid="R175">175</xref>]. However, there have only been a few investigations into the benefits of split-dosing during pregnancy; although, based on these preliminary findings, further studies are warranted.</p></sec></sec><sec><label>2.1.4.3</label><title>Methadone and Postnatal Outcomes</title><p>Postnatal effects from MMT exposure during pregnancy include reduced postnatal weight gain, head circumference and height [<xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R127"> 127</xref>,<xref ref-type="bibr" rid="R346"> 346</xref>,<xref ref-type="bibr" rid="R353"> 353</xref>,<xref ref-type="bibr" rid="R365"> 365</xref>]. However, although opiate-induced growth reductions have a tendency to diminish with age [<xref ref-type="bibr" rid="R226">226</xref>,<xref ref-type="bibr" rid="R231"> 231</xref>,<xref ref-type="bibr" rid="R446"> 446</xref>], they can persist for up to 5.5 years [<xref ref-type="bibr" rid="R369">369</xref>]. A weak association has also been made between MMT and sudden infant death syndrome, although a causal effect is yet to be established [<xref ref-type="bibr" rid="R89">89</xref>,<xref ref-type="bibr" rid="R142"> 142</xref>,<xref ref-type="bibr" rid="R197"> 197</xref>,<xref ref-type="bibr" rid="R304"> 304</xref>]. Other postnatal effects include an increase in the incidence of mortality [<xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R221"> 221</xref>,<xref ref-type="bibr" rid="R346"> 346</xref>], microcephaly [<xref ref-type="bibr" rid="R6">6</xref>], strabismus [<xref ref-type="bibr" rid="R112">112</xref>] and behavioural effects such as mood, attention and cognitive deficits [<xref ref-type="bibr" rid="R13">13</xref>,<xref ref-type="bibr" rid="R43"> 43</xref>,<xref ref-type="bibr" rid="R115"> 115</xref>]; behavioural outcomes following prenatal exposure to opiates have previously been reviewed [<xref ref-type="bibr" rid="R193">193</xref>]. It was recently shown that at four months of age, a highly significant difference in neurological development exists between control infants, and infants exposed to methadone during the prenatal period, with methadone-exposed infants displaying a 14% greater latency in reaching peak visual evoked potentials (VEPs), in response to changing patterned visual cues [<xref ref-type="bibr" rid="R392">392</xref>]. Infants of mothers who underwent MMT during pregnancy display higher scores for disorganised and avoidant behaviour, as well as lower scores of contact-maintaining behaviour at 12 months of age [<xref ref-type="bibr" rid="R115">115</xref>,<xref ref-type="bibr" rid="R127"> 127</xref>]. Furthermore, infants of drug-dependent mothers receiving methadone had delayed cognitive development, persisting in up to 50% of these infants until 5 years of age [<xref ref-type="bibr" rid="R369">369</xref>]. These infants are also less interactive at 5 years of age compared to the normal population. In addition, 7 year old methadone-exposed infants differed from controls in their behaviour at school, displaying poorer achievement, increased aggression and school disruptions [<xref ref-type="bibr" rid="R323">323</xref>]. However, other reports found no difference between methadone-exposed, heroin-exposed and control infants aged 3 to 5 years with respect to cognitive and social function [<xref ref-type="bibr" rid="R115">115</xref>,<xref ref-type="bibr" rid="R127"> 127</xref>,<xref ref-type="bibr" rid="R192"> 192</xref>,<xref ref-type="bibr" rid="R231"> 231</xref>,<xref ref-type="bibr" rid="R352"> 352</xref>]. </p></sec></sec><sec><label>2.1.5</label><title>Concomitant Heroin Use During Methadone Maintenance Treatment</title><p>Although heroin-using women who stabilise on methadone at or around the time of conception show good prognosis, those who fail to stabilise and continue regular heroin use throughout pregnancy show significantly poorer prognosis [<xref ref-type="bibr" rid="R152">152</xref>-<xref ref-type="bibr" rid="R154">154</xref>]. For example, a meta-analysis of neonatal birthweight showed a lower relative risk estimate for women stabilised on methadone at or near the time of conception (RR 1.36; 95% CI 0.83-2.22) compared to those who failed to stabilise and continued to use heroin (RR 3.28; 95% CI 2.47-4.39) [<xref ref-type="bibr" rid="R154">154</xref>]. Despite improvements over those continuing to use heroin, neonatal outcomes such as birthweight and delivery at term for those on MMT are significantly poorer than for matched controls who do not use heroin [<xref ref-type="bibr" rid="R152">152</xref>,<xref ref-type="bibr" rid="R155"> 155</xref>]. Furthermore, neonates/infants of those treated with methadone who also co-use illicit opiates are at increased risk of death [<xref ref-type="bibr" rid="R154">154</xref>]. Similarly, there is an increased likelihood of infants developing NAS when mothers undergoing MMT supplement with heroin [<xref ref-type="bibr" rid="R61">61</xref>]. </p><p>There are major improvements associated with MMT in the risk of exposure to infection, negative lifestyle factors, reduction of heroin use, antenatal attendance and neonatal outcomes such as antepartum haemorrhage, low birthweight and neonatal mortality [<xref ref-type="bibr" rid="R139">139</xref>,<xref ref-type="bibr" rid="R152"> 152</xref>-<xref ref-type="bibr" rid="R154">154</xref>,<xref ref-type="bibr" rid="R194"> 194</xref>,<xref ref-type="bibr" rid="R221"> 221</xref>]. However, there are adverse effects associated with MMT during pregnancy which may lead some clinicians to consider alternative treatments. The critical issue in improving outcomes for opioid-dependent pregnant women is either achieving a stable intra-uterine milieu, with minimal intoxication and withdrawal, or minimising exposure to opioids and the associated potential growth-suppressive effects. Clinical evidence suggests greater benefit from the former. Whilst abstinence from any drug is ideal during pregnancy, detoxification from MMT might not be ideal if the consequences include a reversion to illicit opiate or other drug use. Although detoxification from methadone before parturition can be accomplished in highly motivated patients [<xref ref-type="bibr" rid="R60">60</xref>,<xref ref-type="bibr" rid="R155"> 155</xref>], continued illicit drug use is likely and the high level of maternal complications suggests that improvements are needed in the treatment of pregnant heroin users [<xref ref-type="bibr" rid="R198">198</xref>].</p></sec></sec><sec><label>2.2</label><title>Buprenorphine</title><sec><label>2.2.1</label><title>Pharmacology and Role of Buprenorphine in Treatment of Dependence</title><p>Buprenorphine ([9-cyclopropylmethyl-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3-hydroxy-6-methoxy-3,3-dimethyl-butan-2-ol) is a semi-synthetic thebaine derivative which selectively binds as a partial agonist to the &#x003bc;-opioid receptor, and to the &#x003ba;-opioid receptor as an antagonist [<xref ref-type="bibr" rid="R225">225</xref>, <xref ref-type="bibr" rid="R230">230</xref>, <xref ref-type="bibr" rid="R280">280</xref>], although the latter role is unclear as a more recent study implicates agonistic activity at the &#x003ba;-opioid receptor in relation to analgesia [<xref ref-type="bibr" rid="R303">303</xref>]. Buprenorphine was first evaluated for its potential in maintaining the opioid-dependent person in 1978 [<xref ref-type="bibr" rid="R179">179</xref>], although it was not approved by the United States legislature until 2000, and by the FDA until 2002 [<xref ref-type="bibr" rid="R98">98</xref>]. As a partial agonist, buprenorphine potently induces morphine-like effects at a relatively low-dose, but at higher doses, it has a submaximal response compared to full agonists, such as morphine and heroin, and begins to attenuate in its agonistic effect [<xref ref-type="bibr" rid="R230">230</xref>, <xref ref-type="bibr" rid="R308">308</xref>]. Buprenorphine also attenuates the effects of other opioid agonists, through increased competition for binding at the &#x003bc;-opioid receptor [<xref ref-type="bibr" rid="R355">355</xref>]. Sublingual buprenorphine is rapidly absorbed and distributed, with a bioavailability of approximately 50% (range: 16-94%), which is marginally less than the bioavailability of methadone [<xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R52">52</xref>]. However, it slowly dissociates from the opioid receptor binding sites resulting in a biphasic elimination half-life of approximately 30 hours with an initial rapid phase of 3 to 5 hours, followed by a slow phase greater than 24 hours [<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R216">216</xref>]. </p><p>Buprenorphine is a highly lipophilic agent which is extensively metabolised in the liver by N-dealkylation to norbuprenorphine; similar to methadone, the process is mainly (~75%) mediated through CYP3A4 [<xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R172">172</xref>, <xref ref-type="bibr" rid="R205">205</xref>], with the remaining ~25% mediated by CYP-3A5, -3A7 and -2C8 [<xref ref-type="bibr" rid="R172">172</xref>, <xref ref-type="bibr" rid="R205">205</xref>, <xref ref-type="bibr" rid="R270">270</xref>]. The active metabolite, norbuprenorphine, along with its parent compound, undergo inactivation by conjugation with glucuronic acid [<xref ref-type="bibr" rid="R53">53</xref>, <xref ref-type="bibr" rid="R290">290</xref>].</p><p>The regimen commonly employed clinically is daily sublingual administration (Subutex&#x000ae;) [<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R363">363</xref>]; buprenorphine&#x02019;s efficacy has been reviewed elsewhere [<xref ref-type="bibr" rid="R62">62</xref>, <xref ref-type="bibr" rid="R207">207</xref>, <xref ref-type="bibr" rid="R235">235</xref>, <xref ref-type="bibr" rid="R236">236</xref>]. Buprenorphine doses used to manage the opioid-dependent person vary considerably (mean dose range: 1-24 mg/day) [<xref ref-type="bibr" rid="R184">184</xref>, <xref ref-type="bibr" rid="R208">208</xref>, <xref ref-type="bibr" rid="R234">234</xref>, <xref ref-type="bibr" rid="R355">355</xref>, <xref ref-type="bibr" rid="R363">363</xref>]. In comparison to lower doses (1-4 mg/day), the typical dose range of 8-16 mg/day is associated with improvements in patient compliance and abstinence from other opioids [<xref ref-type="bibr" rid="R236">236</xref>, <xref ref-type="bibr" rid="R332">332</xref>, <xref ref-type="bibr" rid="R333">333</xref>, <xref ref-type="bibr" rid="R355">355</xref>]. However, its effect in reducing abuse of non-opioid drugs, such as cocaine, is less pronounced [<xref ref-type="bibr" rid="R119">119</xref>, <xref ref-type="bibr" rid="R333">333</xref>, <xref ref-type="bibr" rid="R389">389</xref>]. Further benefit of buprenorphine for managing addiction resides in its partial agonist properties since reduced liability for abuse, accidental overdose and adverse effects are attributed to buprenorphine&#x02019;s ceiling effect, whereby higher doses are associated with much smaller increases in morphine-like effects [<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R230">230</xref>, <xref ref-type="bibr" rid="R236">236</xref>]. In addition, withdrawal is generally well tolerated, being less severe than for heroin or methadone [<xref ref-type="bibr" rid="R114">114</xref>, <xref ref-type="bibr" rid="R238">238</xref>, <xref ref-type="bibr" rid="R355">355</xref>]. Despite its advantages, buprenorphine carries the potential for abuse [<xref ref-type="bibr" rid="R30">30</xref>]. However, the Suboxone&#x000ae; formulation prevents abuse since buprenorphine is combined with the short acting &#x003bc;-opioid receptor antagonist, naloxone [<xref ref-type="bibr" rid="R3">3</xref>]. When taken sublingually, the poor bioavailability of nalo-xone (&#x0003c;10%) results in minimal interference with systemic buprenorphine; however, if taken intravenously, naloxone blocks the pleasurable effects of buprenorphine [<xref ref-type="bibr" rid="R97">97</xref>, <xref ref-type="bibr" rid="R130">130</xref>, <xref ref-type="bibr" rid="R259">259</xref>]. </p></sec><sec><label>2.2.2</label><title>Role of Buprenorphine in Treatment of Dependence During Pregnancy</title><p>The benefits of buprenorphine maintenance of the nonpregnant heroin user are also seen in pregnancy [<xref ref-type="bibr" rid="R286">286</xref>], with retention to treatment, reduced illicit drug use, and improved safety with regards to overdose [<xref ref-type="bibr" rid="R185">185</xref>, <xref ref-type="bibr" rid="R188">188</xref>, <xref ref-type="bibr" rid="R189">189</xref>]. The TGA and FDA have classified buprenorphine into the same pregnancy category (C) as methadone [<xref ref-type="bibr" rid="R38">38</xref>] (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>), although, its use as a maintenance treatment during pregnancy is restricted due to a lack of data. Nevertheless, human studies have been conducted where FDA restrictions do not apply, including France, Belgium and Austria. In France, buprenorphine has been used as a standard treatment for opioid-dependence for over a decade. Whilst some women continued buprenorphine maintenance after conceiving, others underwent detoxification from heroin, followed by induction onto buprenorphine [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R228">228</xref>, <xref ref-type="bibr" rid="R286">286</xref>]. Buprenorphine doses used to maintain the pregnant woman are variable, with a mean dose range of 5.3-18.7 mg/day [<xref ref-type="bibr" rid="R93">93</xref>-<xref ref-type="bibr" rid="R95">95</xref>, <xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R189">189</xref>, <xref ref-type="bibr" rid="R218">218</xref>, <xref ref-type="bibr" rid="R228">228</xref>, <xref ref-type="bibr" rid="R331">331</xref>]. Similar to methadone, buprenorphine is transferred across the placenta to the neonate [<xref ref-type="bibr" rid="R273">273</xref>], although this occurs to a lesser extent, presumably due to buprenorphine&#x02019;s greater molecular weight (504.1 Da).</p></sec><sec><label>2.2.3</label><title>Pharmacokinetics of Buprenorphine During Pregnancy</title><p>Also in parallel with methadone, buprenorphine is metabolised by the placenta [<xref ref-type="bibr" rid="R70">70</xref>, <xref ref-type="bibr" rid="R273">273</xref>]. Transfer of buprenorphine and norbuprenorphine across the placenta is evidenced by its detection in umbilical cord and neonatal blood, urine and meconium, with cord levels ranging 101-137 ng/ml [<xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R248">248</xref>]. The placenta can also accumulate buprenorphine, thereby acting as a depot and allowing slow dissociation to the fetus [<xref ref-type="bibr" rid="R273">273</xref>]. Nonetheless, placental metabolism, mediated <italic>via</italic> the placental enzyme aromatase (CYP19), reduces the amount of transferred [<xref ref-type="bibr" rid="R70">70</xref>, <xref ref-type="bibr" rid="R273">273</xref>]. A further reduction in fetal exposure is mediated by the efflux transporter molecule P-glycoprotein [<xref ref-type="bibr" rid="R282">282</xref>]. There are low levels of CYP3A4 in fetal liver and so fetal metabolism does occur, although this is minimal. However, buprenorphine metabolism is also mediated through CYP3A7 [<xref ref-type="bibr" rid="R125">125</xref>, <xref ref-type="bibr" rid="R400">400</xref>] which would account for the higher neonatal plasma levels at term compared to maternal trough levels [<xref ref-type="bibr" rid="R248">248</xref>]. During lactation, buprenorphine is transferred <italic>via</italic> breast milk at a similar concentration to that found in maternal plasma (0.230 to 0.720 ng/ml) but this level of neonatal exposure is considered to be negligible [<xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R248">248</xref>]. </p></sec><sec><label>2.2.4</label><title>Buprenorphine and Developmental Effects</title><sec><label>2.2.4.1</label><title>Buprenorphine and Offspring Outcomes</title><p>Clinical retrospective and prospective studies on buprenorphine maintenance for pregnant opioid-dependent women indicate that it is a well tolerated and safe [<xref ref-type="bibr" rid="R93">93</xref>, <xref ref-type="bibr" rid="R185">185</xref>, <xref ref-type="bibr" rid="R188">188</xref>, <xref ref-type="bibr" rid="R228">228</xref>]. Neonatal outcomes are not conclusive as studies are limited [<xref ref-type="bibr" rid="R93">93</xref>, <xref ref-type="bibr" rid="R186">186</xref>, <xref ref-type="bibr" rid="R228">228</xref>]. Nevertheless, most pregnancies lack complications with neonatal outcomes, including birthweight, APGAR scores, head circumference and body length, being within normal ranges [<xref ref-type="bibr" rid="R93">93</xref>, <xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R331">331</xref>]. In addition, mortality is not a major problem, with one stillbirth and one spontaneous abortion being the only reported cases [<xref ref-type="bibr" rid="R218">218</xref>]. Notwithstanding the benefits of managing pregnant opioid-dependent women with buprenorphine, caution is needed as adverse effects have been associated with this treatment. For example, one study reported that 10% of buprenorphine-exposed newborns (of 259) were delivered prematurely, compared to a normal incidence of 7% [<xref ref-type="bibr" rid="R228">228</xref>]. Furthermore, another study reported that 5.8% (2/34) newborns had malformations [<xref ref-type="bibr" rid="R218">218</xref>]. Follow-up postnatal studies are also scarce, although in a recent study, neurological development of infants exposed to buprenorphine during gestation was shown not to differ from control infants at four months, as assessed by measurement of VEP latencies [<xref ref-type="bibr" rid="R392">392</xref>]. It is of concern that lower limb hypertonia, jerky movements and jitteriness in some newborns have been reported to last for 3-9 months [<xref ref-type="bibr" rid="R201">201</xref>], although these may be a consequence of maternal poly drug use during pregnancy and/or lactation [<xref ref-type="bibr" rid="R126">126</xref>, <xref ref-type="bibr" rid="R377">377</xref>, <xref ref-type="bibr" rid="R378">378</xref>].</p></sec><sec><label>2.2.4.2</label><title>Buprenorphine and Neonatal Abstinence Syndrome</title><p>Neonatal abstinence syndrome is apparent in only a few buprenorphine-exposed newborns, a feature considered to be a major advantage of this drug treatment during pregnancy, [<xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R185">185</xref>, <xref ref-type="bibr" rid="R218">218</xref>]. However, one study of 13 neonates reported a NAS incidence rate of 85% [<xref ref-type="bibr" rid="R201">201</xref>]. Nonetheless, in most cases, NAS presented as mild and did not require treatment [<xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R185">185</xref>, <xref ref-type="bibr" rid="R218">218</xref>]. This may, at least in part, be explained by the extensive metabolism of buprenorphine within, and relatively low transfer across, the placenta. Symptoms appear at 12 hours, peak at around 72 hours and alleviate at 120 hours after the last buprenorphine dose [<xref ref-type="bibr" rid="R95">95</xref>, <xref ref-type="bibr" rid="R186">186</xref>], although this timing could be confounded by the use of other drugs, such as tobacco [<xref ref-type="bibr" rid="R46">46</xref>]. Plasma levels above 0.7 ng/ml reportedly prevent withdrawal [<xref ref-type="bibr" rid="R217">217</xref>]. There are currently no evidence-based guidelines for breastfeeding in women maintained on buprenorphine during pregnancy and breast feeding due to lack of conclusive data [<xref ref-type="bibr" rid="R94">94</xref>, <xref ref-type="bibr" rid="R185">185</xref>, <xref ref-type="bibr" rid="R228">228</xref>, <xref ref-type="bibr" rid="R248">248</xref>]. However, breastfeeding occurs and buprenorphine, regardless of maternal dose, does not alter the effectiveness of using morphine to treating NAS [<xref ref-type="bibr" rid="R116">116</xref>, <xref ref-type="bibr" rid="R186">186</xref>]. </p></sec></sec><sec><label>2.2.5</label><title>Sublingual Buprenorphine Versus Methadone Maintenance</title><p>A number of investigations have made comparisons between neonatal outcomes from buprenorphine or methadone maintenance during pregnancy. A buprenorphine dose of 8 mg/kg is comparable to a methadone dose of 60 mg/day with respect to efficacy in treating addiction and reducing drug abuse [<xref ref-type="bibr" rid="R236">236</xref>]. MMT is associated with lowered use of additional opioids, as indicated by random toxicological screening, whereas buprenorphine is associated with greater patient compliance [<xref ref-type="bibr" rid="R95">95</xref>, <xref ref-type="bibr" rid="R389">389</xref>]. Whilst buprenorphine is less toxic to the fetus than methadone [<xref ref-type="bibr" rid="R288">288</xref>], the increased use of other drugs during the buprenorphine-maintained pregnancy may produce worse outcomes for the neonate [<xref ref-type="bibr" rid="R82">82</xref>, <xref ref-type="bibr" rid="R126">126</xref>, <xref ref-type="bibr" rid="R151">151</xref>]. </p><p>In general, however, management with buprenorphine during pregnancy is comparable to MMT, with regards to safety of the neonate. In 2006, a study with 259 participants did not identify any major differences for perinatal outcome between methadone (57+/-30.4 mg) and buprenorphine (5.4 +/- 4.5 mg) [<xref ref-type="bibr" rid="R228">228</xref>]. However, the peak NAS severity was observed earlier in newborns exposed to buprenorphine during gestation, compared to newborns exposed to methadone (66 <italic>versus</italic> 81 h) [<xref ref-type="bibr" rid="R228">228</xref>]. Conversely, the onset of NAS was earlier following MMT (60 h) compared with buprenorphine (72 h) [<xref ref-type="bibr" rid="R95">95</xref>], which may be explained by the longer terminal half-life of buprenorphine [<xref ref-type="bibr" rid="R35">35</xref>, <xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R216">216</xref>]. Furthermore, NAS is generally more severe following MMT [<xref ref-type="bibr" rid="R228">228</xref>], as indicated by a higher amount of morphine required to treat NAS in comparison to the amount required for treating buprenorphine-exposed infants [<xref ref-type="bibr" rid="R189">189</xref>]. Reduced NAS in buprenorphine exposed infants may be due to decreased placental transport. As discussed earlier, VEP latencies of infants exposed to methadone were significantly longer than control infants, whereas maternal use of buprenorphine during pregnancy resulted in infant VEPs similar to controls, conferring an advantage over methadone [<xref ref-type="bibr" rid="R392">392</xref>].</p></sec></sec><sec><label>2.3</label><title>Naltrexone</title><sec><label>2.3.1</label><title>Pharmacology and Role of Naltrexone in Treatment of Dependence</title><p>Naltrexone (N-cyclopropylmethyl-noroxymorphone) is a thebaine-derivative that binds non-selectively to opioid receptors as an antagonist, its pharmacological action in blocking the effects of opioids (such as methadone, morphine and heroin) may be useful to prevent relapse in opioid-dependent patients [<xref ref-type="bibr" rid="R113">113</xref>, <xref ref-type="bibr" rid="R120">120</xref>]. Systemic naltrexone efficiently crosses the human blood-brain barrier [<xref ref-type="bibr" rid="R96">96</xref>, <xref ref-type="bibr" rid="R199">199</xref>, <xref ref-type="bibr" rid="R227">227</xref>, <xref ref-type="bibr" rid="R267">267</xref>]. Compared to other antagonists (such as nalorphine and naloxone), naltrexone has a long duration of action (elimination half-life: ~4 hours) and greater antagonist potency [<xref ref-type="bibr" rid="R380">380</xref>, <xref ref-type="bibr" rid="R402">402</xref>]. Naltrexone is principally eliminated by the liver, where metabolic (NADPH-dependent) reduction of its 6-keto group produces 6,&#x003b2;-naltrexol [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R266">266</xref>, <xref ref-type="bibr" rid="R381">381</xref>]. Additional hepatic metabolism is mediated by glucuronic acid conjugation and catechol-O-methyl transferases, resulting in the formation of a number of minor metabolites which are excreted primarily by the kidney [<xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R266">266</xref>, <xref ref-type="bibr" rid="R375">375</xref>, <xref ref-type="bibr" rid="R380">380</xref>-<xref ref-type="bibr" rid="R382">382</xref>]. In humans, plasma naltrexone concentrations are 10 times less than that of its primary metabolite, 6,&#x003b2;-naltrexol [<xref ref-type="bibr" rid="R40">40</xref>] which has about a 1/100 the antagonistic potency of naltrexone at the &#x003bc;-opioid receptor [<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R170">170</xref>]. The ability of naltrexone to effectively antagonise heroin use has been clearly established, but the exact level required is still in question. It has been shown that serum naltrexone blood levels of 2.8 ng/ml block 500 mg of snorted pure pharmaceutical diacetylmorphine [<xref ref-type="bibr" rid="R32">32</xref>], &#x02264;2ng/ml blocks the effects of 25 mg of intravenously administered heroin [<xref ref-type="bibr" rid="R279">279</xref>, <xref ref-type="bibr" rid="R376">376</xref>] and &#x02264;1 ng/ml antagonises 15 mg morphine [<xref ref-type="bibr" rid="R45">45</xref>]. The generally cited therapeutic blood level for the management of heroin dependence is 2 ng/ml [<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R50">50</xref>, <xref ref-type="bibr" rid="R156">156</xref>, <xref ref-type="bibr" rid="R264">264</xref>], which is 87% effective in blocking the effects of 25 mg intravenously administered heroin [<xref ref-type="bibr" rid="R51">51</xref>], although higher values may be needed to provide 100% coverage. Notwithstanding the poor oral bioavailability (40%) of naltrexone, it has been available for many years as an oral formulation (ReVia&#x000ae;), commonly involving daily self-administration (50 mg) to maintain therapeutic blood levels, although other prescribing patterns, such as 100 mg three times per week are also used [<xref ref-type="bibr" rid="R264">264</xref>]. The standard oral dose of one 50 mg tablet per day produces a peak of ~8 ng/ml of blood naltrexone, decaying to 1.1 ng/ml within 24 hours [<xref ref-type="bibr" rid="R380">380</xref>]. However, oral naltrexone is associated with poor compliance [<xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R328">328</xref>].</p><p>An alternative to oral naltrexone involves either injection of a depot formulation or surgical insertion of a sustained-release implant. Either approach removes the onus on patients to use oral naltrexone on a daily basis. Several sustained-release naltrexone implants have been developed which maintain therapeutic blood levels (&#x02265;2 ng/ml) for 4-8 weeks [<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R49">49</xref>, <xref ref-type="bibr" rid="R209">209</xref>, <xref ref-type="bibr" rid="R263">263</xref>, <xref ref-type="bibr" rid="R362">362</xref>]. Depotrex&#x000ae; (192 or 384 mg naltrexone) is an injectable depot formulation which antagonises the effects of intravenously-administered heroin (0-25 mg) for 3-5 weeks, and is safe and well tolerated in opioid abusers, supporting its use as a treatment for opioid dependence [<xref ref-type="bibr" rid="R50">50</xref>]. Similarly, Vivitrol&#x000ae; (formally known as Vivitrex) is an injectable depot formulation which produces peak naltrexone plasma levels within 3 days, dropping to an undetectable level (&#x02264; ng/ml) by 35 days [<xref ref-type="bibr" rid="R15">15</xref>]. Preliminary data indicate that in humans, intramuscular Vivitrol is also well tolerated with reported adverse effects being mild to moderate [<xref ref-type="bibr" rid="R106">106</xref>]. </p><p>However, although sustained-release injectable and implantable preparations help overcome the issue of daily medication and non-compliance, they only last for short periods and still incur significant levels of non-compliance. For example, in an 8-week Depotrex trial, with re-treatment at 4 weeks, 32% of the high dose and 40% of the low dose participants dropped out of the study [<xref ref-type="bibr" rid="R51">51</xref>]. Extrapolating from pharmacokinetic data derived from those with alcohol dependence, re-treatment of those with opioid dependence with injectable naltrexone would be required on a monthly basis [<xref ref-type="bibr" rid="R106">106</xref>, <xref ref-type="bibr" rid="R210">210</xref>]. Therefore, although these newer sustained-release preparations help to overcome the issue of non-compliance for short periods (typically 21-28 days), they still incur significant levels of attrition with patients required to return every 3-4 weeks for re-treatment. Longer lasting sustained-release preparations might offer advantages for individual patients and the community.</p><p>An implantable naltrexone formula (GoMedical Industries Pty Ltd) has been used under the Commonwealth Therapeutic Goods Administration Special Access Scheme (&#x0201c;Compassionate Guidelines&#x0201d;) in Western Australia since August 2000. GoMedical implants in humans maintain naltrexone at therapeutic levels, i.e. above 2 ng/ml, for approximately 5.5 months, and 1 ng/ml for 9 months [<xref ref-type="bibr" rid="R147">147</xref>-<xref ref-type="bibr" rid="R149">149</xref>], and are associated with a significant reduction in hospital presentations and accidental overdose [<xref ref-type="bibr" rid="R159">159</xref>, <xref ref-type="bibr" rid="R160">160</xref>]. However, there is concern regarding an increased risk of accidental overdose if relapse to opioids were to follow maintenance treatment with naltrexone [<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R265">265</xref>, <xref ref-type="bibr" rid="R315">315</xref>, <xref ref-type="bibr" rid="R336">336</xref>, <xref ref-type="bibr" rid="R349">349</xref>, <xref ref-type="bibr" rid="R370">370</xref>]. </p><p>Fatal and non-fatal overdoses may be prevalent with naltrexone because, being an antagonist, it reduces tolerance to opioids; in addition, chronic exposure may result in up-regulation of opioid receptors thereby increasing sensitivity [<xref ref-type="bibr" rid="R72">72</xref>, <xref ref-type="bibr" rid="R390">390</xref>]. Increased risk of mortality due to reduced tolerance has been shown in humans following periods of abstinence, such as following incarceration [<xref ref-type="bibr" rid="R58">58</xref>] but, although receptor up-regulation has been demonstrated in animal models [<xref ref-type="bibr" rid="R361">361</xref>, <xref ref-type="bibr" rid="R403">403</xref>], it is still unclear if it occurs in humans [<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R390">390</xref>]. Furthermore, naltrexone has been shown to suppress the <italic>subjective</italic> effects of opioids more than <italic>objective</italic> physiological effects [<xref ref-type="bibr" rid="R334">334</xref>, <xref ref-type="bibr" rid="R376">376</xref>]. This dichotomy may increase the chance of an overdose as the user does not receive the expected level of feedback from a given level of opioid use, but still experiences physiological effects such as respiratory depression [<xref ref-type="bibr" rid="R72">72</xref>]. </p></sec><sec><label>2.3.2</label><title>Role of Naltrexone in Treatment of Dependence During Pregnancy</title><p>Naltrexone is not recommended for use during pregnancy due to lack of data on prenatal exposure and in Australia is classified as a B3 drug (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>) &#x02013; one where &#x0201c;&#x02026;studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans&#x0201d; [<xref ref-type="bibr" rid="R38">38</xref>]. The FDA classifies naltrexone in the same category (C) as methadone and buprenorphine (Table <bold><xref ref-type="table" rid="T1">1</xref></bold>). However, because termination of maintenance therapies may be associated with relapse to heroin use, some pregnant women elect to remain on oral naltrexone during at least part, and some for the entirety, of their pregnancies [<xref ref-type="bibr" rid="R158">158</xref>]. One potential reason for remaining on naltrexone is that its lack of agonist activity circumvents neonatal abstinence syndrome [<xref ref-type="bibr" rid="R191">191</xref>, <xref ref-type="bibr" rid="R427">427</xref>]. Detoxification of pregnant women onto oral or implanted naltrexone maintenance has also occurred in 6 cases, when these patients were unable to stabilise onto other maintenance treatments [<xref ref-type="bibr" rid="R146">146</xref>, <xref ref-type="bibr" rid="R156">156</xref>-<xref ref-type="bibr" rid="R158">158</xref>]. The efficacy of naltrexone for treatment of the opioid-dependent pregnant woman has not sufficiently been assessed; the limited studies did not comment on toxicological screening for substance abuse.</p></sec><sec><label>2.3.3</label><title>Pharmacokinetics of Naltrexone During Pregnancy</title><p>Whilst transfer of naltrexone into breast milk has been shown in sheep and humans [<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R40">40</xref>], and placental transfer demonstrated in rat [<xref ref-type="bibr" rid="R406">406</xref>, <xref ref-type="bibr" rid="R407">407</xref>], naltrexone transfer across the human placenta has not been reported. Indeed, transfer of both naltrexone and 6,&#x003b2;-naltrexol may be limited by their extensive conjugation with glucuronic acid thereby reducing their permeability [<xref ref-type="bibr" rid="R71">71</xref>, <xref ref-type="bibr" rid="R211">211</xref>, <xref ref-type="bibr" rid="R326">326</xref>, <xref ref-type="bibr" rid="R380">380</xref>, <xref ref-type="bibr" rid="R382">382</xref>]. However, conjugated naltrexone and 6,&#x003b2;-naltrexol may be transferred by some as yet unknown transport mechanism. Nevertheless unconjugated transfer presumably does occur in humans, as occurs for many other drugs [<xref ref-type="bibr" rid="R292">292</xref>, <xref ref-type="bibr" rid="R371">371</xref>, <xref ref-type="bibr" rid="R387">387</xref>]. A single case study confirmed that maternal naltrexone levels can be sustained above a therapeutically effective threshold of 2 ng/ml for at least the first 214 days of pregnancy, reflecting similar levels measured in non-pregnant patients [<xref ref-type="bibr" rid="R147">147</xref>-<xref ref-type="bibr" rid="R149">149</xref>]. Placental transfer of naltrexone occurs in rat [<xref ref-type="bibr" rid="R406">406</xref>, <xref ref-type="bibr" rid="R407">407</xref>], and despite interspecies difference in placental morphology, transport and metabolism is functionally similar [<xref ref-type="bibr" rid="R262">262</xref>, <xref ref-type="bibr" rid="R358">358</xref>]. Indeed, opioidergic drugs, including morphine and naloxone, which are very similar to naltrexone [<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R44">44</xref>], rapidly cross the human placenta and enter the fetal circulation [<xref ref-type="bibr" rid="R47">47</xref>, <xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R206">206</xref>]. Furthermore, the physiochemical properties of naltrexone, namely its alkalinity (pKa: 8.13), high lipid solubility (octanol/water distribution: 13.08) [<xref ref-type="bibr" rid="R200">200</xref>], small molecular weight (341.41 Da) [<xref ref-type="bibr" rid="R182">182</xref>], and low plasma protein binding of 21-8% [<xref ref-type="bibr" rid="R68">68</xref>, <xref ref-type="bibr" rid="R241">241</xref>] are factors which facilitate placental transfer [<xref ref-type="bibr" rid="R71">71</xref>, <xref ref-type="bibr" rid="R140">140</xref>, <xref ref-type="bibr" rid="R296">296</xref>, <xref ref-type="bibr" rid="R354">354</xref>]. In contrast, 6,&#x003b2;-naltrexol, is hydrophilic [<xref ref-type="bibr" rid="R374">374</xref>] and its placental transfer is likely to be minimal compared to naltrexone. Transfer of naltrexone and 6,&#x003b2;-naltrexol in human lactate is low with an estimated total relative infant dose of 1.06% in a 24 hour period. Moreover, whilst 1.1 ng/ml 6,&#x003b2;-naltrexol was detected in neonatal plasma, no naltrexone was identified [<xref ref-type="bibr" rid="R40">40</xref>].</p></sec><sec><label>2.3.4</label><title>Naltrexone and Neonatal Outcomes</title><p>Few data are available on the impact of oral or implantable naltrexone exposure and feto-maternal complications in pregnant humans [<xref ref-type="bibr" rid="R146">146</xref>, <xref ref-type="bibr" rid="R149">149</xref>, <xref ref-type="bibr" rid="R156">156</xref>-<xref ref-type="bibr" rid="R158">158</xref>]. Whilst all were co-authored by one of the contributors to this review (GKH), they include data from Australia, United Kingdom and Portugal and are the only publications on maternal and neonatal outcomes in humans following naltrexoneexposure during pregnancy. Australian cases were treated through the Australian Medical Procedures Research Foundation (AMPRF): until August 1999, oral naltrexone was only available in Western Australia (WA) from AMPRF. Clinic records indicate that 1196 patients had oral naltrexone maintenance between June 1997 and August 1999. A review of the first 300 patients indicated that 136 (45.3%) were females of reproductive age [<xref ref-type="bibr" rid="R150">150</xref>].</p><p>To January 2006, treatment files (AMPRF) indicated that 46 pregnant women treated with oral naltrexone had maintained contact with the clinic at time of birth (GKH, personal communication). Data on 10 cases treated with oral naltrexone in Australia, Portugal and United Kingdom indicate that outcomes of the seven births delivered at the time of study were generally unremarkable in terms of gestation age (between 38-40 weeks), good birth weight, head circumference, and APGAR scores. This was with the exception of one case in which the baby was induced at 36 weeks (resulting in low birth weight) due to maternal hypertension, and one other case of a baby weighing 2626 g at birth, born to a mother under 40 kg before conception and a father under 50 kg. Periodic foetal monitoring of the remaining three cases at the time showed normal development [<xref ref-type="bibr" rid="R158">158</xref>]. As the authors admit, the data may be biased since it only involved patients who maintained contact with the clinic, a factor which is known to improve outcome [<xref ref-type="bibr" rid="R221">221</xref>, <xref ref-type="bibr" rid="R228">228</xref>]. No post-birth follow-up has taken place on any infants exposed during pregnancy. There is no indication as to the outcome in those who failed to maintain contact.</p><p>To January 2006 in Western Australia, approximately 650 women of reproductive age, had undergone treatment with the GoMedical naltrexone implant and, of these, 43 pregnant women were in contact with the drug treatment clinic at the time of birth (GKH, personal communication). Similar to oral naltrexone, review of the first nine neonatal cases with exposure at different stages of pregnancy for different patients indicate that neonatal and obstetric outcome was unremarkable. Some statistics of interest were: half (4) of the case babies were delivered <italic>via</italic> spontaneous vaginal delivery, gestation age ranging between 37.5 and 41 weeks, birth weight between 2720 g and 3845 g, length 47-53cm, head circumference 31-35.3 cm, and 5-minute APGAR scores of at least 9 [<xref ref-type="bibr" rid="R146">146</xref>, <xref ref-type="bibr" rid="R156">156</xref>]. Again, these cases may be biased to more positive outcomes in patients who maintained contact with the drug treatment service. Taken together, the reports suggest no adverse effects on neonates from naltrexone exposure during pregnancy in humans. </p></sec><sec><label>2.3.5</label><title>Implantable Naltrexone Versus Methadone Maintenance</title><p>Obstetric and neonatal outcomes in a sequential cohort of seventeen of the above 43 heroin-dependent pregnant women managed by naltrexone implant have been compared with ninety women receiving MMT [<xref ref-type="bibr" rid="R157">157</xref>]. Following MMT,deliveries prior to 37 weeks (24%) and low birthweight (&#x0003c;2500 g, 23%) were both significantly greater (p&#x0003c;0.001) compared to Australian national data for the normal population (delivery prior to 37 weeks: 5.6%; birthweight&#x0003c;2500 g: 4.6%) [<xref ref-type="bibr" rid="R317">317</xref>]. By contrast, there was no significant difference between naltrexone implant-managed women (delivery prior to 37 weeks: 5.9%; birthweight&#x0003c;2500 g: 11.7%) when compared to National data [<xref ref-type="bibr" rid="R157">157</xref>]. In addition, the difficulty of adjusting to extra-uterine life for babies born to mothers receiving MMT was indicated by significantly worse one minute APGAR scores compared to infants of mothers treated with a naltrexone implant (p&#x0003c;0.005). However, the lack of significance with regards to adverse neonatal effects from naltrexone exposure during pregnancy could be a consequence of limited statistical power from the small sample size of 17.</p></sec></sec></sec><sec><label>3</label><title>ANIMAL STUDIES</title><p>To appropriately reflect the clinical situation of drug use during pregnancy, a number of factors need to be considered in animals studies. First, due to interspecies differences in pharmacokinetics, delivering a clinically comparable drug dosage in animal studies is not simply a case of using relative dose-to-weight ratio, but requires consideration of blood levels, duration of drug retention, and fluctuation from repeated dosing. In comparison to humans, where drug fluctuations tend to be minimal and blood levels are maintained within the therapeutic range [<xref ref-type="bibr" rid="R164">164</xref>], laboratory animals generally have a much higher rate of drug elimination [<xref ref-type="bibr" rid="R278">278</xref>], and produce a series of narrow and high-drug concentration peaks. Although peak plasma drug concentrations can be matched between animals and humans, the duration of clinically relevant blood levels is often harder to control [<xref ref-type="bibr" rid="R162">162</xref>, <xref ref-type="bibr" rid="R164">164</xref>]. Second, the route of administration, and whether it is delivered maternally or directly to the offspring, will also influence the extent of offspring exposure. Therefore, the dose, route of administration, and the total exposure (reflected by the area under the concentration-time curve) should be assessed [<xref ref-type="bibr" rid="R168">168</xref>, <xref ref-type="bibr" rid="R278">278</xref>]. Third, interspecies differences in parameters such as the onset, duration and intensity of tolerance, withdrawal, stress, and ontogenic response to a given dose of drug may also account for differences between human and animal offspring development [<xref ref-type="bibr" rid="R168">168</xref>, <xref ref-type="bibr" rid="R408">408</xref>, <xref ref-type="bibr" rid="R409">409</xref>]. </p><p>Fourth, the period of exposure during development will influence outcome. Different species have different absolute developmental timetables. Nevertheless, mammals develop to a relative common timetable defined by the caecal period, namely the length of time from conception to eye-opening [<xref ref-type="bibr" rid="R77">77</xref>, <xref ref-type="bibr" rid="R322">322</xref>]. In humans eye-opening occurs during the third trimester (182 days), but in rat occurs ~2 weeks after birth (gestation = 21 days), i.e. at post-conceptional day 36 days [<xref ref-type="bibr" rid="R59">59</xref>]. For example, the corpus callosum in rat appears at 18.5 days post-conception, and in humans appears at 87.5 days post-conception, respectively corresponding with 51% and 48% of the caecal period [<xref ref-type="bibr" rid="R59">59</xref>]. Likewise, the end of rapid axon loss in the nervous system of rats occurs at day 27 post-conception, and in humans at 136 days, which both correspond to 75% of the caecal period [<xref ref-type="bibr" rid="R77">77</xref>].</p><p>Fifth, when using animal models to study the direct, biological effects of a drug on development, it is desirable to control for potential indirect drug effects. For example, deprivation of nutrition has a profound effect on development and may result from a number of factors related to drug exposure, such as drug-induced appetite suppression, nutritional value of the milk and maternal behaviour [<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R99">99</xref>, <xref ref-type="bibr" rid="R168">168</xref>, <xref ref-type="bibr" rid="R408">408</xref>]. Prenatal drug manipulations of pregnant rats can modify maternal behaviour and so affect developmental parameters in offspring. These include circadian rhythms, milk consumption, activity level, heart rates, oxygen intake and growth hormone [<xref ref-type="bibr" rid="R168">168</xref>]. The effects can be controlled for prenatally by introducing a pair-fed control group, which involves matching the food consumption to that of the experimental group [<xref ref-type="bibr" rid="R162">162</xref>]; postnatally, drug-induced maternal effects can be isolated by cross-fostering [<xref ref-type="bibr" rid="R162">162</xref>], involving transfer of offspring from drug treated-mothers to non-treated mothers, and <italic>vice-versa</italic> [<xref ref-type="bibr" rid="R121">121</xref>]. Furthermore, in animals which typically birth multiple offspring, a drug may affect litter size, which would alter sibling competition with, for example, larger litter sizes decreasing nutritional distribution during gestation and lactation; a small litter size is also sub-optimal for offspring nutritional intake as reduced suckling limits maternal milk production and sustenance [<xref ref-type="bibr" rid="R173">173</xref>, <xref ref-type="bibr" rid="R271">271</xref>, <xref ref-type="bibr" rid="R287">287</xref>]. Such effects can be overcome by culling to an optimal litter size which in rat, for example, is 8-10 pups.</p><sec><label>3.1</label><title>Methadone</title><sec><label>3.1.1</label><title>Doses, Metabolism and Transfer</title><p>In humans, daily oral methadone dosing, combined with the long terminal half-life (24 h), avoids withdrawal syndrome and results in continuous exposure of the neonate. However, in the pregnant rat, methadone metabolism is rapid (terminal half-life: 3-5 hours) and once-daily dosing can result in daily maternal and offspring withdrawal [<xref ref-type="bibr" rid="R163">163</xref>]. To achieve clinically relevant blood levels (150-500 ng/ml) [<xref ref-type="bibr" rid="R101">101</xref>, <xref ref-type="bibr" rid="R135">135</xref>] in rats, a daily oral dose of approximately 12.5 mg/kg is required [<xref ref-type="bibr" rid="R166">166</xref>]. However, in most studies (Table <bold><xref ref-type="table" rid="T2">2</xref></bold>), a daily dose of 5 mg/kg of methadone was administered maternally, indicating an apparent &#x0201c;under-dosing&#x0201d;. However, compared to the clinical situation of oral dosing, intraperitoneal injections were used which result in high plasma levels, as first-pass hepatic metabolism is evaded. Furthermore, intraperitoneal injections can result in extraplacental transfer directly from the peritoneal cavity to fetal tissues and fluids [<xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R300">300</xref>], which may account for increased exposure compared to other routes of administration. Nonetheless, in rat, methadone crosses the placenta, enters the fetal circulation [<xref ref-type="bibr" rid="R166">166</xref>] and transfers to the lactate [<xref ref-type="bibr" rid="R409">409</xref>]. However, in most studies, blood plasma levels were not reported and interspecies differences in the rate of metabolism of methadone means that it is hard to replicate fetal plasma exposure found in humans [<xref ref-type="bibr" rid="R105">105</xref>, <xref ref-type="bibr" rid="R107">107</xref>, <xref ref-type="bibr" rid="R233">233</xref>]. Regardless, ontogenesis in rat is affected by a sub-therapeutically relevant dose (5 mg/kg) of methadone (Table <bold><xref ref-type="table" rid="T2">2</xref></bold>).</p></sec><sec><label>3.1.2</label><title>Effects on Offspring: Growth and Brain Development</title><p>Decreased birthweights found in humans are consistent with animal studies which report that gestational methadone exposure reduces growth [<xref ref-type="bibr" rid="R99">99</xref>, <xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R256">256</xref>, <xref ref-type="bibr" rid="R410">410</xref>]. An early study on maternally administered methadone (10-13 mg/kg/day) in primates showed significantly reduced birthweights in the offspring [<xref ref-type="bibr" rid="R135">135</xref>]. In rat, a number of deleterious effects are associated with perinatal methadone exposure including increased mortality of mothers [<xref ref-type="bibr" rid="R167">167</xref>] and offspring [<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R408">408</xref>], as well as low birthweights and growth retardation [<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R257">257</xref>, <xref ref-type="bibr" rid="R408">408</xref>]. Prenatal methadone also delays the initial onset of various physical characteristics in rats, such as the appearance of hair and opening of the vagina, eyes and ears [<xref ref-type="bibr" rid="R103">103</xref>, <xref ref-type="bibr" rid="R253">253</xref>, <xref ref-type="bibr" rid="R383">383</xref>, <xref ref-type="bibr" rid="R412">412</xref>].</p><p>The inhibitory growth effects are, to a certain extent dose-dependent [<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R166">166</xref>, <xref ref-type="bibr" rid="R420">420</xref>], and influence the animals as a whole as well as individual organs, with some being affected more than others [<xref ref-type="bibr" rid="R257">257</xref>]. In particular, the central nervous system (CNS) is a sensitive target [<xref ref-type="bibr" rid="R409">409</xref>, <xref ref-type="bibr" rid="R428">428</xref>]. Adverse effects include reduced brain size and weight, decreases in cell density and total cell number, as well as neurochemical alterations (Table <bold><xref ref-type="table" rid="T2">2</xref></bold>). In particular, there are consistent decreases in protein, DNA, RNA and neurotransmitter content (serotonin, dopamine, norepinephrine) [<xref ref-type="bibr" rid="R87">87</xref>, <xref ref-type="bibr" rid="R145">145</xref>, <xref ref-type="bibr" rid="R253">253</xref>, <xref ref-type="bibr" rid="R301">301</xref>, <xref ref-type="bibr" rid="R344">344</xref>], enzymatic protein levels (tyrosine hydroxylase, acetylcholine-esterase, choline acetyltransferase, ornithine decarboxylase) [<xref ref-type="bibr" rid="R87">87</xref>, <xref ref-type="bibr" rid="R224">224</xref>, <xref ref-type="bibr" rid="R327">327</xref>, <xref ref-type="bibr" rid="R338">338</xref>, <xref ref-type="bibr" rid="R342">342</xref>, <xref ref-type="bibr" rid="R343">343</xref>], and receptor expression (&#x003b2;-adrenergic) [<xref ref-type="bibr" rid="R66">66</xref>]. Moreover, some of these effects are region-specific and age-dependent; for example, norepinephrine content has been found to decrease in the forebrain but not the hindbrain [<xref ref-type="bibr" rid="R253">253</xref>], and whilst acetylcholine-esterase levels following prenatal methadone exposure are normal at birth, they are reduced at 21-days postnatal [<xref ref-type="bibr" rid="R87">87</xref>]. Acetylcholine, enkephalin and nerve growth factor are also reduced at birth following exposure during pregnancy [<xref ref-type="bibr" rid="R123">123</xref>, <xref ref-type="bibr" rid="R319">319</xref>, <xref ref-type="bibr" rid="R366">366</xref>, <xref ref-type="bibr" rid="R399">399</xref>].</p></sec><sec><label>3.1.3</label><title>Effects on Offspring: Behaviour</title><p>Methadone during prenatal development affects postnatal behaviour. The withdrawal syndrome has been observed in newborn rat offspring following maternal treatment with an osmotic minipump throughout pregnancy; NAS was precipitated by a challenge of the opioid antagonist, naltrexone and observed as increased motor activity and vocalisation [<xref ref-type="bibr" rid="R13">13</xref>]. Neonatal abstinence syndrome was also associated with alterations in the latency of visually evoked potentials [<xref ref-type="bibr" rid="R305">305</xref>]. Young and mature adult offspring also displayed increased withdrawal-like symptoms in comparison to control animals, such as head and body shakes [<xref ref-type="bibr" rid="R416">416</xref>].</p><p>Prenatal exposure to methadone also delayed development of reflex and motor coordination [<xref ref-type="bibr" rid="R253">253</xref>, <xref ref-type="bibr" rid="R383">383</xref>, <xref ref-type="bibr" rid="R412">412</xref>]. In most studies, there was an initial decrease in open field ambulation and exploration in rat offspring up to 45 days postnatal [<xref ref-type="bibr" rid="R103">103</xref>, <xref ref-type="bibr" rid="R122">122</xref>, <xref ref-type="bibr" rid="R253">253</xref>, <xref ref-type="bibr" rid="R261">261</xref>, <xref ref-type="bibr" rid="R383">383</xref>, <xref ref-type="bibr" rid="R436">436</xref>]. Conversely, there was a consistent increase in open-field activity in rat offspring after 45 days postnatal [<xref ref-type="bibr" rid="R122">122</xref>, <xref ref-type="bibr" rid="R347">347</xref>, <xref ref-type="bibr" rid="R436">436</xref>]. </p><p>Methadone exposure during pregnancyhas also been found to affect analgesic responses later in life, although the effect has been variable; some studies report an increase [<xref ref-type="bibr" rid="R414">414</xref>, <xref ref-type="bibr" rid="R415">415</xref>, <xref ref-type="bibr" rid="R417">417</xref>, <xref ref-type="bibr" rid="R426">426</xref>] and another a decrease [<xref ref-type="bibr" rid="R143">143</xref>, <xref ref-type="bibr" rid="R416">416</xref>]. Moreover, the analgesic effects of drugs, such as amphetamine and methadone, were greater in methadone-exposed offspring [<xref ref-type="bibr" rid="R415">415</xref>, <xref ref-type="bibr" rid="R426">426</xref>]. There was also an increased propensity to self-administer oral morphine [<xref ref-type="bibr" rid="R144">144</xref>, <xref ref-type="bibr" rid="R261">261</xref>]. Furthermore, decreased latency to step down from a platform could indicate increased anxiety [<xref ref-type="bibr" rid="R436">436</xref>]. Consistent with human studies, memory and learning tests revealed poorer cognitive skills [<xref ref-type="bibr" rid="R372">372</xref>, <xref ref-type="bibr" rid="R413">413</xref>, <xref ref-type="bibr" rid="R437">437</xref>]. Another study demonstrated that decreased discrimination learning was dependent on the period of methadone exposure; rats exposed prenatally or postnatally displayed an effect, those exposed both pre- and post-natally showed none [<xref ref-type="bibr" rid="R372">372</xref>].</p></sec></sec><sec><label>3.2</label><title>Buprenorphine </title><p>Animal studies of the ontogenic effects of buprenorphine are relatively limited in comparison to more extensive studies on the effects of methadone or naltrexone. The pharmacokinetics of buprenorphine in pregnant rats is yet to be investigated.</p><sec><label>3.2.1</label><title>Effects on Offspring: Growth and Brain Development</title><p>Maternal exposure to buprenorphine (0.67-2 mg/kg) during pregnancy results in an increase in offspring mortality within 6 days of birth [<xref ref-type="bibr" rid="R83">83</xref>, <xref ref-type="bibr" rid="R320">320</xref>, <xref ref-type="bibr" rid="R366">366</xref>], whilst resorptions were unaffected [<xref ref-type="bibr" rid="R165">165</xref>]. In contrast to methadone, buprenorphine increases the duration of gestation [<xref ref-type="bibr" rid="R83">83</xref>]. It is unclear what impact prenatal buprenorphine (0.07 or 0.67 mg/kg/day) has on birthweight with one study reporting no effect [<xref ref-type="bibr" rid="R165">165</xref>], and another a decrease [<xref ref-type="bibr" rid="R83">83</xref>]. However, prenatal exposure to buprenorphine results in decreased postnatal weight gain [<xref ref-type="bibr" rid="R320">320</xref>].</p><p>There are more data on biochemical and protein changes following prenatal exposure to buprenorphine (Table <bold><xref ref-type="table" rid="T3">3</xref></bold>). &#x003bc;-opioid receptor expression is down-regulated in newborn rat offspring [<xref ref-type="bibr" rid="R19">19</xref>], but this effect is transient and diminishes by postnatal day 7 [<xref ref-type="bibr" rid="R20">20</xref>]. Whilst these effects were associated with low doses of buprenorphine (0.15-0.5 mg/kg/day), a higher dose (2.5 mg/kg/day) resulted in &#x003ba;-opioid receptors up-regulation in neonatal offspring [<xref ref-type="bibr" rid="R19">19</xref>]. In both studies, the ligand binding affinities (Kd) for &#x003bc;- and &#x003ba;-opioid receptors were unaffected. However, in 2-day-old offspring exposed to buprenorphine prenatally, receptor function is diminished, as evidenced by decreased coupling activity of the stimulatory G-protein following agonist stimulation of &#x003bc;- (ventral tegmental area) and N/OFQ-opioid receptors (lateral septum and nucleus accumbens), [<xref ref-type="bibr" rid="R141">141</xref>]. The decline in receptor activity was transient, diminishing by postnatal day 7, and a gender related difference was reported, with males having greater decreases in receptor function. </p><p>Prenatal buprenorphine exposure also results in a decrease in choline acetyltransferase mRNA in postnatal offspring [<xref ref-type="bibr" rid="R318">318</xref>] although striatal mRNA levels for the &#x003bc;-, &#x003b4;- and &#x003ba;-opioid receptors are unaffected [<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R366">366</xref>]. Administration of 0.3 mg/kg of buprenorphine during gestation resulted in a decrease of striatal acetylcholine content in 4 day old rat offspring, although there was an overshoot with greater levels than controls at 21 days [<xref ref-type="bibr" rid="R319">319</xref>]. However, treatment with a higher dose (3 mg/kg) decreased striatal acetylcholine content in both 4- and 21-day-old rat offspring. Prenatal buprenorphine does not affect NGF mRNA levels in postnatal day 10 [<xref ref-type="bibr" rid="R318">318</xref>] although striatal NGF content was decreased [<xref ref-type="bibr" rid="R318">318</xref>, <xref ref-type="bibr" rid="R321">321</xref>]. </p><p>The effects of postnatal exposure have also been investigated, but the studies are few and did not show significant effects [<xref ref-type="bibr" rid="R165">165</xref>, <xref ref-type="bibr" rid="R169">169</xref>]. Due to the mixed agonist-antagonist action of buprenorphine, translation of its mechanism of action has been limited because of the following: 1) the pharmacokinetics of buprenorphine in the pregnant rat, or any other animal, does not appear to have been evaluated; 2) the ontogenic role of the &#x003ba;-opioid receptor requires clarification, as does the pharmacological action of buprenorphine at this receptor; and 3) levels change during each 24 hour cycle of a daily dosing regime; initial high doses result in antagonism at the &#x003bc;-opioid receptor and later low doses result in agonist action. Presumably, during each 24 hour period, the developmental effects would alternate as blood levels fluctuate. Avoidance of fluctuating levels using constant infusion may help to separate the agonist/antagonist effects of buprenorphine. However, such studies would be difficult during lacation because maternal delivery <italic>via</italic> the milk would also fluctuate; furthermore, constant infusion in neonatal rats is difficult. Differential impact on receptor expression has been demonstrated with up-regulation of &#x003ba;- and &#x003b4;-opioid receptors and down-regulation of &#x000b5;-opioid receptors from daily intraperitoneal injections &#x02265;0.5 mg/kg during the postnatal period [<xref ref-type="bibr" rid="R18">18</xref>]. Gestational exposure was shown to have similar effect on &#x003ba;- and &#x000b5;-opioid receptors, when evaluated at the time of birth [<xref ref-type="bibr" rid="R19">19</xref>]. These effects are similar to that expected from methadone at &#x003bc;-opioid receptors, although with less efficacy, and similar to naltrexone at the kappa-opioid receptor. It is unknown what effect buprenorphine has on the &#x003b6;-opioid receptor; considering the significance of this receptor&#x02019;s role in ontogenesis, this warrants further investigation. </p></sec><sec><label>3.2.2</label><title>Effects on Offspring: Behaviour</title><p>Following buprenorphine exposure, a number of behavioural changes are detected including decreased sensitivity to morphine, increased morphine-withdrawal and an earlier onset of the righting reflex, as well as a delayed ear opening [<xref ref-type="bibr" rid="R320">320</xref>]. A gender-related difference in preference for saccharine is diminished following offspring exposure to prenatal buprenorphine [<xref ref-type="bibr" rid="R14">14</xref>], although rest-activity was unaffected [<xref ref-type="bibr" rid="R165">165</xref>]. The effects could be explained by parental behaviour (i.e. pup retrieval, grooming and hovering/crouching over the pups), being impaired during the prenatal or postnatal period [<xref ref-type="bibr" rid="R14">14</xref>].</p></sec></sec><sec><label>3.3</label><title>Naltrexone </title><p>While the initial clinical data may appear to provide some evidence that outcomes associated with both implant and oral naltrexone may be as good, if not better, than observed with methadone, research data from animal work raises concern.</p><sec><label>3.3.1</label><title>Doses, Metabolism and Transfer</title><p>In rat, naltrexone is metabolised to 6,&#x003b2;-naltrexol and the minor metabolites <italic>via</italic> the same metabolic pathways [<xref ref-type="bibr" rid="R380">380</xref>]. The elimination half-life is 4.6 hours [<xref ref-type="bibr" rid="R402">402</xref>] being very similar to human (4 h). However, relative to naltrexone, small amounts of 6,&#x003b2;-naltrexol are found in rat plasma and urine, whereas significant quantities are found in humans [<xref ref-type="bibr" rid="R240">240</xref>]. Notwithstanding the difference, naltrexone-plasma levels of 2 ng/ml in rat have been shown to block the analgesic effects of morphine (plasma concentration: &#x0003e;1000 ng/ml) [<xref ref-type="bibr" rid="R402">402</xref>], which parallels the pharmacodynamic efficacy of naltrexone in humans [<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R181">181</xref>]. </p><p>Most experiments used high doses of naltrexone (50 mg/kg/day) that are above those used clinically and may, therefore, be misleading. Naltrexone levels which affect development are reportedly small (0.05-2.5% of the LD<sub>50</sub> in adult rats) [<xref ref-type="bibr" rid="R428">428</xref>]. With an LD<sub>50</sub> of approximately 2000 mg/kg in adult rats [<xref ref-type="bibr" rid="R31">31</xref>, <xref ref-type="bibr" rid="R439">439</xref>], the dosages required to induce and effect in rats are 1-50 mg/kg, with 1 mg/kg considered a low dose (Table <bold><xref ref-type="table" rid="T5">5</xref></bold>), and 50 mg/kg a high dose (Table <bold><xref ref-type="table" rid="T4">4</xref></bold>) [<xref ref-type="bibr" rid="R425">425</xref>]. </p><p>Naltrexone transfer across the placenta has been established in rats [<xref ref-type="bibr" rid="R406">406</xref>, <xref ref-type="bibr" rid="R407">407</xref>]. Naltrexone has not yet been measured in rat lactate. However, since naltrexone transfer to milk has been confirmed in humans and sheep, it is presumed that transfer into rat milk will also occur. Indeed, naltrexone has been detected in the blood of 4-week-old offspring when naltrexone was only delivered maternally<sup><xref ref-type="fn" rid="FN1">1</xref></sup>, suggesting that it is indeed transferred to the rat lactate and can therefore affect development after birth [<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R40">40</xref>].</p></sec><sec><label>3.3.2</label><title>Effects on Offspring: Growth and Brain Development</title><p>The effects of naltrexone on growth are somewhat opposite to the suppression following prenatal exposure to methadone and other opioids [<xref ref-type="bibr" rid="R161">161</xref>, <xref ref-type="bibr" rid="R223">223</xref>, <xref ref-type="bibr" rid="R345">345</xref>, <xref ref-type="bibr" rid="R421">421</xref>]. A number of studies indicate increased body weight and length and also increased dry and wet weights of body organs including the brain [<xref ref-type="bibr" rid="R254">254</xref>, <xref ref-type="bibr" rid="R255">255</xref>, <xref ref-type="bibr" rid="R442">442</xref>]. However, an increased level of complexity is that the effects of naltrexone on growth can be either stimulatory or inhibitory depending on the dose and its duration [<xref ref-type="bibr" rid="R423">423</xref>, <xref ref-type="bibr" rid="R425">425</xref>, <xref ref-type="bibr" rid="R428">428</xref>, <xref ref-type="bibr" rid="R430">430</xref>], a scenario that is likely in the clinical setting. However, in these studies, blood plasma concentrations were not measured and have to be inferred from the dose regime. For example, in rat, daily administration of a high dose (50 mg/kg) of naltrexone, ensures continuous blockade of receptors and results in accelerated growth (Table <bold><xref ref-type="table" rid="T4">4</xref></bold>). In contrast, daily administration of a low dose (1 mg/kg) blocks receptors temporarily because the agent is eliminated before dosing the next day; this intermittent blockade has been associated with inhibition of growth (Table <bold><xref ref-type="table" rid="T5">5</xref></bold>). The inhibitory effect is similar to that seen following developmental exposure to an opioid agonist, such as morphine or methadone [<xref ref-type="bibr" rid="R431">431</xref>]. However, some studies adhering to similar dosing regimens report no effect [<xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R137">137</xref>, <xref ref-type="bibr" rid="R302">302</xref>], a discrepancy which has yet to be clarified.</p><p>Nevertheless, the duration of opioid receptor blockade appears to be more important in modulating development rather than its actual dose [<xref ref-type="bibr" rid="R425">425</xref>]. Multiple doses of naltrexone (3 mg/kg three times per day), which ensure continuous receptor blockade, accelerates body and brain development. By contrast, a single cumulatively equivalent dose (9 mg/kg once per day), which induces intermittent receptor blockade, has an inhibitory effect [<xref ref-type="bibr" rid="R425">425</xref>]. </p><p>Intermittent blockade by antagonists can exert its effects <italic>via</italic> a mechanism termed <italic>supersensitivity</italic>, which is characterised by accentuation in receptor expression and function [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R335">335</xref>, <xref ref-type="bibr" rid="R428">428</xref>]. In the absence of activation, alterations in receptor structure can result in a change to a high agonist affinity state [<xref ref-type="bibr" rid="R309">309</xref>, <xref ref-type="bibr" rid="R445">445</xref>]. In the high affinity state, a dose which previously elicited a response of a particular magnitude may induce a response of a much greater magnitude due to the higher incidence of binding and subsequent receptor activation. An increase in the number of opioid receptor binding sites also contributes to a higher incidence of binding and hence, supersensitivity to opioids [<xref ref-type="bibr" rid="R423">423</xref>, <xref ref-type="bibr" rid="R428">428</xref>, <xref ref-type="bibr" rid="R431">431</xref>]. Supersensitivity can also be associated with increased endogenous agonist levels and/or increased affinity, and/or efficacy of the receptor-agonist complex. Indeed, opioid antagonists are also known to increase the levels of endogenous opioids, such as &#x003b2;-endorphin [<xref ref-type="bibr" rid="R429">429</xref>]. Thus, compared to normal, in a supersensitive state, basal or elevated endogenous opioid levels can exert a greater inhibitory action, manifested by a reduced rate of cell proliferation and growth [<xref ref-type="bibr" rid="R428">428</xref>].</p><p>Experimental studies have yet to investigate the developmental effects of naltrexone delivered as a sustained-release implant or depot. GoMedical implants release approximately 220 &#x003bc;g/kg/day in humans and achieve plasma levels of 2-10 ng/ml [<xref ref-type="bibr" rid="R147">147</xref>-<xref ref-type="bibr" rid="R149">149</xref>]. The amount released is 4-5 times lower than the minimum dose that is thought to affect development and it is not yet known whether naltrexone delivered in this way will have an effect, an issue that warrants investigation. Nevertheless, one study showed that continuous naltrexone exposure (10 mg/kg/day <italic>via</italic> osmotic mini-pump) during the pre- and post-natal period resulted in increased thickness of the cerebral cortex and decreased, packing density although cortical cell number remained the same [<xref ref-type="bibr" rid="R337">337</xref>]. In contrast to accelerated growth from continuous prenatal exposure, it is hypothesised that, during the postnatal period, a maternally administered sustained-release naltrexone implant will do the opposite compared to intrauterine exposure, i.e. offspring will be exposed intermittently during feeding from the mother. Furthermore, as tolerance is not observed with naltrexone exposure [<xref ref-type="bibr" rid="R204">204</xref>, <xref ref-type="bibr" rid="R266">266</xref>, <xref ref-type="bibr" rid="R376">376</xref>], it is hypothesised that the resulting developmental effects would be influenced by the developmental phase taking place during exposure with differential opioid receptor expression playing a crucial role [<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R132">132</xref>].</p><p>Whilst developmental studies on naltrexone&#x02019;s effect on neurochemistry are sparse, daily injections (50 mg/kg) of rat pups had variable effects on NGF, with decreases in cerebellum and increases in the hippocampus [<xref ref-type="bibr" rid="R268">268</xref>]. Exposure to 1 mg/kg also decreased NGF content in hippocampus, septum and neostriatum whereas 50 mg/kg had no effect on NGF content but decreased the number of NGF high affinity binding sites [<xref ref-type="bibr" rid="R298">298</xref>]. A lower dose (1 mg/kg) administered to pups from birth until day 21 decreased striatal and hippocampal serotonin levels in adulthood [<xref ref-type="bibr" rid="R379">379</xref>], following an increase in striatal serotonin at 22 days postnatal [<xref ref-type="bibr" rid="R63">63</xref>].</p></sec><sec><label>3.3.3</label><title>Effects on Offspring: Behaviour</title><p>Behavioural differences are manifested at the cellular level by alterations in excitability and changes in the morphology and connectivity [<xref ref-type="bibr" rid="R348">348</xref>]. Daily injections into pregnant rats result in changed behaviour of offspring after birth, for example, decreased grooming, ambulation and defecation [<xref ref-type="bibr" rid="R254">254</xref>, <xref ref-type="bibr" rid="R255">255</xref>, <xref ref-type="bibr" rid="R442">442</xref>]. The effects of gestational and/or postnatal exposure to naltrexone on behaviour have been explored [<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R48">48</xref>, <xref ref-type="bibr" rid="R65">65</xref>, <xref ref-type="bibr" rid="R131">131</xref>, <xref ref-type="bibr" rid="R202">202</xref>, <xref ref-type="bibr" rid="R255">255</xref>, <xref ref-type="bibr" rid="R258">258</xref>, <xref ref-type="bibr" rid="R297">297</xref>, <xref ref-type="bibr" rid="R427">427</xref>, <xref ref-type="bibr" rid="R438">438</xref>]. Daily exposure to 50 mg/kg during the pre-weaning period accelerates the development of spontaneous motor and sensorimotor behaviours, namely initial appearance and the age at which 100% of the animals demonstrate a particular behaviour [<xref ref-type="bibr" rid="R255">255</xref>]. In contrast, daily exposure to 1 mg/kg delayed the initiation of developmental events such as ear opening, eye opening and walking. Whilst control and 1 mg/kg naltrexone groups are comparable in motor activity at 21 days, an increase of 32% in activity was recorded in animals of the 50 mg/kg group [<xref ref-type="bibr" rid="R427">427</xref>]. Mice administered with 10 mg/kg twice daily through-out gestation and lactation reared offspring who displayed increased locomotor activity in adulthood [<xref ref-type="bibr" rid="R258">258</xref>].</p><p>Naltrexone exposure during gestation and the post-weaning period decreased the sensitivity of the offspring to the analgesic effects of morphine [<xref ref-type="bibr" rid="R131">131</xref>, <xref ref-type="bibr" rid="R297">297</xref>, <xref ref-type="bibr" rid="R438">438</xref>]. Only one study has examined the behavioural effects of sustained-release naltrexone (<italic>via</italic> a minipump; 10 mg/kg/day), starting on day 17 of gestation [<xref ref-type="bibr" rid="R202">202</xref>]. As prenatal stress was included as a treatment in this paradigm, only a few independent effects of naltrexone on the offspring were identified. These included increased anxiety, decreased preference for saccharin and decreased sensitivity to pain. Increased anxiety and emotionality was found in another study exploring conditioned emotional response, although exposure to naltrexone was <italic>via</italic> daily maternal administration of 1 mg/kg throughout gestation [<xref ref-type="bibr" rid="R131">131</xref>]. Other behavioural effects of naltrexone exposure during development include facilitation of male sex behaviour as indicated by a shorter mount time [<xref ref-type="bibr" rid="R48">48</xref>], and reduced food intake after 14 days of postnatal exposure [<xref ref-type="bibr" rid="R8">8</xref>]. Another study in sheep showed that acute naltrexone administration (1.5 or 3 mg/kg, intrapeitoneal) within 24 hours of birth prevented lambs from recognising their mother, suggesting an interruption of bonding <italic>via</italic> the opioid reward system [<xref ref-type="bibr" rid="R340">340</xref>].</p></sec></sec></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Studies in humans to date have shown that MMT during pregnancy is associated with a number of adverse neonatal effects, including reduced birth-weight and the incidence of NAS. However, the negative outcomes associated with MMT outweigh the detrimental effects associated with heroin use during pregnancy, although whether these benefits are due to MMT or to improved psychosocial stability needs clarification through well-controlled randomised trials. There are an abundance of data from animal pregnancy studies that reflect many of the adverse effects seen in humans, many of which have involved clinically applicable dosing regimens. However, various aspects of MMT, such as the potential benefits of split-dosing and breast feeding to treat NAS have received little attention in animal research and warrant elucidation. </p><p>Buprenorphine has arisen more recently as an alternative treatment for the pregnant addict and there is evidence to suggest a number of advantages over MMT, such as a reduced incidence and severity of NAS. However, both human and animal data are limited. Moreover, notwithstanding the complexity of interpreting the developmental effects of a partial agonist, both human and animal studies have highlighted detrimental neonatal outcomes. In particular, the differential pharmacological activity, which is dependent upon dose, needs to be investigated in terms of ontogeny, to determine which regimen offers optimal outcomes for the newborn.</p><p>An even more novel approach for treating the pregnant heroin user, using naltrexone, offers the advantage of evading withdrawal in the newborn and is accounted for by its lack of agonist activity. The advent of administering naltrexone as a sustained-release implantable preparation has resulted in an increase in the frequency of inadvertent exposure of the neonate to naltrexone. Nonetheless, based on human data, this mode of delivery is promising as early indications suggest an absence of detrimental neonatal outcomes, although the work urgently requires validation. Moreover, animal research, examining oral or injected naltrexone, has demonstrated that the developing neonate is affected following gestational exposure. The sustained-release implant described for use in humans results in chronic and low-dose exposure, a regimen which has yet to be applied in animal studies. Since animal studies using other dosing regimens raise concern, research on the sustained-release preparation is also necessary.</p><p>Pregnancy remains a unique situation where very important and considerable ethical judgment is required when commenting on pharmacological treatment and more animal data should be made available to determine which pharmacotherapy provides the optimal neonatal outcomes. Given the detrimental impact of illicit drug use during pregnancy, investigation of pharmacological treatment during pregnancy is very important, urgently needed and appropriate further investigation should be undertaken.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>SAD is a Senior Research Fellow (NH&#x00026;MRC; ID: 254679). The work was supported by the Australian Children&#x02019;s Trust.</p></ack><fn-group><fn id="FN1"><label>1</label><p>Farid, W.O., Tait, R.J., Hulse, G.K., Dunlop, S.A. (2006) The effects of maternally administered methadone and naltrexone on the developing brain (Poster Abstract).<italic>Proceedings of the Australian Neuroscience Society: 26th Annual Meeting,</italic><bold>17,</bold> 76.</p></fn></fn-group><glossary><title>ABBREVIATIONS</title><def-list><def-item><term id="A1">AMPRF</term><def><p>= Australian Medical Procedures Research Foundation</p></def></def-item><def-item><term id="A2">BBB</term><def><p>= Blood brain barrier</p></def></def-item><def-item><term id="A3">CYP</term><def><p>= cytochrome P<sub>450</sub></p></def></def-item><def-item><term id="A4">EDDP</term><def><p>= 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine</p></def></def-item><def-item><term id="A5">EMDP</term><def><p>= 2-ethyl-5-methy-3,3-diphenyl-pyrroline</p></def></def-item><def-item><term id="A6">FDA</term><def><p>= Food and Drug Administration</p></def></def-item><def-item><term id="A7">MMT</term><def><p>= methadone maintenance treatment</p></def></def-item><def-item><term id="A8">NAS</term><def><p>= neonatal abstinence syndrome</p></def></def-item><def-item><term id="A9">OGFr</term><def><p>= opioid growth factor receptor</p></def></def-item><def-item><term id="A10">TGA</term><def><p>= Therapeutic Goods Administration</p></def></def-item><def-item><term id="A11">VEP</term><def><p>= visual evoked potential</p></def></def-item><def-item><term id="A12">WA</term><def><p>= Western Australia</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Latif</surname><given-names>ME</given-names></name><name><surname>Pinner</surname><given-names>J</given-names></name><name><surname>Clews</surname><given-names>S</given-names></name><name><surname>Cooke</surname><given-names>F</given-names></name><name><surname>Lui</surname><given-names>K</given-names></name><name><surname>Oei</surname><given-names>J</given-names></name></person-group><article-title>Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers</article-title><source>Pediatrics</source><year>2006</year><volume>117</volume><fpage>e1163</fpage><lpage>1169</lpage><pub-id pub-id-type="pmid">16740817</pub-id></citation></ref><ref id="R2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>MH</given-names></name></person-group><article-title>Detoxification considerations in the medical management of substance abuse in pregnancy</article-title><source>Bull. N. Y. Acad. Med</source><year>1991</year><volume>67</volume><fpage>270</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">1868278</pub-id></citation></ref><ref id="R3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amass</surname><given-names>L</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name><name><surname>Freese</surname><given-names>TE</given-names></name><name><surname>Reiber</surname><given-names>C</given-names></name><name><surname>Annon</surname><given-names>JJ</given-names></name><name><surname>Cohen</surname><given-names>AJ</given-names></name><name><surname>McCarty</surname><given-names>D</given-names></name><name><surname>Reid</surname><given-names>MS</given-names></name><name><surname>Brown</surname><given-names>LS</given-names></name><name><surname>Clark</surname><given-names>C</given-names></name><name><surname>Ziedonis</surname><given-names>DM</given-names></name><name><surname>Krejci</surname><given-names>J</given-names></name><name><surname>Stine</surname><given-names>S</given-names></name><name><surname>Winhusen</surname><given-names>T</given-names></name><name><surname>Brigham</surname><given-names>G</given-names></name><name><surname>Babcock</surname><given-names>D</given-names></name><name><surname>Muir</surname><given-names>JA</given-names></name><name><surname>Buchan</surname><given-names>BJ</given-names></name><name><surname>Horton</surname><given-names>T</given-names></name></person-group><article-title>Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience</article-title><source>Am. J. Addict</source><year>2004</year><volume>13</volume><issue>Suppl 1</issue><fpage>S42</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">15204675</pub-id></citation></ref><ref id="R4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amato</surname><given-names>L</given-names></name><name><surname>Davoli</surname><given-names>M</given-names></name><name><surname>Minozzi</surname><given-names>S</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>Ferri</surname><given-names>M</given-names></name></person-group><article-title>Methadone at tapered doses for the management of opioid withdrawal</article-title><source>Cochrane Database Syst. Rev</source><year>2005</year><comment>CD003409</comment></citation></ref><ref id="R5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Annitto</surname><given-names>WJ</given-names></name></person-group><article-title>Detoxification with buprenorphine of a pregnant heroin addict</article-title><source>Am. J. Addict</source><year>2000</year><volume>9</volume><fpage>92</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">10914298</pub-id></citation></ref><ref id="R6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arlettaz</surname><given-names>R</given-names></name><name><surname>Kashiwagi</surname><given-names>M</given-names></name><name><surname>Das-Kundu</surname><given-names>S</given-names></name><name><surname>Fauchere</surname><given-names>JC</given-names></name><name><surname>Lang</surname><given-names>A</given-names></name><name><surname>Bucher</surname><given-names>HU</given-names></name></person-group><article-title>Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources</article-title><source>Acta Obstet. Gynecol. Scand</source><year>2005</year><volume>84</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">15683374</pub-id></citation></ref><ref id="R7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnold-Reed</surname><given-names>DE</given-names></name><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Hansson</surname><given-names>RC</given-names></name><name><surname>Murray</surname><given-names>SD</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Basso</surname><given-names>MR</given-names></name><name><surname>Holman</surname><given-names>CD</given-names></name></person-group><article-title>Blood morphine levels in naltrexone-exposed compared to non-naltrexone-exposed fatal heroin overdoses</article-title><source>Addict. Biol</source><year>2003</year><volume>8</volume><fpage>343</fpage><lpage>350</lpage><pub-id pub-id-type="pmid">13129837</pub-id></citation></ref><ref id="R8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aroyewun</surname><given-names>O</given-names></name><name><surname>Barr</surname><given-names>GA</given-names></name></person-group><article-title>The effects of opiate antagonists on milk intake of preweanling rats</article-title><source>Neuropharmacology</source><year>1982</year><volume>21</volume><fpage>757</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">7121747</pub-id></citation></ref><ref id="R9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>JL</given-names></name></person-group><article-title>Treatment of neonatal abstinence syndrome with breast milk containing methadone</article-title><source>J. Perinat. Neonatal. Nurs</source><year>2002</year><volume>15</volume><fpage>76</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">11911622</pub-id></citation></ref><ref id="R10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>CD</given-names></name></person-group><article-title>Overdosage of buprenorphine: case report</article-title><source>N. Z. Med. J</source><year>1979</year><volume>89</volume><fpage>255</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">286917</pub-id></citation></ref><ref id="R11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name></person-group><article-title>Developmental profile of kappa, mu and delta opioid receptors in the rat and guinea pig cerebellum</article-title><source>Dev. Neurosci</source><year>1989</year><volume>11</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">2553387</pub-id></citation></ref><ref id="R12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name></person-group><article-title>Transient expression of opioid receptors in defined regions of developing brain: are embryonic receptors selective?</article-title><source>J. Neurochem</source><year>1991</year><volume>57</volume><fpage>1978</fpage><lpage>1984</lpage><pub-id pub-id-type="pmid">1658229</pub-id></citation></ref><ref id="R13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barr</surname><given-names>GA</given-names></name><name><surname>Zmitrovich</surname><given-names>A</given-names></name><name><surname>Hamowy</surname><given-names>AS</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Hutchings</surname><given-names>DE</given-names></name></person-group><article-title>Neonatal withdrawal following pre- and postnatal exposure to methadone in the rat</article-title><source>Pharmacol. Biochem. Behav</source><year>1998</year><volume>60</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">9610930</pub-id></citation></ref><ref id="R14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barron</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>VM</given-names></name></person-group><article-title>Prenatal buprenorphine exposure and sexually dimorphic nonreproductive behaviors in rats</article-title><source>Pharmacol. Biochem. Behav</source><year>1997</year><volume>58</volume><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">9300589</pub-id></citation></ref><ref id="R15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartus</surname><given-names>RT</given-names></name><name><surname>Emerich</surname><given-names>DF</given-names></name><name><surname>Hotz</surname><given-names>J</given-names></name><name><surname>Blaustein</surname><given-names>M</given-names></name><name><surname>Dean</surname><given-names>RL</given-names></name><name><surname>Perdomo</surname><given-names>B</given-names></name><name><surname>Basile</surname><given-names>AS</given-names></name></person-group><article-title>Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><fpage>1973</fpage><lpage>1982</lpage><pub-id pub-id-type="pmid">12931140</pub-id></citation></ref><ref id="R16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>EJ</given-names></name><name><surname>Malpas</surname><given-names>TJ</given-names></name><name><surname>Hackett</surname><given-names>LP</given-names></name><name><surname>Ilett</surname><given-names>KF</given-names></name></person-group><article-title>Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing</article-title><source>Br. J. Clin. Pharmacol</source><year>2001</year><volume>52</volume><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">11736879</pub-id></citation></ref><ref id="R17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belcheva</surname><given-names>MM</given-names></name><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>McHale</surname><given-names>R</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name></person-group><article-title>Naltrexone induces down- and upregulation of delta opioid receptors in rat brain regions</article-title><source>Brain Res. Bull</source><year>1994</year><volume>35</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">7953760</pub-id></citation></ref><ref id="R18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belcheva</surname><given-names>MM</given-names></name><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>McHale</surname><given-names>RJ</given-names></name><name><surname>Dawn</surname><given-names>S</given-names></name><name><surname>Ho</surname><given-names>MT</given-names></name><name><surname>Ignatova</surname><given-names>E</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name></person-group><article-title>Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine</article-title><source>Mol. Pharmacol</source><year>1993</year><volume>44</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">8393519</pub-id></citation></ref><ref id="R19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belcheva</surname><given-names>MM</given-names></name><name><surname>Bohn</surname><given-names>LM</given-names></name><name><surname>Ho</surname><given-names>MT</given-names></name><name><surname>Johnson</surname><given-names>FE</given-names></name><name><surname>Yanai</surname><given-names>J</given-names></name><name><surname>Barron</surname><given-names>S</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name></person-group><article-title>Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine</article-title><source>Brain Res. Dev. Brain Res</source><year>1998</year><volume>111</volume><fpage>35</fpage><lpage>42</lpage></citation></ref><ref id="R20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belcheva</surname><given-names>MM</given-names></name><name><surname>Dawn</surname><given-names>S</given-names></name><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>McHale</surname><given-names>RJ</given-names></name><name><surname>Ho</surname><given-names>MT</given-names></name><name><surname>Ignatova</surname><given-names>E</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name></person-group><article-title>Transient down-regulation of neonatal rat brain mu-opioid receptors upon in utero exposure to buprenorphine</article-title><source>Brain Res. Dev. Brain Res</source><year>1994</year><volume>80</volume><fpage>158</fpage><lpage>162</lpage></citation></ref><ref id="R21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>JR</given-names></name><name><surname>Young</surname><given-names>MR</given-names></name><name><surname>Masterman</surname><given-names>SC</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name><name><surname>Bammer</surname><given-names>G</given-names></name></person-group><article-title>A pilot study of naltrexone-accelerated detoxification in opioid dependence</article-title><source>Med. J. Aust</source><year>1999</year><volume>171</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">10451668</pub-id></citation></ref><ref id="R22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bem</surname><given-names>WT</given-names></name><name><surname>Yeung</surname><given-names>SJ</given-names></name><name><surname>Belcheva</surname><given-names>M</given-names></name><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name></person-group><article-title>Age-dependent changes in the subcellular distribution of rat brain mu-opioid receptors and GTP binding regulatory proteins</article-title><source>J. Neurochem</source><year>1991</year><volume>57</volume><fpage>1470</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">1655974</pub-id></citation></ref><ref id="R23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berghella</surname><given-names>V</given-names></name><name><surname>Lim</surname><given-names>PJ</given-names></name><name><surname>Hill</surname><given-names>MK</given-names></name><name><surname>Cherpes</surname><given-names>J</given-names></name><name><surname>Chennat</surname><given-names>J</given-names></name><name><surname>Kaltenbach</surname><given-names>K</given-names></name></person-group><article-title>Maternal methadone dose and neonatal withdrawal</article-title><source>Am. J. Obstet. Gynecol</source><year>2003</year><volume>189</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">14520184</pub-id></citation></ref><ref id="R24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Best</surname><given-names>D</given-names></name><name><surname>Gossop</surname><given-names>M</given-names></name><name><surname>Man</surname><given-names>LH</given-names></name><name><surname>Finch</surname><given-names>E</given-names></name><name><surname>Greenwood</surname><given-names>J</given-names></name><name><surname>Strang</surname><given-names>J</given-names></name></person-group><article-title>Accidental and deliberate overdose among opiate addicts in methadone maintenance treatment: are deliberate overdoses systematically different?</article-title><source>Drug Alcohol Rev</source><year>2000</year><volume>19</volume><fpage>213</fpage><lpage>216</lpage></citation></ref><ref id="R25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blinick</surname><given-names>G</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name><name><surname>Jerez</surname><given-names>E</given-names></name><name><surname>Wallach</surname><given-names>RC</given-names></name></person-group><article-title>Methadone assays in pregnant women and progeny</article-title><source>Am. J. Obstet. Gynecol</source><year>1975</year><volume>121</volume><fpage>617</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">1115163</pub-id></citation></ref><ref id="R26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blumberg</surname><given-names>H</given-names></name><name><surname>Dayton</surname><given-names>HB</given-names></name></person-group><article-title>Naloxone, naltrexone, and related noroxymorphones</article-title><source>Adv. Biochem. Psychopharmacol</source><year>1973</year><volume>8</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">4794989</pub-id></citation></ref><ref id="R27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boerner</surname><given-names>U</given-names></name></person-group><article-title>The metabolism of morphine and heroin in man</article-title><source>Drug Metab. Rev</source><year>1975</year><volume>4</volume><fpage>39</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">1204496</pub-id></citation></ref><ref id="R28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boulton</surname><given-names>DW</given-names></name><name><surname>Arnaud</surname><given-names>P</given-names></name><name><surname>DeVane</surname><given-names>CL</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate</article-title><source>Clin. Pharmacol. Ther</source><year>2001</year><volume>70</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">11452244</pub-id></citation></ref><ref id="R29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouza</surname><given-names>C</given-names></name><name><surname>Angeles</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Amate</surname><given-names>JM</given-names></name></person-group><article-title>Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependenc:e a systematic review</article-title><source>Addiction</source><year>2004</year><volume>99</volume><fpage>811</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">15200577</pub-id></citation></ref><ref id="R30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>J</given-names></name><name><surname>Randell</surname><given-names>T</given-names></name><name><surname>Luurila</surname><given-names>H</given-names></name><name><surname>Kuisma</surname><given-names>M</given-names></name></person-group><article-title>Serious overdoses involving buprenorphine in Helsinki</article-title><source>Acta Anaesthesiol. Scand</source><year>2003</year><volume>47</volume><fpage>1031</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">12904197</pub-id></citation></ref><ref id="R31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braude</surname><given-names>MC</given-names></name><name><surname>Morrison</surname><given-names>JM</given-names></name></person-group><article-title>Preclinical toxicity studies of naltrexone</article-title><source>NIDA Res. Monogr</source><year>1976</year><volume>9</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">826824</pub-id></citation></ref><ref id="R32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brewer</surname><given-names>C</given-names></name></person-group><article-title>Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases</article-title><source>Addict. Biol</source><year>2002</year><volume>7</volume><fpage>321</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">12126492</pub-id></citation></ref><ref id="R33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>HL</given-names></name><name><surname>Britton</surname><given-names>KA</given-names></name><name><surname>Mahaffey</surname><given-names>D</given-names></name><name><surname>Brizendine</surname><given-names>E</given-names></name><name><surname>Hiett</surname><given-names>AK</given-names></name><name><surname>Turnquest</surname><given-names>MA</given-names></name></person-group><article-title>Methadone maintenance in pregnancy: a reappraisal</article-title><source>Am. J. Obstet. Gynecol</source><year>1998</year><volume>179</volume><fpage>459</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">9731853</pub-id></citation></ref><ref id="R34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchenauer</surname><given-names>D</given-names></name><name><surname>Turnbow</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>MA</given-names></name></person-group><article-title>Effect of chronic methadone adminstration on pregnant rats and their offspring</article-title><source>J. Pharmacol. Exp. Ther</source><year>1974</year><volume>189</volume><fpage>66</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">4823301</pub-id></citation></ref><ref id="R35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bullingham</surname><given-names>RE</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name><name><surname>Moore</surname><given-names>A</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name></person-group><article-title>Buprenorphine kinetics</article-title><source>Clin. Pharmacol. Ther</source><year>1980</year><volume>28</volume><fpage>667</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">7438685</pub-id></citation></ref><ref id="R36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bullingham</surname><given-names>RE</given-names></name><name><surname>McQuay</surname><given-names>HJ</given-names></name><name><surname>Porter</surname><given-names>EJ</given-names></name><name><surname>Allen</surname><given-names>MC</given-names></name><name><surname>Moore</surname><given-names>RA</given-names></name></person-group><article-title>Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis</article-title><source>Br. J. Clin. Pharmacol</source><year>1982</year><volume>13</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="pmid">7082534</pub-id></citation></ref><ref id="R37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carney</surname><given-names>EW</given-names></name><name><surname>Zablotny</surname><given-names>CL</given-names></name><name><surname>Marty</surname><given-names>MS</given-names></name><name><surname>Crissman</surname><given-names>JW</given-names></name><name><surname>Anderson</surname><given-names>P</given-names></name><name><surname>Woolhiser</surname><given-names>M</given-names></name><name><surname>Holsapple</surname><given-names>M</given-names></name></person-group><article-title>The effects of feed restriction during in utero and postnatal development in rats</article-title><source>Toxicol. Sci</source><year>2004</year><volume>82</volume><fpage>237</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">15310860</pub-id></citation></ref><ref id="R38"><label>38</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Caswell</surname><given-names>A</given-names></name></person-group><source>MIMS Bi-Monthly</source><year>2005</year><publisher-loc>Sydney,Australia</publisher-loc><publisher-name>CMP Medica Australia</publisher-name></citation></ref><ref id="R39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CF</given-names></name><name><surname>Chiswell</surname><given-names>GM</given-names></name><name><surname>Bencini</surname><given-names>R</given-names></name><name><surname>Hackett</surname><given-names>LP</given-names></name><name><surname>Dusci</surname><given-names>LJ</given-names></name><name><surname>Ilett</surname><given-names>KF</given-names></name></person-group><article-title>Quantification of naltrexone and 6,beta-naltrexol in plasma and milk using gas chromatography-mass spectrometry. Application to studies in the lactating sheep</article-title><source>J. Chromatogr. B.Biomed. Sci. Appl</source><year>2001</year><volume>761</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">11585135</pub-id></citation></ref><ref id="R40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>CF</given-names></name><name><surname>Page-Sharp</surname><given-names>M</given-names></name><name><surname>Kristensen</surname><given-names>JH</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Ilett</surname><given-names>KF</given-names></name></person-group><article-title>Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk</article-title><source>J. Hum. Lact</source><year>2004</year><volume>20</volume><fpage>322</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">15296587</pub-id></citation></ref><ref id="R41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chandler</surname><given-names>JM</given-names></name><name><surname>Robie</surname><given-names>PW</given-names></name><name><surname>Schoolar</surname><given-names>JC</given-names></name><name><surname>Desmond</surname><given-names>MM</given-names></name></person-group><article-title>The effects of methadone on maternal-fetal interactions in the rat</article-title><source>J. Pharmacol. Exp. Ther</source><year>1975</year><volume>192</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">1168255</pub-id></citation></ref><ref id="R42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chasnoff</surname><given-names>IJ</given-names></name><name><surname>Hatcher</surname><given-names>R</given-names></name><name><surname>Burns</surname><given-names>WJ</given-names></name></person-group><article-title>Early growth patterns of methadone-addicted infants</article-title><source>Am. J. Dis. Child</source><year>1980</year><volume>134</volume><fpage>1049</fpage><lpage>1051</lpage><pub-id pub-id-type="pmid">7435463</pub-id></citation></ref><ref id="R43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chasnoff</surname><given-names>IJ</given-names></name><name><surname>Hatcher</surname><given-names>R</given-names></name><name><surname>Burns</surname><given-names>WJ</given-names></name></person-group><article-title>Polydrug- and methadone-addicted newborns: a continuum of impairment?</article-title><source>Pediatrics</source><year>1982</year><volume>70</volume><fpage>210</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">7099786</pub-id></citation></ref><ref id="R44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheney</surname><given-names>BV</given-names></name><name><surname>Duchamp</surname><given-names>DJ</given-names></name><name><surname>Christoffersen</surname><given-names>RE</given-names></name></person-group><article-title>Assessment of quantum mechanical techniques for use in structure activity relationship development, and application to analgesics and other drugs</article-title><source>NIDA Res. Monogr</source><year>1978</year><volume>22</volume><fpage>218</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">30908</pub-id></citation></ref><ref id="R45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>CN</given-names></name><name><surname>Hollister</surname><given-names>LE</given-names></name><name><surname>Gillespie</surname><given-names>HK</given-names></name><name><surname>Foltz</surname><given-names>RL</given-names></name></person-group><article-title>Clinical evaluation of a naltrexone sustained-release preparation</article-title><source>Drug Alcohol Depend</source><year>1985</year><volume>16</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">4064907</pub-id></citation></ref><ref id="R46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>RE</given-names></name><name><surname>Huestis</surname><given-names>MA</given-names></name><name><surname>Schroeder</surname><given-names>JR</given-names></name><name><surname>Shin</surname><given-names>AS</given-names></name><name><surname>Jones</surname><given-names>HE</given-names></name></person-group><article-title>Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure</article-title><source>Drug Alcohol Depend</source><year>2004</year><volume>75</volume><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">15283946</pub-id></citation></ref><ref id="R47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>RB</given-names></name><name><surname>Beard</surname><given-names>AG</given-names></name><name><surname>Greifenstein</surname><given-names>FE</given-names></name><name><surname>Barclay</surname><given-names>DL</given-names></name></person-group><article-title>Naloxone in the parturient and her infant</article-title><source>South Med. J</source><year>1976</year><volume>69</volume><fpage>570</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">775651</pub-id></citation></ref><ref id="R48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>E</given-names></name><name><surname>Keshet</surname><given-names>G</given-names></name><name><surname>Shavit</surname><given-names>Y</given-names></name><name><surname>Weinstock</surname><given-names>M</given-names></name></person-group><article-title>Prenatal naltrexone facilitates male sexual behavior in the rat</article-title><source>Pharmacol. Biochem. Behav</source><year>1996</year><volume>54</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">8728556</pub-id></citation></ref><ref id="R49"><label>49</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Comer</surname><given-names>SD</given-names></name></person-group><year>2004</year><conf-name>Effectiveness of an injectable, 30-day, sustained-release, depot formulation of naltrexone in the treatment of opioid dependence. APSAD 2004 National Conference: Beyond the Drug</conf-name><conf-loc>Fremantle, Western Australia</conf-loc></citation></ref><ref id="R50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comer</surname><given-names>SD</given-names></name><name><surname>Collins</surname><given-names>ED</given-names></name><name><surname>Kleber</surname><given-names>HD</given-names></name><name><surname>Nuwayser</surname><given-names>ES</given-names></name><name><surname>Kerrigan</surname><given-names>JH</given-names></name><name><surname>Fischman</surname><given-names>MW</given-names></name></person-group><article-title>Depot naltrexone: long-lasting antagonism of the effects of heroin in humans</article-title><source>Psychopharmacology (Berl.)</source><year>2002</year><volume>159</volume><fpage>351</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">11823887</pub-id></citation></ref><ref id="R51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comer</surname><given-names>SD</given-names></name><name><surname>Sullivan</surname><given-names>MA</given-names></name><name><surname>Yu</surname><given-names>E</given-names></name><name><surname>Rothenberg</surname><given-names>JL</given-names></name><name><surname>Kleber</surname><given-names>HD</given-names></name><name><surname>Kampman</surname><given-names>K</given-names></name><name><surname>Dackis</surname><given-names>C</given-names></name><name><surname>O'Brien</surname><given-names>CP</given-names></name></person-group><article-title>Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial</article-title><source>Arch. Gen. Psychiatry</source><year>2006</year><volume>63</volume><fpage>210</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">16461865</pub-id></citation></ref><ref id="R52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Compton</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name><name><surname>Moody</surname><given-names>D</given-names></name><name><surname>Chiang</surname><given-names>N</given-names></name></person-group><article-title>Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine</article-title><source>Drug Alcohol Depend</source><year>2006</year><volume>82</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">16144748</pub-id></citation></ref><ref id="R53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cone</surname><given-names>EJ</given-names></name><name><surname>Gorodetzky</surname><given-names>CW</given-names></name><name><surname>Yousefnejad</surname><given-names>D</given-names></name><name><surname>Buchwald</surname><given-names>WF</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name></person-group><article-title>The metabolism and excretion of buprenorphine in humans</article-title><source>Drug Metab. Dispos</source><year>1984</year><volume>12</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">6149907</pub-id></citation></ref><ref id="R54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Connaughton</surname><given-names>JF</given-names></name><name><surname>Reeser</surname><given-names>D</given-names></name><name><surname>Schut</surname><given-names>J</given-names></name><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Perinatal addiction: outcome and management</article-title><source>Am. J. Obstet. Gynecol</source><year>1977</year><volume>129</volume><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">303464</pub-id></citation></ref><ref id="R55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cornish</surname><given-names>JW</given-names></name><name><surname>Metzger</surname><given-names>D</given-names></name><name><surname>Woody</surname><given-names>GE</given-names></name><name><surname>Wilson</surname><given-names>D</given-names></name><name><surname>McLellan</surname><given-names>AT</given-names></name><name><surname>Vandergrift</surname><given-names>B</given-names></name><name><surname>O'Brien</surname><given-names>CP</given-names></name></person-group><article-title>Naltrexone pharmacotherapy for opioid dependent federal probationers</article-title><source>J. Subst. Abuse Treat</source><year>1997</year><volume>14</volume><fpage>529</fpage><lpage>534</lpage><pub-id pub-id-type="pmid">9437624</pub-id></citation></ref><ref id="R56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Aunno</surname><given-names>T</given-names></name><name><surname>Pollack</surname><given-names>HA</given-names></name></person-group><article-title>Changes in methadone treatment practices: results from a national panel study, 1988-2000</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>850</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">12186602</pub-id></citation></ref><ref id="R57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dailey</surname><given-names>PA</given-names></name><name><surname>Brookshire</surname><given-names>GL</given-names></name><name><surname>Shnider</surname><given-names>SM</given-names></name><name><surname>Abboud</surname><given-names>TK</given-names></name><name><surname>Kotelko</surname><given-names>DM</given-names></name><name><surname>Noueihid</surname><given-names>R</given-names></name><name><surname>Thigpen</surname><given-names>JW</given-names></name><name><surname>Khoo</surname><given-names>SS</given-names></name><name><surname>Raya</surname><given-names>JA</given-names></name><name><surname>Foutz</surname><given-names>SE</given-names></name><name><surname>Brizgys</surname><given-names>RV</given-names></name><name><surname>Goebelsmann</surname><given-names>U</given-names></name><name><surname>Lo</surname><given-names>M</given-names></name></person-group><article-title>The effects of naloxone associated with the intrathecal use of morphine in labor</article-title><source>Anesth. Analg</source><year>1985</year><volume>64</volume><fpage>658</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">3160259</pub-id></citation></ref><ref id="R58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darke</surname><given-names>S</given-names></name><name><surname>Ross</surname><given-names>J</given-names></name></person-group><article-title>Heroin-related deaths in New South Wales, Australia, 1992-1996</article-title><source>Drug Alcohol Rev</source><year>2000</year><volume>19</volume><fpage>35</fpage><lpage>40</lpage></citation></ref><ref id="R59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darlington</surname><given-names>RB</given-names></name><name><surname>Dunlop</surname><given-names>SA</given-names></name><name><surname>Finlay</surname><given-names>BL</given-names></name></person-group><article-title>Neural development in metatherian and eutherian mammals: variation and constraint</article-title><source>J. Comp. Neurol</source><year>1999</year><volume>411</volume><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">10413772</pub-id></citation></ref><ref id="R60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dashe</surname><given-names>JS</given-names></name><name><surname>Jackson</surname><given-names>GL</given-names></name><name><surname>Olscher</surname><given-names>DA</given-names></name><name><surname>Zane</surname><given-names>EH</given-names></name><name><surname>Wendel GD</surname><given-names>Jr</given-names></name></person-group><article-title>Opioid detoxification in pregnancy</article-title><source>Obstet. Gynecol</source><year>1998</year><volume>92</volume><fpage>854</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">9794682</pub-id></citation></ref><ref id="R61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dashe</surname><given-names>JS</given-names></name><name><surname>Sheffield</surname><given-names>JS</given-names></name><name><surname>Olscher</surname><given-names>DA</given-names></name><name><surname>Todd</surname><given-names>SJ</given-names></name><name><surname>Jackson</surname><given-names>GL</given-names></name><name><surname>Wendel</surname><given-names>GD</given-names></name></person-group><article-title>Relationship between maternal methadone dosage and neonatal withdrawal</article-title><source>Obstet. Gynecol</source><year>2002</year><volume>100</volume><fpage>1244</fpage><lpage>1249</lpage><pub-id pub-id-type="pmid">12468169</pub-id></citation></ref><ref id="R62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davids</surname><given-names>E</given-names></name><name><surname>Gastpar</surname><given-names>M</given-names></name></person-group><article-title>Buprenorphine in the treatment of opioid dependence</article-title><source>Eur. Neuropsychopharmacol</source><year>2004</year><volume>14</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">15056480</pub-id></citation></ref><ref id="R63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Cabo</surname><given-names>C</given-names></name><name><surname>Colado</surname><given-names>MI</given-names></name><name><surname>Pujol</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>MI</given-names></name><name><surname>Viveros</surname><given-names>MP</given-names></name></person-group><article-title>Naltrexone administration effects on regional brain monoamines in developing rats</article-title><source>Brain Res. Bull</source><year>1994</year><volume>34</volume><fpage>395</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">8082032</pub-id></citation></ref><ref id="R64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Cabo</surname><given-names>C</given-names></name><name><surname>Paz Viveros</surname><given-names>M</given-names></name></person-group><article-title>Effects of neonatal naltrexone on neurological and somatic development in rats of both genders</article-title><source>Neurotoxicol. Teratol</source><year>1997</year><volume>19</volume><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">9392785</pub-id></citation></ref><ref id="R65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Cabo de la Vega</surname><given-names>C</given-names></name><name><surname>Pujol</surname><given-names>A</given-names></name><name><surname>Paz Viveros</surname><given-names>M</given-names></name></person-group><article-title>Neonatally administered naltrexone affects several behavioral responses in adult rats of both genders</article-title><source>Pharmacol. Biochem. Behav</source><year>1995</year><volume>50</volume><fpage>277</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">7740068</pub-id></citation></ref><ref id="R66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Montis</surname><given-names>GM</given-names></name><name><surname>Devoto</surname><given-names>P</given-names></name><name><surname>Angioi</surname><given-names>RM</given-names></name><name><surname>Curreli</surname><given-names>V</given-names></name><name><surname>Tagliamonte</surname><given-names>A</given-names></name></person-group><article-title>In utero exposure to methadone produces a stable decrease of the cortex 5-HT transport system in rats</article-title><source>Eur. J. Pharmacol</source><year>1983</year><volume>90</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">6307722</pub-id></citation></ref><ref id="R67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DePetrillo</surname><given-names>PB</given-names></name><name><surname>Rice</surname><given-names>JM</given-names></name></person-group><article-title>Methadone dosing and pregnancy: impact on program compliance</article-title><source>Int. J. Addict</source><year>1995</year><volume>30</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">7759173</pub-id></citation></ref><ref id="R68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Derendorf</surname><given-names>H</given-names></name><name><surname>El-Din</surname><given-names>A</given-names></name><name><surname>El-Koussi</surname><given-names>A</given-names></name><name><surname>Garrett</surname><given-names>ER</given-names></name></person-group><article-title>Electrochemical chromatographic determinations of morphine antagonists in biological fluids, with applications</article-title><source>J. Pharm. Sci</source><year>1984</year><volume>73</volume><fpage>621</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">6737235</pub-id></citation></ref><ref id="R69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Des Jarlais</surname><given-names>DC</given-names></name><name><surname>Joseph</surname><given-names>H</given-names></name><name><surname>Dole</surname><given-names>VP</given-names></name></person-group><article-title>Long-term outcomes after termination from methadone maintenance treatment</article-title><source>Ann. N. Y.Acad. Sci</source><year>1981</year><volume>362</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">6942709</pub-id></citation></ref><ref id="R70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deshmukh</surname><given-names>SV</given-names></name><name><surname>Nanovskaya</surname><given-names>TN</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Aromatase is the major enzyme metabolizing buprenorphine in human placenta</article-title><source>J. Pharmacol. Exp. Ther</source><year>2003</year><volume>306</volume><fpage>1099</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">12808001</pub-id></citation></ref><ref id="R71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickinson</surname><given-names>RG</given-names></name><name><surname>Fowler</surname><given-names>DW</given-names></name><name><surname>Kluck</surname><given-names>RM</given-names></name></person-group><article-title>Maternofetal transfer of phenytoin, p-hydroxy-phenytoin and p-hydroxy-phenytoin-glucuronide in the perfused human placenta</article-title><source>Clin. Exp. Pharmacol. Physiol</source><year>1989</year><volume>16</volume><fpage>789</fpage><lpage>797</lpage><pub-id pub-id-type="pmid">2612061</pub-id></citation></ref><ref id="R72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Digiusto</surname><given-names>E</given-names></name><name><surname>Shakeshaft</surname><given-names>A</given-names></name><name><surname>Ritter</surname><given-names>A</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name></person-group><article-title>Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD)</article-title><source>Addiction</source><year>2004</year><volume>99</volume><fpage>450</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">15049745</pub-id></citation></ref><ref id="R73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doberczak</surname><given-names>TM</given-names></name><name><surname>Kandall</surname><given-names>SR</given-names></name><name><surname>Friedmann</surname><given-names>P</given-names></name></person-group><article-title>Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal</article-title><source>Obstet. Gynecol</source><year>1993</year><volume>81</volume><fpage>936</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">8497359</pub-id></citation></ref><ref id="R74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doberczak</surname><given-names>TM</given-names></name><name><surname>Thornton</surname><given-names>JC</given-names></name><name><surname>Bernstein</surname><given-names>J</given-names></name><name><surname>Kandall</surname><given-names>SR</given-names></name></person-group><article-title>Impact of maternal drug dependency on birth weight and head circumference of offspring</article-title><source>Am. J. Dis. Child</source><year>1987</year><volume>141</volume><fpage>1163</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">3673965</pub-id></citation></ref><ref id="R75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dole</surname><given-names>VP</given-names></name><name><surname>Joseph</surname><given-names>H</given-names></name></person-group><article-title>Methadone maintenance Outcome after termination</article-title><source>N. Y. State J. Med</source><year>1977</year><volume>77</volume><fpage>1409</fpage><lpage>1412</lpage><pub-id pub-id-type="pmid">267831</pub-id></citation></ref><ref id="R76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dole</surname><given-names>VP</given-names></name><name><surname>Nyswander</surname><given-names>ME</given-names></name></person-group><article-title>Heroin addiction: a metabolic disease</article-title><source>Arch. Intern. Med</source><year>1967</year><volume>120</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">6028693</pub-id></citation></ref><ref id="R77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dreher</surname><given-names>B</given-names></name><name><surname>Robinson</surname><given-names>SR</given-names></name></person-group><article-title>Development of the retinofugal pathway in birds and mammals: evidence for a common &#x02018;timetable&#x02019;</article-title><source>Brain Behav. Evol</source><year>1988</year><volume>31</volume><fpage>369</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">3046710</pub-id></citation></ref><ref id="R78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drozdick J</surname><given-names>3rd</given-names></name><name><surname>Berghella</surname><given-names>V</given-names></name><name><surname>Hill</surname><given-names>M</given-names></name><name><surname>Kaltenbach</surname><given-names>K</given-names></name></person-group><article-title>Methadone trough levels in pregnancy</article-title><source>Am. J. Obstet. Gynecol</source><year>2002</year><volume>187</volume><fpage>1184</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">12439500</pub-id></citation></ref><ref id="R79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drummond</surname><given-names>DC</given-names></name><name><surname>Turkington</surname><given-names>D</given-names></name><name><surname>Rahman</surname><given-names>MZ</given-names></name><name><surname>Mullin</surname><given-names>PJ</given-names></name><name><surname>Jackson</surname><given-names>P</given-names></name></person-group><article-title>Chlordiazepoxide <italic>vs</italic> methadone in opiate withdrawal: a preliminary double blind trial</article-title><source>Drug Alcohol Depend</source><year>1989</year><volume>23</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">2646089</pub-id></citation></ref><ref id="R80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ebner</surname><given-names>N</given-names></name><name><surname>Rohrmeister</surname><given-names>K</given-names></name><name><surname>Winklbaur</surname><given-names>B</given-names></name><name><surname>Baewert</surname><given-names>A</given-names></name><name><surname>Jagsch</surname><given-names>R</given-names></name><name><surname>Peternell</surname><given-names>A</given-names></name><name><surname>Thau</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name></person-group><article-title>Management of neonatal abstinence syndrome in neonates born to opioid maintained women</article-title><source>Drug Alcohol Depend</source><year>2007</year><volume>87</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">17000060</pub-id></citation></ref><ref id="R81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellwood</surname><given-names>DA</given-names></name><name><surname>Sutherland</surname><given-names>P</given-names></name><name><surname>Kent</surname><given-names>C</given-names></name><name><surname>O'Connor</surname><given-names>M</given-names></name></person-group><article-title>Maternal narcotic addiction: pregnancy outcome in patients managed by a specialized drug-dependency antenatal clinic</article-title><source>Aust. N.Z. J. Obstet. Gynaecol</source><year>1987</year><volume>27</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">3675451</pub-id></citation></ref><ref id="R82"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Milne</surname><given-names>E</given-names></name><name><surname>Holman</surname><given-names>CD</given-names></name><name><surname>Bower</surname><given-names>CI</given-names></name></person-group><article-title>Maternal cannabis use and birth weight: a meta-analysis</article-title><source>Addiction</source><year>1997</year><volume>92</volume><fpage>1553</fpage><lpage>1560</lpage><pub-id pub-id-type="pmid">9519497</pub-id></citation></ref><ref id="R83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>RG</given-names></name><name><surname>Olley</surname><given-names>JE</given-names></name><name><surname>Rice</surname><given-names>GE</given-names></name><name><surname>Abrahams</surname><given-names>JM</given-names></name></person-group><article-title>Effects of subacute opioid administration during late pregnancy in the rat on the initiation duration and outcome of parturition and maternal levels of oxytocin and arginine vasopressin</article-title><source>Clin. Exp. Pharmacol. Physiol</source><year>1989</year><volume>16</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">2721029</pub-id></citation></ref><ref id="R84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Faggiano</surname><given-names>F</given-names></name><name><surname>Vigna-Taglianti</surname><given-names>F</given-names></name><name><surname>Versino</surname><given-names>E</given-names></name><name><surname>Lemma</surname><given-names>P</given-names></name></person-group><article-title>Methadone maintenance at different dosages for opioid dependence</article-title><source>Cochrane Database Syst. Rev</source><year>2003</year><comment>CD002208</comment></citation></ref><ref id="R85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fajemirokun-Odudeyi</surname><given-names>O</given-names></name><name><surname>Sinha</surname><given-names>C</given-names></name><name><surname>Tutty</surname><given-names>S</given-names></name><name><surname>Pairaudeau</surname><given-names>P</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Phillips</surname><given-names>T</given-names></name><name><surname>Lindow</surname><given-names>SW</given-names></name></person-group><article-title>Pregnancy outcome in women who use opiates</article-title><source>Eur. J. Obstet. Gynecol. Reprod. Biol</source><year>2006</year><volume>126</volume><fpage>170</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">16202501</pub-id></citation></ref><ref id="R86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Coccia</surname><given-names>CP</given-names></name><name><surname>Bertolini</surname><given-names>A</given-names></name><name><surname>Sternieri</surname><given-names>E</given-names></name></person-group><article-title>Methadone metabolism, pharmacokinetics and interactions</article-title><source>Pharmacol. Res</source><year>2004</year><volume>50</volume><fpage>551</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">15501692</pub-id></citation></ref><ref id="R87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>T</given-names></name><name><surname>McNelly</surname><given-names>A</given-names></name><name><surname>Sadava</surname><given-names>D</given-names></name></person-group><article-title>Effect of maternal methadone addiction on offspring in rats</article-title><source>Arch. Int. Pharmacodyn. Ther</source><year>1977</year><volume>228</volume><fpage>300</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">562648</pub-id></citation></ref><ref id="R88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finnegan</surname><given-names>L</given-names></name></person-group><article-title>Clinical effects of pharmacologic agents on pregnancy, the fetus, and the neonate</article-title><source>Ann. N.Y. Acad. Sci</source><year>1976</year><volume>281</volume><fpage>74</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">798531</pub-id></citation></ref><ref id="R89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Pathophysiological and behavioural effects of the transplacental transfer of narcotic drugs to the foetuses and neonates of narcotic-dependent mothers</article-title><source>Bull. Narc</source><year>1979</year><volume>31</volume><fpage>1</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">397848</pub-id></citation></ref><ref id="R90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Treatment issues for opioid-dependent women during the perinatal period</article-title><source>J. Psychoactive Drugs</source><year>1991</year><volume>23</volume><fpage>191</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">1765892</pub-id></citation></ref><ref id="R91"><label>91</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Finnegan</surname><given-names>LP</given-names></name><name><surname>Kaltenbach</surname><given-names>K</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Hoeckelman</surname><given-names>R.A</given-names></name><name><surname>Friedman</surname><given-names>S.B</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name><name><surname>Seidel</surname><given-names>H.M</given-names></name></person-group><article-title>Neonatal abstinence syndrome</article-title><source>Pediatric Care</source><year>1992</year><publisher-loc>St. Louis</publisher-loc><publisher-name>Mosby</publisher-name><fpage>1367</fpage><lpage>1378</lpage></citation></ref><ref id="R92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>G</given-names></name></person-group><article-title>Treatment of opioid dependence in pregnant women</article-title><source>Addiction</source><year>2000</year><volume>95</volume><fpage>1141</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">11092062</pub-id></citation></ref><ref id="R93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Etzersdorfer</surname><given-names>P</given-names></name><name><surname>Eder</surname><given-names>H</given-names></name><name><surname>Jagsch</surname><given-names>R</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><name><surname>Weninger</surname><given-names>M</given-names></name></person-group><article-title>Buprenorphine maintenance in pregnant opiate addicts</article-title><source>Eur. Addict. Res</source><year>1998</year><volume>4</volume><issue>Suppl. 1</issue><fpage>32</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">9767205</pub-id></citation></ref><ref id="R94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Eder</surname><given-names>H</given-names></name><name><surname>Jagsch</surname><given-names>R</given-names></name><name><surname>Peternell</surname><given-names>A</given-names></name><name><surname>Weninger</surname><given-names>M</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><name><surname>Aschauer</surname><given-names>HN</given-names></name></person-group><article-title>Treatment of opioid-dependent pregnant women with buprenorphine</article-title><source>Addiction</source><year>2000</year><volume>95</volume><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">10723852</pub-id></citation></ref><ref id="R95"><label>95</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>G</given-names></name><name><surname>Ortner</surname><given-names>R</given-names></name><name><surname>Rohrmeister</surname><given-names>K</given-names></name><name><surname>Jagsch</surname><given-names>R</given-names></name><name><surname>Baewert</surname><given-names>A</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><name><surname>Aschauer</surname><given-names>H</given-names></name></person-group><article-title>Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study</article-title><source>Addiction</source><year>2006</year><volume>101</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">16445556</pub-id></citation></ref><ref id="R96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>EF</given-names></name><name><surname>Norton</surname><given-names>BI</given-names></name></person-group><article-title>Comparative <italic>in vivo</italic> distribution of opiate agonists and antagonists by means of double isotope techniques</article-title><source>Life Sci</source><year>1975</year><volume>17</volume><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">1196002</pub-id></citation></ref><ref id="R97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fishman</surname><given-names>J</given-names></name><name><surname>Roffwarg</surname><given-names>H</given-names></name><name><surname>Hellman</surname><given-names>L</given-names></name></person-group><article-title>Disposition of naloxone-7,8,3H in normal and narcotic-dependent men</article-title><source>J. Pharmacol. Exp. Ther</source><year>1973</year><volume>187</volume><fpage>575</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">4588968</pub-id></citation></ref><ref id="R98"><label>98</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Affairs</surname><given-names>O.O.P</given-names></name></person-group><collab>Food and Drug Administration (FDA)</collab><article-title>Subutex and Suboxone approved to treat opiate dependence</article-title><source>FDA Talk</source><year>2002</year><publisher-name>FDA Talk Paper,Office of Public Affairs FDA Talk Paper</publisher-name></citation></ref><ref id="R99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>DH</given-names></name><name><surname>Rhines</surname><given-names>RK</given-names></name></person-group><article-title>Prenatal exposure to methadone HCL in relationship to body and brain growth in the rat</article-title><source>Acta Neurol. Scand</source><year>1979</year><volume>59</volume><fpage>248</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">474066</pub-id></citation></ref><ref id="R100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>DJ</given-names></name><name><surname>Somogyi</surname><given-names>AA</given-names></name><name><surname>Bochner</surname><given-names>F</given-names></name></person-group><article-title>Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4</article-title><source>Br. J. Clin. Pharmacol</source><year>1999</year><volume>47</volume><fpage>403</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">10233205</pub-id></citation></ref><ref id="R101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>DJ</given-names></name><name><surname>Somogyi</surname><given-names>AA</given-names></name><name><surname>Dyer</surname><given-names>KR</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Bochner</surname><given-names>F</given-names></name></person-group><article-title>Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients</article-title><source>Br. J. Clin. Pharmacol</source><year>2000</year><volume>50</volume><fpage>427</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">11069437</pub-id></citation></ref><ref id="R102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fricker</surname><given-names>HS</given-names></name><name><surname>Segal</surname><given-names>S</given-names></name></person-group><article-title>Narcotic addiction, pregnancy, and the newborn</article-title><source>Am. J. Dis. Child</source><year>1978</year><volume>132</volume><fpage>360</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">645651</pub-id></citation></ref><ref id="R103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedler</surname><given-names>G</given-names></name></person-group><article-title>Effect of pregestational morphine and methadone administration to mice on the development of their offspring</article-title><source>Fed. Proc</source><year>1977</year><volume>36</volume><fpage>1001</fpage></citation></ref><ref id="R104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fulroth</surname><given-names>R</given-names></name><name><surname>Phillips</surname><given-names>B</given-names></name><name><surname>Durand</surname><given-names>DJ</given-names></name></person-group><article-title>Perinatal outcome of infants exposed to cocaine and/or heroin <italic>in utero</italic></article-title><source>Am. J. Dis. Child</source><year>1989</year><volume>143</volume><fpage>905</fpage><lpage>910</lpage><pub-id pub-id-type="pmid">2756964</pub-id></citation></ref><ref id="R105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabrielsson</surname><given-names>JL</given-names></name><name><surname>Johansson</surname><given-names>P</given-names></name><name><surname>Bondesson</surname><given-names>U</given-names></name><name><surname>Paalzow</surname><given-names>LK</given-names></name></person-group><article-title>Analysis of methadone disposition in the pregnant rat by means of a physiological flow model</article-title><source>J. Pharmacokinet. Biopharm</source><year>1985</year><volume>13</volume><fpage>355</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">4087168</pub-id></citation></ref><ref id="R106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garbutt</surname><given-names>JC</given-names></name><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>O'Malley</surname><given-names>SS</given-names></name><name><surname>Gastfriend</surname><given-names>DR</given-names></name><name><surname>Pettinati</surname><given-names>HM</given-names></name><name><surname>Silverman</surname><given-names>BL</given-names></name><name><surname>Loewy</surname><given-names>JW</given-names></name><name><surname>Ehrich</surname><given-names>EW</given-names></name></person-group><article-title>Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial</article-title><source>JAMA</source><year>2005</year><volume>293</volume><fpage>1617</fpage><lpage>1625</lpage><pub-id pub-id-type="pmid">15811981</pub-id></citation></ref><ref id="R107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garrido</surname><given-names>MJ</given-names></name><name><surname>Troconiz</surname><given-names>IF</given-names></name></person-group><article-title>Methadone: a review of its pharmacokinetic/pharmacodynamic properties</article-title><source>J. Pharmacol. Toxicol. Methods</source><year>1999</year><volume>42</volume><fpage>61</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">10924887</pub-id></citation></ref><ref id="R108"><label>108</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gaulden</surname><given-names>EC</given-names></name><name><surname>Littlefield</surname><given-names>DC</given-names></name><name><surname>Putoff</surname><given-names>OE</given-names></name><name><surname>Seivert</surname><given-names>AL</given-names></name></person-group><article-title>Menstrual Abnormalities Associated With Heroin Addiction</article-title><source>Am. J. Obstet. Gynecol</source><year>1964</year><volume>90</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">14215871</pub-id></citation></ref><ref id="R109"><label>109</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geber</surname><given-names>WF</given-names></name><name><surname>Schramm</surname><given-names>LC</given-names></name></person-group><article-title>Postpartum weight alteration in hamster offspring from females injected during pregnancy with either heroin, methadone, a composite drug mixture, or mescaline</article-title><source>Am. J. Obstet. Gynecol</source><year>1974</year><volume>120</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">4432899</pub-id></citation></ref><ref id="R110"><label>110</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geraghty</surname><given-names>B</given-names></name><name><surname>Graham</surname><given-names>EA</given-names></name><name><surname>Logan</surname><given-names>B</given-names></name><name><surname>Weiss</surname><given-names>EL</given-names></name></person-group><article-title>Methadone levels in breast milk</article-title><source>J. Hum. Lact</source><year>1997</year><volume>13</volume><fpage>227</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">9341416</pub-id></citation></ref><ref id="R111"><label>111</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gerber</surname><given-names>JG</given-names></name><name><surname>Rhodes</surname><given-names>RJ</given-names></name><name><surname>Gal</surname><given-names>J</given-names></name></person-group><article-title>Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19</article-title><source>Chirality</source><year>2004</year><volume>16</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">14628297</pub-id></citation></ref><ref id="R112"><label>112</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>AC</given-names></name><name><surname>Oei</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>NL</given-names></name><name><surname>Younan</surname><given-names>N</given-names></name><name><surname>Kennedy</surname><given-names>I</given-names></name><name><surname>Lui</surname><given-names>K</given-names></name></person-group><article-title>Strabismus in infants of opiate-dependent mothers</article-title><source>Acta Paediatr</source><year>2003</year><volume>92</volume><fpage>379</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">12725555</pub-id></citation></ref><ref id="R113"><label>113</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginzburg</surname><given-names>HM</given-names></name><name><surname>Glass</surname><given-names>WJ</given-names></name></person-group><article-title>The role of the National Institute on Drug Abuse in the development of naltrexone</article-title><source>J. Clin. Psychiatry</source><year>1984</year><volume>45</volume><fpage>4</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6088469</pub-id></citation></ref><ref id="R114"><label>114</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glasper</surname><given-names>A</given-names></name><name><surname>Reed</surname><given-names>LJ</given-names></name><name><surname>de Wet</surname><given-names>CJ</given-names></name><name><surname>Gossop</surname><given-names>M</given-names></name><name><surname>Bearn</surname><given-names>J</given-names></name></person-group><article-title>Induction of patients with moderately severe methadone dependence onto buprenorphine</article-title><source>Addict. Biol</source><year>2005</year><volume>10</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">16191667</pub-id></citation></ref><ref id="R115"><label>115</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>G</given-names></name><name><surname>Hans</surname><given-names>SL</given-names></name><name><surname>Cox</surname><given-names>SM</given-names></name></person-group><article-title>Attachment behavior and its antecedents in offspring born to methadone-maintained women</article-title><source>J. Clin. Child Psychol</source><year>1999</year><volume>28</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">10070607</pub-id></citation></ref><ref id="R116"><label>116</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>AL</given-names></name><name><surname>Stacey</surname><given-names>H</given-names></name><name><surname>Pearson</surname><given-names>V</given-names></name><name><surname>Haslam</surname><given-names>RR</given-names></name><name><surname>Lopatko</surname><given-names>OV</given-names></name><name><surname>White</surname><given-names>JM</given-names></name></person-group><article-title>Buprenorphine and methadone in pregnancy: Effects on the mother, fetus and neonate</article-title><year>2005</year><conf-name>Annual Scientific Conference of the Australasian Professional Society for Alcohol and Other Drugs</conf-name><conf-loc>Melbourne, Australia</conf-loc></citation></ref><ref id="R117"><label>117</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gossop</surname><given-names>M</given-names></name><name><surname>Bradley</surname><given-names>B</given-names></name><name><surname>Phillips</surname><given-names>GT</given-names></name></person-group><article-title>An investigation of withdrawal symptoms shown by opiate addicts during and subsequent to a 21-day in-patient methadone detoxification procedure</article-title><source>Addict. Behav</source><year>1987</year><volume>12</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3565107</pub-id></citation></ref><ref id="R118"><label>118</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gowing</surname><given-names>L</given-names></name><name><surname>Ali</surname><given-names>R</given-names></name><name><surname>White</surname><given-names>J</given-names></name></person-group><article-title>Buprenorphine for the management of opioid withdrawal</article-title><source>Cochrane Database Syst. Rev</source><year>2006</year><comment>CD002025</comment></citation></ref><ref id="R119"><label>119</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gowing</surname><given-names>LR</given-names></name><name><surname>Lopatko</surname><given-names>O</given-names></name></person-group><article-title>Office based treatment with buprenorphine plus naloxone, or buprenorphine alone reduces opiate use and craving</article-title><source>Evid. Based Ment. Health</source><year>2004</year><volume>7</volume><fpage>54</fpage><pub-id pub-id-type="pmid">15107350</pub-id></citation></ref><ref id="R120"><label>120</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Greenstein</surname><given-names>RA</given-names></name><name><surname>Arndt</surname><given-names>IC</given-names></name><name><surname>McLellan</surname><given-names>AT</given-names></name><name><surname>O'Brien</surname><given-names>CP</given-names></name><name><surname>Evans</surname><given-names>B</given-names></name></person-group><article-title>Naltrexone: a clinical perspective</article-title><source>J. Clin. Psychiatry</source><year>1984</year><volume>45</volume><fpage>25</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">6469933</pub-id></citation></ref><ref id="R121"><label>121</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grota</surname><given-names>LJ</given-names></name></person-group><article-title>Effects of litter size, age of young, and parity on foster mother behaviour in Rattus norvegicus</article-title><source>Anim. Behav</source><year>1973</year><volume>21</volume><fpage>78</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">4706768</pub-id></citation></ref><ref id="R122"><label>122</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grove</surname><given-names>LV</given-names></name><name><surname>Etkin</surname><given-names>MK</given-names></name><name><surname>Rosecrans</surname><given-names>JA</given-names></name></person-group><article-title>Behavioral effects of fetal and neonatal exposure to methadone in the rat</article-title><source>Neurobehav. Toxicol</source><year>1979</year><volume>1</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">551308</pub-id></citation></ref><ref id="R123"><label>123</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>HZ</given-names></name><name><surname>Enters</surname><given-names>EK</given-names></name><name><surname>McDowell</surname><given-names>KP</given-names></name><name><surname>Robinson</surname><given-names>SE</given-names></name></person-group><article-title>The effect of prenatal exposure to methadone on neurotransmitters in neonatal rats</article-title><source>Brain Res. Dev. Brain Res</source><year>1990</year><volume>57</volume><fpage>296</fpage><lpage>298</lpage></citation></ref><ref id="R124"><label>124</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hagopian</surname><given-names>GS</given-names></name><name><surname>Wolfe</surname><given-names>HM</given-names></name><name><surname>Sokol</surname><given-names>RJ</given-names></name><name><surname>Ager</surname><given-names>JW</given-names></name><name><surname>Wardell</surname><given-names>JN</given-names></name><name><surname>Cepeda</surname><given-names>EE</given-names></name></person-group><article-title>Neonatal outcome following methadone exposure in utero</article-title><source>J. Matern. Fetal Med</source><year>1996</year><volume>5</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">8972413</pub-id></citation></ref><ref id="R125"><label>125</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakkola</surname><given-names>J</given-names></name><name><surname>Pasanen</surname><given-names>M</given-names></name><name><surname>Purkunen</surname><given-names>R</given-names></name><name><surname>Saarikoski</surname><given-names>S</given-names></name><name><surname>Pelkonen</surname><given-names>O</given-names></name><name><surname>Maenpaa</surname><given-names>J</given-names></name><name><surname>Rane</surname><given-names>A</given-names></name><name><surname>Raunio</surname><given-names>H</given-names></name></person-group><article-title>Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver</article-title><source>Biochem. Pharmacol</source><year>1994</year><volume>48</volume><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">8043031</pub-id></citation></ref><ref id="R126"><label>126</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hannigan</surname><given-names>JH</given-names></name><name><surname>Armant</surname><given-names>DR</given-names></name></person-group><article-title>Alcohol in pregnancy and neonatal outcome</article-title><source>Semin. Neonatol</source><year>2000</year><volume>5</volume><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">10956449</pub-id></citation></ref><ref id="R127"><label>127</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hans</surname><given-names>SL</given-names></name></person-group><article-title>Developmental consequences of prenatal exposure to methadone</article-title><source>Ann. N. Y. Acad. Sci</source><year>1989</year><volume>562</volume><fpage>195</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">2742277</pub-id></citation></ref><ref id="R128"><label>128</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>RG</given-names></name><name><surname>Solish</surname><given-names>G</given-names></name><name><surname>Feingold</surname><given-names>E</given-names></name><name><surname>Gersten-Woolf</surname><given-names>NB</given-names></name><name><surname>Sokal</surname><given-names>MM</given-names></name></person-group><article-title>Maternal ingested methadone, body fluid methadone, and the neonatal withdrawal syndrome</article-title><source>Am. J. Obstet. Gynecol</source><year>1977</year><volume>129</volume><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">910821</pub-id></citation></ref><ref id="R129"><label>129</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harper</surname><given-names>RG</given-names></name><name><surname>Solish</surname><given-names>GI</given-names></name><name><surname>Purow</surname><given-names>HM</given-names></name><name><surname>Sang</surname><given-names>E</given-names></name><name><surname>Panepinto</surname><given-names>WC</given-names></name></person-group><article-title>The effect of a methadone treatment program upon pregnant heroin addicts and their newborn infants</article-title><source>Pediatric</source><year>1974</year><volume>54</volume><fpage>300</fpage><lpage>305</lpage></citation></ref><ref id="R130"><label>130</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>DS</given-names></name><name><surname>Mendelson</surname><given-names>JE</given-names></name><name><surname>Lin</surname><given-names>ET</given-names></name><name><surname>Upton</surname><given-names>RA</given-names></name><name><surname>Jones</surname><given-names>RT</given-names></name></person-group><article-title>Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality</article-title><source>Clin. Pharmacokinet</source><year>2004</year><volume>43</volume><fpage>329</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">15080765</pub-id></citation></ref><ref id="R131"><label>131</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harry</surname><given-names>GJ</given-names></name><name><surname>Rosecrans</surname><given-names>JA</given-names></name></person-group><article-title>Behavioral effects of perinatal naltrexone exposure: a preliminary investigation</article-title><source>Pharmacol. Biochem. Behav</source><year>1979</year><volume>11</volume><issue>Suppl</issue><fpage>19</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">550130</pub-id></citation></ref><ref id="R132"><label>132</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>Houdi</surname><given-names>AA</given-names></name><name><surname>Turbek</surname><given-names>CS</given-names></name><name><surname>Elde</surname><given-names>RP</given-names></name><name><surname>Maxson W</surname><given-names>3rd</given-names></name></person-group><article-title>Opioids intrinsically inhibit the genesis of mouse cerebellar granule neuron precursors <italic>in vitro</italic>: differential impact of mu and delta receptor activation on proliferation and neurite elongation</article-title><source>Eur. J. Neurosci</source><year>2000</year><volume>12</volume><fpage>1281</fpage><lpage>1293</lpage><pub-id pub-id-type="pmid">10762357</pub-id></citation></ref><ref id="R133"><label>133</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Endogenous opioids regulate dendritic growth and spine formation in developing rat brain</article-title><source>Brain Res</source><year>1987</year><volume>416</volume><fpage>157</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">3040177</pub-id></citation></ref><ref id="R134"><label>134</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>KF</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Endogenous opioid systems and the regulation of dendritic growth and spine formation</article-title><source>J. Comp. Neurol</source><year>1989</year><volume>281</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">2925898</pub-id></citation></ref><ref id="R135"><label>135</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hein</surname><given-names>PR</given-names></name><name><surname>Schatorje</surname><given-names>JS</given-names></name><name><surname>Frencken</surname><given-names>HJ</given-names></name></person-group><article-title>The effect of chronic methadone treatment on intra-uterine growth of the cynomolgus monkey (Macaca fascicularis)</article-title><source>Eur. J. Obstet. Gynecol. Reprod. Biol</source><year>1988</year><volume>27</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">3338613</pub-id></citation></ref><ref id="R136"><label>136</label><citation citation-type="gov"><person-group person-group-type="author"><name><surname>Henry-Edwards</surname><given-names>S</given-names></name><name><surname>Gowing</surname><given-names>L</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>RAJ</given-names></name><name><surname>Brough</surname><given-names>R</given-names></name><name><surname>Lintzeris</surname><given-names>N</given-names></name><name><surname>Ritter</surname><given-names>A</given-names></name><name><surname>Quigley</surname><given-names>A</given-names></name></person-group><article-title>Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioid dependence</article-title><source>Canberra, Australian Government Department of Health and Ageing</source><year>2003</year><fpage>1</fpage><lpage>16</lpage></citation></ref><ref id="R137"><label>137</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>GD</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Endogenous opioid systems and neural development: ultrastructural studies in the cerebellar cortex of infant and weanling rats</article-title><source>Brain Res. Bull</source><year>1988</year><volume>20</volume><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">2840175</pub-id></citation></ref><ref id="R138"><label>138</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hieronymus</surname><given-names>TL</given-names></name><name><surname>Nanovskaya</surname><given-names>TN</given-names></name><name><surname>Deshmukh</surname><given-names>SV</given-names></name><name><surname>Vargas</surname><given-names>R</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Methadone metabolism by early gestational age placentas</article-title><source>Am. J. Perinatol</source><year>2006</year><volume>23</volume><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">16799915</pub-id></citation></ref><ref id="R139"><label>139</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>ST</given-names></name><name><surname>Stitzer</surname><given-names>ML</given-names></name><name><surname>Bigelow</surname><given-names>GE</given-names></name><name><surname>Liebson</surname><given-names>IA</given-names></name></person-group><article-title>Contingent methadone delivery: effects on illicit-opiate use</article-title><source>Drug Alcohol Depend</source><year>1986</year><volume>17</volume><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">3757767</pub-id></citation></ref><ref id="R140"><label>140</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>MD</given-names></name><name><surname>Abramson</surname><given-names>FP</given-names></name></person-group><article-title>The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state</article-title><source>Clin. Pharmacokinet</source><year>1988</year><volume>14</volume><fpage>156</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">3286084</pub-id></citation></ref><ref id="R141"><label>141</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Belcheva</surname><given-names>MM</given-names></name><name><surname>Clark</surname><given-names>AL</given-names></name><name><surname>Zahm</surname><given-names>DS</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name></person-group><article-title>Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling</article-title><source>Brain Res. Dev. Brain Res</source><year>2004</year><volume>151</volume><fpage>149</fpage><lpage>157</lpage></citation></ref><ref id="R142"><label>142</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Householder</surname><given-names>J</given-names></name><name><surname>Hatcher</surname><given-names>R</given-names></name><name><surname>Burns</surname><given-names>W</given-names></name><name><surname>Chasnoff</surname><given-names>I</given-names></name></person-group><article-title>Infants born to narcotic-addicted mothers</article-title><source>Psychol. Bull</source><year>1982</year><volume>92</volume><fpage>453</fpage><lpage>468</lpage><pub-id pub-id-type="pmid">7146236</pub-id></citation></ref><ref id="R143"><label>143</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hovious</surname><given-names>JR</given-names></name><name><surname>Peters</surname><given-names>MA</given-names></name></person-group><article-title>Analgesic effect of opiates in offspring of opiate-treated female rats</article-title><source>Pharmacol. Biochem. Behav</source><year>1984</year><volume>21</volume><fpage>555</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">6150495</pub-id></citation></ref><ref id="R144"><label>144</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hovious</surname><given-names>JR</given-names></name><name><surname>Peters</surname><given-names>MA</given-names></name></person-group><article-title>Opiate self-administration in adult offspring of methadone-treated female rats</article-title><source>Pharmacol. Biochem. Behav</source><year>1985</year><volume>22</volume><fpage>949</fpage><lpage>953</lpage><pub-id pub-id-type="pmid">4023027</pub-id></citation></ref><ref id="R145"><label>145</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>FW</given-names></name><name><surname>Krikun</surname><given-names>E</given-names></name><name><surname>Smith</surname><given-names>AA</given-names></name></person-group><article-title>Inhibition by d,l-methadone of RNA and protein synthesis in neonatal mice: antagonism by naloxone or naltrexone</article-title><source>Eur. J. Pharmacol</source><year>1978</year><volume>49</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">658129</pub-id></citation></ref><ref id="R146"><label>146</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>G</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name></person-group><article-title>Using naltrexone implants in the management of the pregnant heroin user</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>2002</year><volume>42</volume><fpage>569</fpage><lpage>573</lpage><pub-id pub-id-type="pmid">12495120</pub-id></citation></ref><ref id="R147"><label>147</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Arnold-Reed</surname><given-names>DE</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>CT</given-names></name><name><surname>Hansson</surname><given-names>R</given-names></name><name><surname>O'Neil</surname><given-names>P</given-names></name></person-group><article-title>Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants</article-title><source>Addict. Biol</source><year>2004</year><volume>9</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">15203440</pub-id></citation></ref><ref id="R148"><label>148</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Arnold-Reed</surname><given-names>DE</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Chan</surname><given-names>CT</given-names></name><name><surname>Hansson</surname><given-names>RC</given-names></name></person-group><article-title>Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants</article-title><source>Addict. Biol</source><year>2004</year><volume>9</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">15203441</pub-id></citation></ref><ref id="R149"><label>149</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Arnold-Reed</surname><given-names>DE</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Hansson</surname><given-names>RC</given-names></name></person-group><article-title>Naltrexone implant and blood naltrexone levels over pregnancy</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>2003</year><volume>43</volume><fpage>386</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">14717319</pub-id></citation></ref><ref id="R150"><label>150</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Basso</surname><given-names>MR</given-names></name></person-group><article-title>The association between naltrexone compliance and daily supervision</article-title><source>Drug Alcohol Rev</source><year>2000</year><volume>19</volume><fpage>41</fpage><lpage>48</lpage></citation></ref><ref id="R151"><label>151</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Milne</surname><given-names>E</given-names></name><name><surname>Holman</surname><given-names>CD</given-names></name><name><surname>Bower</surname><given-names>CI</given-names></name></person-group><article-title>Maternal cocaine use and low birth weight newborns: a meta-analysis</article-title><source>Addiction</source><year>1997</year><volume>92</volume><fpage>1561</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">9519498</pub-id></citation></ref><ref id="R152"><label>152</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Milne</surname><given-names>E</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Holman</surname><given-names>CD</given-names></name></person-group><article-title>The relationship between maternal use of heroin and methadone and infant birth weight</article-title><source>Addiction</source><year>1997</year><volume>92</volume><fpage>1571</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">9519499</pub-id></citation></ref><ref id="R153"><label>153</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Milne</surname><given-names>E</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Holman</surname><given-names>CD</given-names></name></person-group><article-title>Assessing the relationship between maternal opiate use and antepartum haemorrhage</article-title><source>Addiction</source><year>1998</year><volume>93</volume><fpage>1553</fpage><lpage>1558</lpage><pub-id pub-id-type="pmid">9926560</pub-id></citation></ref><ref id="R154"><label>154</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Milne</surname><given-names>E</given-names></name><name><surname>English</surname><given-names>DR</given-names></name><name><surname>Holman</surname><given-names>CD</given-names></name></person-group><article-title>Assessing the relationship between maternal opiate use and neonatal mortality</article-title><source>Addiction</source><year>1998</year><volume>93</volume><fpage>1033</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">9744134</pub-id></citation></ref><ref id="R155"><label>155</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name></person-group><article-title>Methadone and the pregnant user: a matter for careful clinical consideration</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>2001</year><volume>41</volume><fpage>329</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">11592552</pub-id></citation></ref><ref id="R156"><label>156</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name></person-group><article-title>A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>2002</year><volume>42</volume><fpage>104</fpage><lpage>105</lpage></citation></ref><ref id="R157"><label>157</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Arnold-Reed</surname><given-names>DE</given-names></name></person-group><article-title>Methadone maintenance <italic>vs.</italic> implantable naltrexone treatment in the pregnant heroin user</article-title><source>Int. J. Gynaecol. Obstet</source><year>2004</year><volume>85</volume><fpage>170</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">15099783</pub-id></citation></ref><ref id="R158"><label>158</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>O'Neil</surname><given-names>G</given-names></name><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Brewer</surname><given-names>C</given-names></name></person-group><article-title>Obstetric and neonatal outcomes associated with maternal naltrexone exposure</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>2001</year><volume>41</volume><fpage>424</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">11787918</pub-id></citation></ref><ref id="R159"><label>159</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Tait</surname><given-names>RJ</given-names></name></person-group><article-title>A pilot study to assess the impact of naltrexone implant on accidental opiate overdose in 'high-risk' adolescent heroin users</article-title><source>Addict. Biol</source><year>2003</year><volume>8</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">13129836</pub-id></citation></ref><ref id="R160"><label>160</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hulse</surname><given-names>GK</given-names></name><name><surname>Tait</surname><given-names>RJ</given-names></name><name><surname>Comer</surname><given-names>SD</given-names></name><name><surname>Sullivan</surname><given-names>MA</given-names></name><name><surname>Jacobs</surname><given-names>IG</given-names></name><name><surname>Arnold-Reed</surname><given-names>D</given-names></name></person-group><article-title>Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants</article-title><source>Drug Alcohol Depend</source><year>2005</year><volume>79</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">15899557</pub-id></citation></ref><ref id="R161"><label>161</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name></person-group><article-title>Methadone and heroin during pregnancy: a review of behavioral effects in human and animal offspring</article-title><source>Neurobehav. Toxicol. Teratol</source><year>1982</year><volume>4</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">7121694</pub-id></citation></ref><ref id="R162"><label>162</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name></person-group><article-title>Issues of methodology and interpretation in clinical and animal behavioral teratology studies</article-title><source>Neurobehav. Toxicol. Teratol</source><year>1985</year><volume>7</volume><fpage>639</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">3835457</pub-id></citation></ref><ref id="R163"><label>163</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name></person-group><article-title>Prenatal opioid exposure and the problem of causal inference</article-title><source>NIDA Res. Monogr</source><year>1985</year><volume>59</volume><fpage>6</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">3929133</pub-id></citation></ref><ref id="R164"><label>164</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name><name><surname>Dow-Edwards</surname><given-names>D</given-names></name></person-group><article-title>Animal models of opiate, cocaine, and cannabis use</article-title><source>Clin. Perinatol</source><year>1991</year><volume>18</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">1645632</pub-id></citation></ref><ref id="R165"><label>165</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name><name><surname>Hamowy</surname><given-names>AS</given-names></name><name><surname>Williams</surname><given-names>EM</given-names></name><name><surname>Zmitrovich</surname><given-names>AC</given-names></name></person-group><article-title>Prenatal administration of buprenorphine in the rat: effects on the rest-activity cycle at 22 and 30 days of age</article-title><source>Pharmacol. Biochem. Behav</source><year>1996</year><volume>55</volume><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">8981591</pub-id></citation></ref><ref id="R166"><label>166</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name><name><surname>Hunt</surname><given-names>HF</given-names></name><name><surname>Towey</surname><given-names>JP</given-names></name><name><surname>Rosen</surname><given-names>TS</given-names></name><name><surname>Gorinson</surname><given-names>HS</given-names></name></person-group><article-title>Methadone during pregnancy in the rat: dose level effects on maternal and perinatal mortality and growth in the offspring</article-title><source>J. Pharmacol. Exp. Ther</source><year>1976</year><volume>197</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">1263128</pub-id></citation></ref><ref id="R167"><label>167</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name><name><surname>Towey</surname><given-names>JP</given-names></name><name><surname>Gorinson</surname><given-names>HS</given-names></name><name><surname>Hunt</surname><given-names>HF</given-names></name></person-group><article-title>Methadone during pregnancy: assessment of behavioral effects in the rat offspring</article-title><source>J. Pharmacol. Exp. Ther</source><year>1979</year><volume>208</volume><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">759603</pub-id></citation></ref><ref id="R168"><label>168</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name><name><surname>Zmitrovich</surname><given-names>A</given-names></name><name><surname>Church</surname><given-names>S</given-names></name><name><surname>Malowany</surname><given-names>D</given-names></name></person-group><article-title>Methadone during pregnancy: the search for a valid animal model</article-title><source>Ann. Ist Super Sanita</source><year>1993</year><volume>29</volume><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">8172463</pub-id></citation></ref><ref id="R169"><label>169</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>DE</given-names></name><name><surname>Zmitrovich</surname><given-names>AC</given-names></name><name><surname>Hamowy</surname><given-names>AS</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name></person-group><article-title>Prenatal administration of buprenorphine using the osmotic minipump: a preliminary study of maternal and offspring toxicity and growth in the rat</article-title><source>Neurotoxicol. Teratol</source><year>1995</year><volume>17</volume><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">7565488</pub-id></citation></ref><ref id="R170"><label>170</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><article-title>Disposition of narcotics and narcotic antagonists</article-title><source>Ann. N. Y. Acad. Sci</source><year>1976</year><volume>281</volume><fpage>273</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">828465</pub-id></citation></ref><ref id="R171"><label>171</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inturrisi</surname><given-names>CE</given-names></name><name><surname>Colburn</surname><given-names>WA</given-names></name><name><surname>Kaiko</surname><given-names>RF</given-names></name><name><surname>Houde</surname><given-names>RW</given-names></name><name><surname>Foley</surname><given-names>KM</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain</article-title><source>Clin. Pharmacol. Ther</source><year>1987</year><volume>41</volume><fpage>392</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">3829576</pub-id></citation></ref><ref id="R172"><label>172</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iribarne</surname><given-names>C</given-names></name><name><surname>Picart</surname><given-names>D</given-names></name><name><surname>Dreano</surname><given-names>Y</given-names></name><name><surname>Bail</surname><given-names>JP</given-names></name><name><surname>Berthou</surname><given-names>F</given-names></name></person-group><article-title>Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes</article-title><source>Life Sci</source><year>1997</year><volume>60</volume><fpage>1953</fpage><lpage>1964</lpage><pub-id pub-id-type="pmid">9180349</pub-id></citation></ref><ref id="R173"><label>173</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>GL</given-names></name><name><surname>Timiras</surname><given-names>PS</given-names></name></person-group><article-title>Litter size and brain development in the rat</article-title><source>Life Sci</source><year>1966</year><volume>5</volume><fpage>1577</fpage><lpage>1582</lpage><pub-id pub-id-type="pmid">5970681</pub-id></citation></ref><ref id="R174"><label>174</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Isayama</surname><given-names>T</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Endogenous opioids regulate cell proliferation in the retina of developing rat</article-title><source>Brain Res</source><year>1991</year><volume>544</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">1649664</pub-id></citation></ref><ref id="R175"><label>175</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>LM</given-names></name><name><surname>Dipietro</surname><given-names>J</given-names></name><name><surname>Elko</surname><given-names>A</given-names></name></person-group><article-title>Fetal response to maternal methadone administration</article-title><source>Am. J. Obstet. Gynecol</source><year>2005</year><volume>193</volume><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">16150250</pub-id></citation></ref><ref id="R176"><label>176</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansson</surname><given-names>LM</given-names></name><name><surname>Velez</surname><given-names>M</given-names></name><name><surname>Harrow</surname><given-names>C</given-names></name></person-group><article-title>Methadone maintenance and lactation: a review of the literature and current management guidelines</article-title><source>J. Hum. Lact</source><year>2004</year><volume>20</volume><fpage>62</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">14974702</pub-id></citation></ref><ref id="R177"><label>177</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>MA</given-names></name><name><surname>Schnoll</surname><given-names>SH</given-names></name></person-group><article-title>Methadone use during pregnancy</article-title><source>NIDA Res. Monogr</source><year>1995</year><volume>149</volume><fpage>58</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">8775835</pub-id></citation></ref><ref id="R178"><label>178</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>MA</given-names></name><name><surname>Wu-Pong</surname><given-names>S</given-names></name><name><surname>Kniseley</surname><given-names>JS</given-names></name><name><surname>Schnoll</surname><given-names>SH</given-names></name></person-group><article-title>Alterations in methadone metabolism during late pregnancy</article-title><source>J. Addict. Dis</source><year>1999</year><volume>18</volume><fpage>51</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10631963</pub-id></citation></ref><ref id="R179"><label>179</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jasinski</surname><given-names>DR</given-names></name><name><surname>Pevnick</surname><given-names>JS</given-names></name><name><surname>Griffith</surname><given-names>JD</given-names></name></person-group><article-title>Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction</article-title><source>Arch. Gen. Psychiatry</source><year>1978</year><volume>35</volume><fpage>501</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">215096</pub-id></citation></ref><ref id="R180"><label>180</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jeremy</surname><given-names>RJ</given-names></name><name><surname>Hans</surname><given-names>SL</given-names></name></person-group><article-title>Behavior of neonates exposed in utero to methadone as assessed on the Brazelton scale</article-title><source>Inf. Behav. Dev</source><year>1985</year><volume>8</volume><fpage>323</fpage><lpage>336</lpage></citation></ref><ref id="R181"><label>181</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BA</given-names></name><name><surname>Ait-Daoud</surname><given-names>N</given-names></name><name><surname>Aubin</surname><given-names>HJ</given-names></name><name><surname>Van Den Brink</surname><given-names>W</given-names></name><name><surname>Guzzetta</surname><given-names>R</given-names></name><name><surname>Loewy</surname><given-names>J</given-names></name><name><surname>Silverman</surname><given-names>B</given-names></name><name><surname>Ehrich</surname><given-names>E</given-names></name></person-group><article-title>A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence</article-title><source>Alcohol Clin. Exp. Res</source><year>2004</year><volume>28</volume><fpage>1356</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">15365306</pub-id></citation></ref><ref id="R182"><label>182</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>H</given-names></name></person-group><article-title>Quantitative stereo-structure-activity relationships I. Opiate receptor binding</article-title><source>NIDA Res. Monogr</source><year>1978</year><fpage>146</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">213724</pub-id></citation></ref><ref id="R183"><label>183</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Leff</surname><given-names>M</given-names></name></person-group><article-title>Children of substance abusers: overview of research findings</article-title><source>Pediatrics</source><year>1999</year><volume>103</volume><fpage>1085</fpage><lpage>1099</lpage><pub-id pub-id-type="pmid">10224196</pub-id></citation></ref><ref id="R184"><label>184</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Eissenberg</surname><given-names>T</given-names></name><name><surname>Stitzer</surname><given-names>ML</given-names></name><name><surname>Strain</surname><given-names>EC</given-names></name><name><surname>Liebson</surname><given-names>IA</given-names></name><name><surname>Bigelow</surname><given-names>GE</given-names></name></person-group><article-title>A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence</article-title><source>Drug Alcohol Depend</source><year>1995</year><volume>40</volume><fpage>17</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">8746920</pub-id></citation></ref><ref id="R185"><label>185</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name></person-group><article-title>Use of buprenorphine in pregnancy: patient management and effects on the neonate</article-title><source>Drug Alcohol Depend</source><year>2003</year><volume>70</volume><fpage>S87</fpage><lpage>S101</lpage><pub-id pub-id-type="pmid">12738353</pub-id></citation></ref><ref id="R186"><label>186</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Jasinski</surname><given-names>DR</given-names></name><name><surname>Svikis</surname><given-names>DS</given-names></name><name><surname>Haug</surname><given-names>N</given-names></name><name><surname>Jansson</surname><given-names>LM</given-names></name><name><surname>Kissin</surname><given-names>WB</given-names></name><name><surname>Alpan</surname><given-names>G</given-names></name><name><surname>Lantz</surname><given-names>ME</given-names></name><name><surname>Cone</surname><given-names>EJ</given-names></name><name><surname>Wilkins</surname><given-names>DG</given-names></name><name><surname>Golden</surname><given-names>AS</given-names></name><name><surname>Huggins</surname><given-names>GR</given-names></name><name><surname>Lester</surname><given-names>BM</given-names></name></person-group><article-title>Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes</article-title><source>Drug Alcohol Depend</source><year>2001</year><volume>63</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">11297835</pub-id></citation></ref><ref id="R187"><label>187</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Haug</surname><given-names>N</given-names></name><name><surname>Silverman</surname><given-names>K</given-names></name><name><surname>Stitzer</surname><given-names>M</given-names></name><name><surname>Svikis</surname><given-names>D</given-names></name></person-group><article-title>The effectiveness of incentives in enhancing treatment attendance and drug abstinence in methadone-maintained pregnant women</article-title><source>Drug Alcohol Depend</source><year>2001</year><volume>61</volume><fpage>297</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">11164694</pub-id></citation></ref><ref id="R188"><label>188</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Jasinski</surname><given-names>DR</given-names></name><name><surname>Milio</surname><given-names>L</given-names></name></person-group><article-title>Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone</article-title><source>Drug Alcohol Depend</source><year>2005</year><volume>78</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15769555</pub-id></citation></ref><ref id="R189"><label>189</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>HE</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Jasinski</surname><given-names>DR</given-names></name><name><surname>O'Grady</surname><given-names>KE</given-names></name><name><surname>Chisholm</surname><given-names>CA</given-names></name><name><surname>Choo</surname><given-names>RE</given-names></name><name><surname>Crocetti</surname><given-names>M</given-names></name><name><surname>Dudas</surname><given-names>R</given-names></name><name><surname>Harrow</surname><given-names>C</given-names></name><name><surname>Huestis</surname><given-names>MA</given-names></name><name><surname>Jansson</surname><given-names>LM</given-names></name><name><surname>Lantz</surname><given-names>M</given-names></name><name><surname>Lester</surname><given-names>BM</given-names></name><name><surname>Milio</surname><given-names>L</given-names></name></person-group><article-title>Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome</article-title><source>Drug Alcohol Depend</source><year>2005</year><volume>79</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15943939</pub-id></citation></ref><ref id="R190"><label>190</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaltenbach</surname><given-names>K</given-names></name><name><surname>Berghella</surname><given-names>V</given-names></name><name><surname>Finnegan</surname><given-names>L</given-names></name></person-group><article-title>Opioid dependence during pregnancy Effects and management</article-title><source>Obstet. Gynecol. Clin. North Am</source><year>1998</year><volume>25</volume><fpage>139</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">9547764</pub-id></citation></ref><ref id="R191"><label>191</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaltenbach</surname><given-names>K</given-names></name><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Neonatal abstinence syndrome, pharmacotherapy and developmental outcome</article-title><source>Neurobehav. Toxicol. Teratol</source><year>1986</year><volume>8</volume><fpage>353</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">3762845</pub-id></citation></ref><ref id="R192"><label>192</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaltenbach</surname><given-names>K</given-names></name><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Perinatal and developmental outcome of infants exposed to methadone in-utero</article-title><source>Neurotoxicol. Teratol</source><year>1987</year><volume>9</volume><fpage>311</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">3683349</pub-id></citation></ref><ref id="R193"><label>193</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaltenbach</surname><given-names>KA</given-names></name></person-group><article-title>Exposure to opiates: behavioral outcomes in preschool and school-age children</article-title><source>NIDA Res. Monogr</source><year>1996</year><volume>164</volume><fpage>230</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">8809874</pub-id></citation></ref><ref id="R194"><label>194</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandall</surname><given-names>SR</given-names></name><name><surname>Albin</surname><given-names>S</given-names></name><name><surname>Gartner</surname><given-names>LM</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Eidelman</surname><given-names>A</given-names></name><name><surname>Lowinson</surname><given-names>J</given-names></name></person-group><article-title>The narcotic-dependent mother: fetal and neonatal consequences</article-title><source>Early Hum. Dev</source><year>1977</year><volume>1</volume><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">617308</pub-id></citation></ref><ref id="R195"><label>195</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandall</surname><given-names>SR</given-names></name><name><surname>Albin</surname><given-names>S</given-names></name><name><surname>Lowinson</surname><given-names>J</given-names></name><name><surname>Berle</surname><given-names>B</given-names></name><name><surname>Eidelman</surname><given-names>AI</given-names></name><name><surname>Gartner</surname><given-names>LM</given-names></name></person-group><article-title>Differential effects of maternal heroin and methadone use on birthweight</article-title><source>Pediatrics</source><year>1976</year><volume>58</volume><fpage>681</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">980601</pub-id></citation></ref><ref id="R196"><label>196</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandall</surname><given-names>SR</given-names></name><name><surname>Doberczak</surname><given-names>TM</given-names></name><name><surname>Jantunen</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name></person-group><article-title>The methadone-maintained pregnancy</article-title><source>Clin. Perinatol</source><year>1999</year><volume>26</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">10214548</pub-id></citation></ref><ref id="R197"><label>197</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandall</surname><given-names>SR</given-names></name><name><surname>Gaines</surname><given-names>J</given-names></name></person-group><article-title>Maternal substance use and subsequent sudden infant death syndrome (SIDS) in offspring</article-title><source>Neurotoxicol. Teratol</source><year>1991</year><volume>13</volume><fpage>235</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">2046641</pub-id></citation></ref><ref id="R198"><label>198</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kashiwagi</surname><given-names>M</given-names></name><name><surname>Arlettaz</surname><given-names>R</given-names></name><name><surname>Lauper</surname><given-names>U</given-names></name><name><surname>Zimmermann</surname><given-names>R</given-names></name><name><surname>Hebisch</surname><given-names>G</given-names></name></person-group><article-title>Methadone maintenance program in a Swiss perinatal center: (I): Management and outcome of 89 pregnancies</article-title><source>Acta Obstet. Gynecol. Scand</source><year>2005</year><volume>84</volume><fpage>140</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">15683373</pub-id></citation></ref><ref id="R199"><label>199</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kastin</surname><given-names>AJ</given-names></name><name><surname>Pearson</surname><given-names>MA</given-names></name><name><surname>Banks</surname><given-names>WA</given-names></name></person-group><article-title>EEG evidence that morphine and an enkephalin analog cross the blood-brain barrier</article-title><source>Pharmacol. Biochem. Behav</source><year>1991</year><volume>40</volume><fpage>771</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">1687763</pub-id></citation></ref><ref id="R200"><label>200</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>JJ</given-names></name><name><surname>Semo</surname><given-names>NM</given-names></name><name><surname>Koski</surname><given-names>WS</given-names></name></person-group><article-title>Microelectrometric titration measurement of the pKa's and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence</article-title><source>J. Med. Chem</source><year>1975</year><volume>18</volume><fpage>647</fpage><lpage>655</lpage><pub-id pub-id-type="pmid">239235</pub-id></citation></ref><ref id="R201"><label>201</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kayemba-Kay's</surname><given-names>S</given-names></name><name><surname>Laclyde</surname><given-names>JP</given-names></name></person-group><article-title>Buprenorphine withdrawal syndrome in newborns: a report of 13 cases</article-title><source>Addiction</source><year>2003</year><volume>98</volume><fpage>1599</fpage><lpage>1604</lpage><pub-id pub-id-type="pmid">14616186</pub-id></citation></ref><ref id="R202"><label>202</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keshet</surname><given-names>GI</given-names></name><name><surname>Weinstock</surname><given-names>M</given-names></name></person-group><article-title>Maternal naltrexone prevents morphological and behavioral alterations induced in rats by prenatal stress</article-title><source>Pharmacol. Biochem. Behav</source><year>1995</year><volume>50</volume><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">7617680</pub-id></citation></ref><ref id="R203"><label>203</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kissin</surname><given-names>WB</given-names></name><name><surname>Svikis</surname><given-names>DS</given-names></name><name><surname>Morgan</surname><given-names>GD</given-names></name><name><surname>Haug</surname><given-names>NA</given-names></name></person-group><article-title>Characterizing pregnant drug-dependent women in treatment and their children</article-title><source>J. Subst. Abuse Treat</source><year>2001</year><volume>21</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11516924</pub-id></citation></ref><ref id="R204"><label>204</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kleber</surname><given-names>HD</given-names></name><name><surname>Kosten</surname><given-names>TR</given-names></name><name><surname>Gaspari</surname><given-names>J</given-names></name><name><surname>Topazian</surname><given-names>M</given-names></name></person-group><article-title>Nontolerance to the opioid antagonism of naltrexone</article-title><source>Biol. Psychiatry</source><year>1985</year><volume>20</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">2981129</pub-id></citation></ref><ref id="R205"><label>205</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Chiba</surname><given-names>K</given-names></name><name><surname>Tani</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Kuroiwa</surname><given-names>Y</given-names></name></person-group><article-title>Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4</article-title><source>Drug Metab. Dispos</source><year>1998</year><volume>26</volume><fpage>818</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">9698298</pub-id></citation></ref><ref id="R206"><label>206</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kopecky</surname><given-names>EA</given-names></name><name><surname>Simone</surname><given-names>C</given-names></name><name><surname>Knie</surname><given-names>B</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Transfer of morphine across the human placenta and its interaction with naloxone</article-title><source>Life Sci</source><year>1999</year><volume>65</volume><fpage>2359</fpage><lpage>2371</lpage><pub-id pub-id-type="pmid">10597891</pub-id></citation></ref><ref id="R207"><label>207</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosten</surname><given-names>TR</given-names></name><name><surname>Rosen</surname><given-names>MI</given-names></name><name><surname>Schottenfeld</surname><given-names>R</given-names></name><name><surname>Ziedonis</surname><given-names>D</given-names></name></person-group><article-title>Buprenorphine for cocaine and opiate dependence</article-title><source>Psychopharmacol. Bull</source><year>1992</year><volume>28</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">1609037</pub-id></citation></ref><ref id="R208"><label>208</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kosten</surname><given-names>TR</given-names></name><name><surname>Schottenfeld</surname><given-names>R</given-names></name><name><surname>Ziedonis</surname><given-names>D</given-names></name><name><surname>Falcioni</surname><given-names>J</given-names></name></person-group><article-title>Buprenorphine versus methadone maintenance for opioid dependence</article-title><source>J. Nerv. Ment. Dis</source><year>1993</year><volume>181</volume><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">8501457</pub-id></citation></ref><ref id="R209"><label>209</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Van Kirk</surname><given-names>J</given-names></name></person-group><article-title>Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis</article-title><source>Alcohol Clin. Exp. Res</source><year>2001</year><volume>25</volume><fpage>1335</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">11584154</pub-id></citation></ref><ref id="R210"><label>210</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kranzler</surname><given-names>HR</given-names></name><name><surname>Wesson</surname><given-names>DR</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name></person-group><article-title>Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial</article-title><source>Alcohol Clin. Exp. Res</source><year>2004</year><volume>28</volume><fpage>1051</fpage><lpage>1059</lpage><pub-id pub-id-type="pmid">15252291</pub-id></citation></ref><ref id="R211"><label>211</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krauer</surname><given-names>B</given-names></name><name><surname>Dayer</surname><given-names>P</given-names></name></person-group><article-title>Fetal drug metabolism and its possible clinical implications</article-title><source>Clin. Pharmacokinet</source><year>1991</year><volume>21</volume><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">1914342</pub-id></citation></ref><ref id="R212"><label>212</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Methadone disposition during the perinatal period in humans</article-title><source>Pharmacol. Biochem. Behav</source><year>1979</year><volume>11</volume><issue>Suppl</issue><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">550136</pub-id></citation></ref><ref id="R213"><label>213</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kreek</surname><given-names>MJ</given-names></name></person-group><article-title>Rationale for maintenance pharmacotherapy of opiate dependence</article-title><source>Res. Publ. Assoc. Res. Nerv. Ment. Dis</source><year>1992</year><volume>70</volume><fpage>205</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">1346939</pub-id></citation></ref><ref id="R214"><label>214</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kristensen</surname><given-names>K</given-names></name><name><surname>Blemmer</surname><given-names>T</given-names></name><name><surname>Angelo</surname><given-names>HR</given-names></name><name><surname>Christrup</surname><given-names>LL</given-names></name><name><surname>Drenck</surname><given-names>NE</given-names></name><name><surname>Rasmussen</surname><given-names>SN</given-names></name><name><surname>Sjogren</surname><given-names>P</given-names></name></person-group><article-title>Stereoselective pharmacokinetics of methadone in chronic pain patients</article-title><source>Ther. Drug Monit</source><year>1996</year><volume>18</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">8738759</pub-id></citation></ref><ref id="R215"><label>215</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kron</surname><given-names>RE</given-names></name><name><surname>Litt</surname><given-names>M</given-names></name><name><surname>Eng</surname><given-names>D</given-names></name><name><surname>Phoenix</surname><given-names>MD</given-names></name><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Neonatal narcotic abstinence: Effects of pharmacotherapeutic agents and maternal drug usage on nutritive sucking behavior</article-title><source>J. Pediatr</source><year>1976</year><volume>88</volume><fpage>637</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">1255326</pub-id></citation></ref><ref id="R216"><label>216</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhlman JJ</surname><given-names>Jr</given-names></name><name><surname>Lalani</surname><given-names>S</given-names></name><name><surname>Magluilo J</surname><given-names>Jr</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Darwin</surname><given-names>WD</given-names></name></person-group><article-title>Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine</article-title><source>J. Anal. Toxicol</source><year>1996</year><volume>20</volume><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">8889672</pub-id></citation></ref><ref id="R217"><label>217</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuhlman JJ</surname><given-names>Jr</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Johnson</surname><given-names>RE</given-names></name><name><surname>Fudala</surname><given-names>PJ</given-names></name><name><surname>Cone</surname><given-names>EJ</given-names></name></person-group><article-title>Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine</article-title><source>Addiction</source><year>1998</year><volume>93</volume><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">9684393</pub-id></citation></ref><ref id="R218"><label>218</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>I</given-names></name><name><surname>Berrebi</surname><given-names>A</given-names></name><name><surname>Chaumerliac</surname><given-names>C</given-names></name><name><surname>Lapeyre-Mestre</surname><given-names>M</given-names></name><name><surname>Montastruc</surname><given-names>JL</given-names></name><name><surname>Damase-Michel</surname><given-names>C</given-names></name></person-group><article-title>Buprenorphine in pregnant opioid-dependent women: first results of a prospective study</article-title><source>Addiction</source><year>2004</year><volume>99</volume><fpage>209</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">14756713</pub-id></citation></ref><ref id="R219"><label>219</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ladona</surname><given-names>MG</given-names></name><name><surname>Lindstrom</surname><given-names>B</given-names></name><name><surname>Thyr</surname><given-names>C</given-names></name><name><surname>Dun-Ren</surname><given-names>P</given-names></name><name><surname>Rane</surname><given-names>A</given-names></name></person-group><article-title>Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man</article-title><source>Br. J. Clin. Pharmacol</source><year>1991</year><volume>32</volume><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">1838002</pub-id></citation></ref><ref id="R220"><label>220</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laken</surname><given-names>MP</given-names></name><name><surname>Ager</surname><given-names>JW</given-names></name></person-group><article-title>Effects of case management on retention in prenatal substance abuse treatment</article-title><source>Am. J. Drug Alcohol Abuse</source><year>1996</year><volume>22</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">8841690</pub-id></citation></ref><ref id="R221"><label>221</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laken</surname><given-names>MP</given-names></name><name><surname>McComish</surname><given-names>JF</given-names></name><name><surname>Ager</surname><given-names>J</given-names></name></person-group><article-title>Predictors of prenatal substance use and birth weight during outpatient treatment</article-title><source>J. Subst. Abuse Treat</source><year>1997</year><volume>14</volume><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">9368212</pub-id></citation></ref><ref id="R222"><label>222</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>SK</given-names></name><name><surname>To</surname><given-names>WK</given-names></name><name><surname>Duthie</surname><given-names>SJ</given-names></name><name><surname>Ma</surname><given-names>HK</given-names></name></person-group><article-title>Narcotic addiction in pregnancy with adverse maternal and perinatal outcome</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>1992</year><volume>32</volume><fpage>216</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">1445130</pub-id></citation></ref><ref id="R223"><label>223</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lasky</surname><given-names>DI</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of maternally administered heroin on the motor activity of rat offspring</article-title><source>Pharmacol. Biochem. Behav</source><year>1977</year><volume>7</volume><fpage>281</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">928485</pub-id></citation></ref><ref id="R224"><label>224</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Bartolome</surname><given-names>M</given-names></name><name><surname>Slotkin</surname><given-names>TA</given-names></name></person-group><article-title>Development of central and peripheral catecholaminergic systems in rats addicted perinatally to methadone</article-title><source>Neuropharmacology</source><year>1977</year><volume>16</volume><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">21355</pub-id></citation></ref><ref id="R225"><label>225</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leander</surname><given-names>JD</given-names></name></person-group><article-title>Buprenorphine has potent kappa opioid receptor antagonist activity</article-title><source>Neuropharmacology</source><year>1987</year><volume>26</volume><fpage>1445</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">2823167</pub-id></citation></ref><ref id="R226"><label>226</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Chiang</surname><given-names>CN</given-names></name></person-group><article-title>Maternal-fetal transfer of abused substances: pharmacokinetic and pharmacodynamic data</article-title><source>NIDA Res. Monogr</source><year>1985</year><volume>60</volume><fpage>110</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">2997613</pub-id></citation></ref><ref id="R227"><label>227</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>MC</given-names></name><name><surname>Wagner HN</surname><given-names>Jr</given-names></name><name><surname>Tanada</surname><given-names>S</given-names></name><name><surname>Frost</surname><given-names>JJ</given-names></name><name><surname>Bice</surname><given-names>AN</given-names></name><name><surname>Dannals</surname><given-names>RF</given-names></name></person-group><article-title>Duration of occupancy of opiate receptors by naltrexone</article-title><source>J. Nucl. Med</source><year>1988</year><volume>29</volume><fpage>1207</fpage><lpage>1211</lpage><pub-id pub-id-type="pmid">2839637</pub-id></citation></ref><ref id="R228"><label>228</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lejeune</surname><given-names>C</given-names></name><name><surname>Simmat-Durand</surname><given-names>L</given-names></name><name><surname>Gourarier</surname><given-names>L</given-names></name><name><surname>Aubisson</surname><given-names>S</given-names></name></person-group><article-title>Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution</article-title><source>Drug Alcohol Depend</source><year>2006</year><volume>82</volume><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">16257138</pub-id></citation></ref><ref id="R229"><label>229</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lenoir</surname><given-names>D</given-names></name><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name></person-group><article-title>Characterization and down-regulation of opiate receptors in aggregating fetal rat brain cells</article-title><source>Brain Res</source><year>1984</year><volume>304</volume><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">6331588</pub-id></citation></ref><ref id="R230"><label>230</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>JW</given-names></name></person-group><article-title>Buprenorphine</article-title><source>Drug Alcohol Depend</source><year>1985</year><volume>14</volume><fpage>363</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">2986930</pub-id></citation></ref><ref id="R231"><label>231</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lifschitz</surname><given-names>MH</given-names></name><name><surname>Wilson</surname><given-names>GS</given-names></name><name><surname>Smith</surname><given-names>EO</given-names></name><name><surname>Desmond</surname><given-names>MM</given-names></name></person-group><article-title>Factors affecting head growth and intellectual function in children of drug addicts</article-title><source>Pediatrics</source><year>1985</year><volume>75</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">3969327</pub-id></citation></ref><ref id="R232"><label>232</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindberg</surname><given-names>BS</given-names></name><name><surname>Hartvig</surname><given-names>P</given-names></name><name><surname>Lilja</surname><given-names>A</given-names></name><name><surname>Lundqvist</surname><given-names>H</given-names></name><name><surname>Langstrom</surname><given-names>B</given-names></name><name><surname>Malmborg</surname><given-names>P</given-names></name><name><surname>Rane</surname><given-names>A</given-names></name><name><surname>Rimland</surname><given-names>A</given-names></name><name><surname>Svard</surname><given-names>H</given-names></name></person-group><article-title>Positron-emission tomography: a new approach to feto-maternal pharmacokinetics</article-title><source>NIDA Res. Monogr</source><year>1985</year><volume>60</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">3932868</pub-id></citation></ref><ref id="R233"><label>233</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>GS</given-names></name><name><surname>Umans</surname><given-names>JG</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><article-title>Methadone: radioimmunoassay and pharmacokinetics in the rat</article-title><source>J. Pharmacol. Exp. Ther</source><year>1981</year><volume>217</volume><fpage>147</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">7205649</pub-id></citation></ref><ref id="R234"><label>234</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>W</given-names></name><name><surname>Charuvastra</surname><given-names>C</given-names></name><name><surname>Collins</surname><given-names>JF</given-names></name><name><surname>Batki</surname><given-names>S</given-names></name><name><surname>Brown LS</surname><given-names>Jr</given-names></name><name><surname>Kintaudi</surname><given-names>P</given-names></name><name><surname>Wesson</surname><given-names>DR</given-names></name><name><surname>McNicholas</surname><given-names>L</given-names></name><name><surname>Tusel</surname><given-names>DJ</given-names></name><name><surname>Malkerneker</surname><given-names>U</given-names></name><name><surname>Renner JA</surname><given-names>Jr</given-names></name><name><surname>Santos</surname><given-names>E</given-names></name><name><surname>Casadonte</surname><given-names>P</given-names></name><name><surname>Fye</surname><given-names>C</given-names></name><name><surname>Stine</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>RI</given-names></name><name><surname>Segal</surname><given-names>D</given-names></name></person-group><article-title>Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial</article-title><source>Addiction</source><year>1998</year><volume>93</volume><fpage>475</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">9684386</pub-id></citation></ref><ref id="R235"><label>235</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>W</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name></person-group><article-title>Buprenorphine: blending practice and research</article-title><source>J. Subst. Abuse Treat</source><year>2002</year><volume>23</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">12220606</pub-id></citation></ref><ref id="R236"><label>236</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>W</given-names></name><name><surname>Wesson</surname><given-names>DR</given-names></name></person-group><article-title>Clinical efficacy of buprenorphine: comparisons to methadone and placebo</article-title><source>Drug Alcohol Depend</source><year>2003</year><volume>70</volume><fpage>S49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">12738350</pub-id></citation></ref><ref id="R237"><label>237</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>BB</given-names></name><name><surname>Snell</surname><given-names>LM</given-names></name><name><surname>Klein</surname><given-names>VR</given-names></name><name><surname>Gilstrap LC</surname><given-names>3rd</given-names></name><name><surname>Knoll</surname><given-names>KA</given-names></name><name><surname>Breckenridge</surname><given-names>JD</given-names></name></person-group><article-title>Maternal and fetal effects of heroin addiction during pregnancy</article-title><source>J. Reprod. Med</source><year>1990</year><volume>35</volume><fpage>159</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">2304039</pub-id></citation></ref><ref id="R238"><label>238</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopatko</surname><given-names>OV</given-names></name><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Huber</surname><given-names>A</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name></person-group><article-title>Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine</article-title><source>Drug Alcohol Depend</source><year>2003</year><volume>69</volume><fpage>317</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">12633918</pub-id></citation></ref><ref id="R239"><label>239</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Loughlin</surname><given-names>SE</given-names></name><name><surname>Leslie</surname><given-names>FM</given-names></name></person-group><source>Opioid receptors and the developing nervous system</source><year> 1993</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name></citation></ref><ref id="R240"><label>240</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludden</surname><given-names>TM</given-names></name><name><surname>Bathala</surname><given-names>MS</given-names></name><name><surname>Malspeis</surname><given-names>L</given-names></name><name><surname>Drum</surname><given-names>MA</given-names></name><name><surname>Reuning</surname><given-names>RH</given-names></name></person-group><article-title>Elimination of radioactivity following administration of [15,16-3H]naltrexone to rats and guinea pigs</article-title><source>Drug Metab. Dispos</source><year>1978</year><volume>6</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">26554</pub-id></citation></ref><ref id="R241"><label>241</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ludden</surname><given-names>TM</given-names></name><name><surname>Malspeis</surname><given-names>L</given-names></name><name><surname>Baggot</surname><given-names>JD</given-names></name><name><surname>Sokoloski</surname><given-names>TD</given-names></name><name><surname>Frank</surname><given-names>SG</given-names></name><name><surname>Reuning</surname><given-names>RH</given-names></name></person-group><article-title>Tritiated naltrexone binding in plasma from several species and tissue distribution in mice</article-title><source>J. Pharm. Sci</source><year>1976</year><volume>65</volume><fpage>712</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">819644</pub-id></citation></ref><ref id="R242"><label>242</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luty</surname><given-names>J</given-names></name><name><surname>Nikolaou</surname><given-names>V</given-names></name><name><surname>Bearn</surname><given-names>J</given-names></name></person-group><article-title>Is opiate detoxification unsafe in pregnancy?</article-title><source>J.Subst. Abuse Treat</source><year>2003</year><volume>24</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">12867211</pub-id></citation></ref><ref id="R243"><label>243</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Giles</surname><given-names>W</given-names></name><name><surname>Buchanan</surname><given-names>N</given-names></name></person-group><article-title>Methadone levels and neonatal withdrawal</article-title><source>J. Paediatr. Child Health</source><year>1991</year><volume>27</volume><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">1883657</pub-id></citation></ref><ref id="R244"><label>244</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Magnan</surname><given-names>J</given-names></name><name><surname>Tiberi</surname><given-names>M</given-names></name></person-group><article-title>Evidence for the presence of mu- and kappa- but not of delta-opioid sites in the human fetal brain</article-title><source>Brain Res. Dev. Brain Res</source><year>1989</year><volume>45</volume><fpage>275</fpage><lpage>281</lpage></citation></ref><ref id="R245"><label>245</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malpas</surname><given-names>TJ</given-names></name><name><surname>Darlow</surname><given-names>BA</given-names></name></person-group><article-title>Neonatal abstinence syndrome following abrupt cessation of breastfeeding</article-title><source>N.Z. Med. J</source><year>1999</year><volume>112</volume><fpage>12</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">10073159</pub-id></citation></ref><ref id="R246"><label>246</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malpas</surname><given-names>TJ</given-names></name><name><surname>Darlow</surname><given-names>BA</given-names></name><name><surname>Lennox</surname><given-names>R</given-names></name><name><surname>Horwood</surname><given-names>LJ</given-names></name></person-group><article-title>Maternal methadone dosage and neonatal withdrawal</article-title><source>Aust. N. Z. J. Obstet. Gynaecol</source><year>1995</year><volume>35</volume><fpage>175</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">7677682</pub-id></citation></ref><ref id="R247"><label>247</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Man</surname><given-names>LH</given-names></name><name><surname>Best</surname><given-names>D</given-names></name><name><surname>Gossop</surname><given-names>M</given-names></name><name><surname>Stillwell</surname><given-names>G</given-names></name><name><surname>Strang</surname><given-names>J</given-names></name></person-group><article-title>Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment</article-title><source>Eur. Addict. Res</source><year>2004</year><volume>10</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">14665804</pub-id></citation></ref><ref id="R248"><label>248</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marquet</surname><given-names>P</given-names></name><name><surname>Chevrel</surname><given-names>J</given-names></name><name><surname>Lavignasse</surname><given-names>P</given-names></name><name><surname>Merle</surname><given-names>L</given-names></name><name><surname>Lachatre</surname><given-names>G</given-names></name></person-group><article-title>Buprenorphine withdrawal syndrome in a newborn</article-title><source>Clin. Pharmacol. Ther</source><year>1997</year><volume>62</volume><fpage>569</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">9390114</pub-id></citation></ref><ref id="R249"><label>249</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>A</given-names></name><name><surname>Kastner</surname><given-names>B</given-names></name><name><surname>Taeusch</surname><given-names>HW</given-names></name></person-group><article-title>Hyperphagia in neonates withdrawing from methadone</article-title><source>Arch. Dis. Child Fetal Neonatal. Ed</source><year>1999</year><volume>80</volume><fpage>F178</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">10212077</pub-id></citation></ref><ref id="R250"><label>250</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>T</given-names></name><name><surname>Maruyama</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>E</given-names></name><name><surname>Katsuyama</surname><given-names>Y</given-names></name><name><surname>Sugihara</surname><given-names>N</given-names></name><name><surname>Ise</surname><given-names>H</given-names></name><name><surname>Negishi</surname><given-names>N</given-names></name><name><surname>Ikeda</surname><given-names>U</given-names></name><name><surname>Ohmori</surname><given-names>S</given-names></name></person-group><article-title>Expression and induction of CYP3As in human fetal hepatocytes</article-title><source>Biochem. Biophys. Res. Commun</source><year>2004</year><volume>318</volume><fpage>428</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">15120618</pub-id></citation></ref><ref id="R251"><label>251</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Leamon</surname><given-names>MH</given-names></name><name><surname>Parr</surname><given-names>MS</given-names></name><name><surname>Anania</surname><given-names>B</given-names></name></person-group><article-title>High-dose methadone maintenance in pregnancy: maternal and neonatal outcomes</article-title><source>Am. J. Obstet. Gynecol</source><year>2005</year><volume>193</volume><fpage>606</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">16150249</pub-id></citation></ref><ref id="R252"><label>252</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JJ</given-names></name><name><surname>Posey</surname><given-names>BL</given-names></name></person-group><article-title>Methadone levels in human milk</article-title><source>J. Hum. Lact</source><year>2000</year><volume>16</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">11153342</pub-id></citation></ref><ref id="R253"><label>253</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McGinty</surname><given-names>JF</given-names></name><name><surname>Ford</surname><given-names>DH</given-names></name></person-group><article-title>Effects of prenatal methadone on rat brain catecholamines</article-title><source>Dev. Neurosci</source><year>1980</year><volume>3</volume><fpage>224</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">7460795</pub-id></citation></ref><ref id="R254"><label>254</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Tobias</surname><given-names>SW</given-names></name><name><surname>Lang</surname><given-names>CM</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Chronic exposure to the opioid antagonist naltrexone during pregnancy: maternal and offspring effects</article-title><source>Physiol. Behav</source><year>1997</year><volume>62</volume><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">9272656</pub-id></citation></ref><ref id="R255"><label>255</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Tobias</surname><given-names>SW</given-names></name><name><surname>Lang</surname><given-names>CM</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Opioid receptor blockade during prenatal life modifies postnatal behavioral development</article-title><source>Pharmacol. Biochem. Behav</source><year>1997</year><volume>58</volume><fpage>1075</fpage><lpage>1082</lpage><pub-id pub-id-type="pmid">9408216</pub-id></citation></ref><ref id="R256"><label>256</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name></person-group><article-title>Body and organ development of young rats maternally exposed to methadone</article-title><source>Biol. Neonate</source><year>1980</year><volume>38</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">7407276</pub-id></citation></ref><ref id="R257"><label>257</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>White</surname><given-names>WJ</given-names></name></person-group><article-title>Perinatal methadone exposure in rats</article-title><source>Biol. Neonate</source><year>1978</year><volume>34</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">698324</pub-id></citation></ref><ref id="R258"><label>258</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Medina Jimenez</surname><given-names>M</given-names></name><name><surname>Lujan Estrada</surname><given-names>M</given-names></name><name><surname>Rodriguez</surname><given-names>R</given-names></name></person-group><article-title>Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice</article-title><source>Arch. Med. Res</source><year>1997</year><volume>28</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">9078589</pub-id></citation></ref><ref id="R259"><label>259</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meissner</surname><given-names>W</given-names></name><name><surname>Schmidt</surname><given-names>U</given-names></name><name><surname>Hartmann</surname><given-names>M</given-names></name><name><surname>Kath</surname><given-names>R</given-names></name><name><surname>Reinhart</surname><given-names>K</given-names></name></person-group><article-title>Oral naloxone reverses opioid-associated constipation</article-title><source>Pain</source><year>2000</year><volume>84</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">10601678</pub-id></citation></ref><ref id="R260"><label>260</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meresaar</surname><given-names>U</given-names></name><name><surname>Nilsson</surname><given-names>MI</given-names></name><name><surname>Holmstrand</surname><given-names>J</given-names></name><name><surname>Anggard</surname><given-names>E</given-names></name></person-group><article-title>Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method</article-title><source>Eur. J. Clin. Pharmacol</source><year>1981</year><volume>20</volume><fpage>473</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">7286059</pub-id></citation></ref><ref id="R261"><label>261</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Middaugh</surname><given-names>LD</given-names></name><name><surname>Simpson</surname><given-names>LW</given-names></name></person-group><article-title>Prenatal maternal methadone effects on pregnant C57BL/6 mice and their offspring</article-title><source>Neurobehav. Toxicol</source><year>1980</year><volume>2</volume><fpage>307</fpage><lpage>313</lpage></citation></ref><ref id="R262"><label>262</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mihaly</surname><given-names>GW</given-names></name><name><surname>Morgan</surname><given-names>DJ</given-names></name></person-group><article-title>Placental drug transfer: effects of gestational age and species</article-title><source>Pharmacol. Ther</source><year>1983</year><volume>23</volume><fpage>253</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">6366827</pub-id></citation></ref><ref id="R263"><label>263</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>WR</given-names></name><name><surname>Wilbourne</surname><given-names>PL</given-names></name></person-group><article-title>Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders</article-title><source>Addiction</source><year>2002</year><volume>97</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">11964100</pub-id></citation></ref><ref id="R264"><label>264</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minozzi</surname><given-names>S</given-names></name><name><surname>Amato</surname><given-names>L</given-names></name><name><surname>Vecchi</surname><given-names>S</given-names></name><name><surname>Davoli</surname><given-names>M</given-names></name><name><surname>Kirchmayer</surname><given-names>U</given-names></name><name><surname>Verster</surname><given-names>A</given-names></name></person-group><article-title>Oral naltrexone maintenance treatment for opioid dependence</article-title><source>Cochrane Database Syst. Rev</source><year>2006</year><comment>CD001333</comment></citation></ref><ref id="R265"><label>265</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miotto</surname><given-names>K</given-names></name><name><surname>McCann</surname><given-names>MJ</given-names></name><name><surname>Rawson</surname><given-names>RA</given-names></name><name><surname>Frosch</surname><given-names>D</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name></person-group><article-title>Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts</article-title><source>Drug Alcohol Depend</source><year>1997</year><volume>45</volume><fpage>131</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">9179515</pub-id></citation></ref><ref id="R266"><label>266</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>AL</given-names></name></person-group><article-title>Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone</article-title><source>NIDA Res. Monogr</source><year>1981</year><volume>28</volume><fpage>132</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">6267469</pub-id></citation></ref><ref id="R267"><label>267</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>AL</given-names></name><name><surname>Bloch</surname><given-names>R</given-names></name><name><surname>Vardy</surname><given-names>J</given-names></name><name><surname>Mule</surname><given-names>SJ</given-names></name><name><surname>Verebely</surname><given-names>K</given-names></name></person-group><article-title>Disposition of (15,16-3H)naltrexone in the central nervous system of the rat</article-title><source>Drug Metab. Dispos</source><year>1976</year><volume>4</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">6233</pub-id></citation></ref><ref id="R268"><label>268</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitsuo</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>JP</given-names></name></person-group><article-title>Chronic treatment of newborn rats with naltrexone alters astrocyte production of nerve growth factor</article-title><source>J. Mol. Neurosci</source><year>1993</year><volume>4</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">7686388</pub-id></citation></ref><ref id="R269"><label>269</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>DE</given-names></name><name><surname>Alburges</surname><given-names>ME</given-names></name><name><surname>Parker</surname><given-names>RJ</given-names></name><name><surname>Collins</surname><given-names>JM</given-names></name><name><surname>Strong</surname><given-names>JM</given-names></name></person-group><article-title>The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone</article-title><source>Drug Metab. Dispos</source><year>1997</year><volume>25</volume><fpage>1347</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">9394023</pub-id></citation></ref><ref id="R270"><label>270</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moody</surname><given-names>DE</given-names></name><name><surname>Slawson</surname><given-names>MH</given-names></name><name><surname>Strain</surname><given-names>EC</given-names></name><name><surname>Laycock</surname><given-names>JD</given-names></name><name><surname>Spanbauer</surname><given-names>AC</given-names></name><name><surname>Foltz</surname><given-names>RL</given-names></name></person-group><article-title>A liquid chromatographic-electro-spray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for <italic>in vivo</italic> and <italic>in vitro</italic> metabolism studies</article-title><source>Anal. Biochem</source><year>2002</year><volume>306</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">12069411</pub-id></citation></ref><ref id="R271"><label>271</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>RC</given-names></name></person-group><article-title>Mammary growth and milk yield as related to litter size</article-title><source>Proc. Soc. Exp. Biol. Med</source><year>1969</year><volume>130</volume><fpage>1126</fpage><lpage>1128</lpage><pub-id pub-id-type="pmid">5813639</pub-id></citation></ref><ref id="R272"><label>272</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naeye</surname><given-names>RL</given-names></name><name><surname>Blanc</surname><given-names>W</given-names></name><name><surname>Leblanc</surname><given-names>W</given-names></name><name><surname>Khatamee</surname><given-names>MA</given-names></name></person-group><article-title>Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress</article-title><source>J. Pediatr</source><year>1973</year><volume>83</volume><fpage>1055</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">4757521</pub-id></citation></ref><ref id="R273"><label>273</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nanovskaya</surname><given-names>T</given-names></name><name><surname>Deshmukh</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Transplacental transfer and metabolism of buprenorphine</article-title><source>J. Pharmacol. Exp. Ther</source><year>2002</year><volume>300</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">11752093</pub-id></citation></ref><ref id="R274"><label>274</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nanovskaya</surname><given-names>T</given-names></name><name><surname>Nekhayeva</surname><given-names>I</given-names></name><name><surname>Karunaratne</surname><given-names>N</given-names></name><name><surname>Audus</surname><given-names>K</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Role of P-glycoprotein in transplacental transfer of methadone</article-title><source>Biochem. Pharmacol</source><year>2005</year><volume>69</volume><fpage>1869</fpage><lpage>1878</lpage><pub-id pub-id-type="pmid">15876424</pub-id></citation></ref><ref id="R275"><label>275</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nanovskaya</surname><given-names>TN</given-names></name><name><surname>Deshmukh</surname><given-names>SV</given-names></name><name><surname>Nekhayeva</surname><given-names>IA</given-names></name><name><surname>Zharikova</surname><given-names>OL</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Methadone metabolism by human placenta</article-title><source>Biochem. Pharmacol</source><year>2004</year><volume>68</volume><fpage>583</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">15242824</pub-id></citation></ref><ref id="R276"><label>276</label><citation citation-type="book"><collab>National Campaign Against Drug Abuse (NCADA)</collab><source>Australian National Drug House-hold Survey, Common Wealth Department of Health</source><year>1993</year><publisher-loc>Canberra</publisher-loc><publisher-name>Australian Government Publishing Services</publisher-name></citation></ref><ref id="R277"><label>277</label><citation citation-type="book"><collab>National Campaign Against Drug Abuse (NCADA)</collab><source>Australian National Drug House-hold Survey, Common Wealth Department of Health</source><year>2001</year><publisher-loc>Canberra</publisher-loc><publisher-name>Australian Government Publishing Services</publisher-name></citation></ref><ref id="R278"><label>278</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nau</surname><given-names>H</given-names></name></person-group><article-title>Species differences in pharmacokinetics and drug teratogenesis</article-title><source>Environ. Health Perspect</source><year>1986</year><volume>70</volume><fpage>113</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">3104022</pub-id></citation></ref><ref id="R279"><label>279</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Navaratnam</surname><given-names>V</given-names></name><name><surname>Jamaludin</surname><given-names>A</given-names></name><name><surname>Raman</surname><given-names>N</given-names></name><name><surname>Mohamed</surname><given-names>M</given-names></name><name><surname>Mansor</surname><given-names>SM</given-names></name></person-group><article-title>Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts</article-title><source>Drug Alcohol Depend</source><year>1994</year><volume>34</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">8033761</pub-id></citation></ref><ref id="R280"><label>280</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Negus</surname><given-names>SS</given-names></name><name><surname>Picker</surname><given-names>MJ</given-names></name><name><surname>Dykstra</surname><given-names>LA</given-names></name></person-group><article-title>Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats</article-title><source>Psychopharmacology (Berl)</source><year>1989</year><volume>98</volume><fpage>141</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">2543017</pub-id></citation></ref><ref id="R281"><label>281</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nekhayeva</surname><given-names>IA</given-names></name><name><surname>Nanovskaya</surname><given-names>TN</given-names></name><name><surname>Deshmukh</surname><given-names>SV</given-names></name><name><surname>Zharikova</surname><given-names>OL</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Bidirectional transfer of methadone across human placenta</article-title><source>Biochem. Pharmacol</source><year>2005</year><volume>69</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15588727</pub-id></citation></ref><ref id="R282"><label>282</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nekhayeva</surname><given-names>IA</given-names></name><name><surname>Nanovskaya</surname><given-names>TN</given-names></name><name><surname>Hankins</surname><given-names>GD</given-names></name><name><surname>Ahmed</surname><given-names>MS</given-names></name></person-group><article-title>Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel</article-title><source>Am. J. Perinatol</source><year>2006</year><volume>23</volume><fpage>423</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">17001553</pub-id></citation></ref><ref id="R283"><label>283</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>RG</given-names></name><name><surname>Bashkow</surname><given-names>S</given-names></name><name><surname>Calko</surname><given-names>D</given-names></name></person-group><article-title>Results of 313 consecutive live births of infants delivered to patients in the New York City Methadone Maintenance Treatment Program</article-title><source>Am. J. Obstet. Gynecol</source><year>1975</year><volume>121</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">1115128</pub-id></citation></ref><ref id="R284"><label>284</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>MI</given-names></name><name><surname>Anggard</surname><given-names>E</given-names></name><name><surname>Holmstrand</surname><given-names>J</given-names></name><name><surname>Gunne</surname><given-names>LM</given-names></name></person-group><article-title>Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase</article-title><source>Eur. J. Clin. Pharmacol</source><year>1982</year><volume>22</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="pmid">7106170</pub-id></citation></ref><ref id="R285"><label>285</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilsson</surname><given-names>MI</given-names></name><name><surname>Meresaar</surname><given-names>U</given-names></name><name><surname>Anggard</surname><given-names>E</given-names></name></person-group><article-title>Clinical pharmacokinetics of methadone</article-title><source>Acta Anaesthesiol. Scand. Suppl</source><year>1982</year><volume>74</volume><fpage>66</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">6953740</pub-id></citation></ref><ref id="R286"><label>286</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nocon</surname><given-names>JJ</given-names></name></person-group><article-title>Buprenorphine in pregnancy the advantages</article-title><source>Addiction</source><year>2006</year><volume>101</volume><fpage>608</fpage><pub-id pub-id-type="pmid">16548940</pub-id></citation></ref><ref id="R287"><label>287</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowosielski-Slepowron</surname><given-names>BJ</given-names></name><name><surname>Park</surname><given-names>AW</given-names></name></person-group><article-title>The criteria of litter size in relation to growth of the rat. I. The influence of numbers</article-title><source>Acta Morphol. Neerl. Scand</source><year>1974</year><volume>12</volume><fpage>299</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">4477445</pub-id></citation></ref><ref id="R288"><label>288</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>Receptor pharmacology of buprenorphine</article-title><source>Res. Clin. Forums</source><year>1997</year><volume>19</volume><fpage>9</fpage><lpage>15</lpage></citation></ref><ref id="R289"><label>289</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>Y</given-names></name><name><surname>Kharasch</surname><given-names>ED</given-names></name></person-group><article-title>Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation</article-title><source>J. Pharmacol.Exp. Ther</source><year>2001</year><volume>298</volume><fpage>1021</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">11504799</pub-id></citation></ref><ref id="R290"><label>290</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtani</surname><given-names>M</given-names></name><name><surname>Kotaki</surname><given-names>H</given-names></name><name><surname>Sawada</surname><given-names>Y</given-names></name><name><surname>Iga</surname><given-names>T</given-names></name></person-group><article-title>Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling</article-title><source>J. Pharmacol. Exp. Ther</source><year>1995</year><volume>272</volume><fpage>505</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">7853163</pub-id></citation></ref><ref id="R291"><label>291</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oleske</surname><given-names>JM</given-names></name></person-group><article-title>Experiences with 118 infants born to narcoticusing mothers. Does a lowered serum-ionized calcium level contribute to the symptoms of withdrawal?</article-title><source>Clin. Pediatr. (Phila)</source><year>1977</year><volume>16</volume><fpage>418</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">849661</pub-id></citation></ref><ref id="R292"><label>292</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Omri</surname><given-names>A</given-names></name><name><surname>Delaloye</surname><given-names>JF</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Bachmann</surname><given-names>F</given-names></name></person-group><article-title>Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy</article-title><source>Thromb. Haemost</source><year>1989</year><volume>61</volume><fpage>55</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">2546279</pub-id></citation></ref><ref id="R293"><label>293</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Opanashuk</surname><given-names>LA</given-names></name><name><surname>Hauser</surname><given-names>KF</given-names></name></person-group><article-title>Opposing actions of the EGF family and opioids: heparin binding-epidermal growth factor (HB-EGF) protects mouse cerebellar neuroblasts against the antiproliferative effect of morphine</article-title><source>Brain Res</source><year>1998</year><volume>804</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9729296</pub-id></citation></ref><ref id="R294"><label>294</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostrea</surname><given-names>EM</given-names></name><name><surname>Chavez</surname><given-names>CJ</given-names></name><name><surname>Strauss</surname><given-names>ME</given-names></name></person-group><article-title>A study of factors that influence the severity of neonatal narcotic withdrawal</article-title><source>J. Pediatr</source><year>1976</year><volume>88</volume><fpage>642</fpage><lpage>645</lpage><pub-id pub-id-type="pmid">1255327</pub-id></citation></ref><ref id="R295"><label>295</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ostrea EM</surname><given-names>Jr</given-names></name><name><surname>Knapp</surname><given-names>DK</given-names></name><name><surname>Tannenbaum</surname><given-names>L</given-names></name><name><surname>Ostrea</surname><given-names>AR</given-names></name><name><surname>Romero</surname><given-names>A</given-names></name><name><surname>Salari</surname><given-names>V</given-names></name><name><surname>Ager</surname><given-names>J</given-names></name></person-group><article-title>Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis</article-title><source>J. Pediatr</source><year>2001</year><volume>138</volume><fpage>344</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">11241040</pub-id></citation></ref><ref id="R296"><label>296</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pacifici</surname><given-names>GM</given-names></name><name><surname>Nottoli</surname><given-names>R</given-names></name></person-group><article-title>Placental transfer of drugs administered to the mother</article-title><source>Clin. Pharmacokinet</source><year>1995</year><volume>28</volume><fpage>235</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">7758253</pub-id></citation></ref><ref id="R297"><label>297</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>L</given-names></name><name><surname>Diaz</surname><given-names>J</given-names></name><name><surname>Bailey</surname><given-names>B</given-names></name></person-group><article-title>Behavioral effects of chronic narcotic antagonist administration of infant rats</article-title><source>Neuropharmacology</source><year>1978</year><volume>17</volume><fpage>655</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">692825</pub-id></citation></ref><ref id="R298"><label>298</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perez-Navarro</surname><given-names>E</given-names></name><name><surname>Alberch</surname><given-names>J</given-names></name><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Marsal</surname><given-names>J</given-names></name></person-group><article-title>Nerve growth factor and its receptor are differentially modified by chronic naltrexone treatment during rat brain development</article-title><source>Neurosci. Lett</source><year>1993</year><volume>149</volume><fpage>47</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">8469378</pub-id></citation></ref><ref id="R299"><label>299</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pertschuk</surname><given-names>LP</given-names></name><name><surname>Ford</surname><given-names>DH</given-names></name><name><surname>Rainford</surname><given-names>EA</given-names></name></person-group><article-title>Localization of methadone in fetal rat eye by the immunofluorescence technic</article-title><source>Exp. Eye Res</source><year>1977</year><volume>24</volume><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">326569</pub-id></citation></ref><ref id="R300"><label>300</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>MA</given-names></name></person-group><article-title>Studies on the time course distribution of methadone in the pregnant, non-pregnant, male and fetal rat</article-title><source>Proc. West Pharmacol. Soc</source><year>1973</year><volume>16</volume><fpage>70</fpage><lpage>76</lpage></citation></ref><ref id="R301"><label>301</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>MA</given-names></name></person-group><article-title>The effect of maternally administered methadone on brain development in the offspring</article-title><source>J. Pharmacol. Exp. Ther</source><year>1977</year><volume>203</volume><fpage>340</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">909067</pub-id></citation></ref><ref id="R302"><label>302</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrie</surname><given-names>BF</given-names></name></person-group><article-title>Naltrexone does not increase brain and body development in rats</article-title><source>Neurotoxicol. Teratol</source><year>1993</year><volume>15</volume><fpage>275</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">8413082</pub-id></citation></ref><ref id="R303"><label>303</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pick</surname><given-names>CG</given-names></name><name><surname>Peter</surname><given-names>Y</given-names></name><name><surname>Schreiber</surname><given-names>S</given-names></name><name><surname>Weizman</surname><given-names>R</given-names></name></person-group><article-title>Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia</article-title><source>Brain Res</source><year>1997</year><volume>744</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">9030411</pub-id></citation></ref><ref id="R304"><label>304</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pierson</surname><given-names>PS</given-names></name><name><surname>Howard</surname><given-names>P</given-names></name><name><surname>Kleber</surname><given-names>HD</given-names></name></person-group><article-title>Sudden deaths in infants born to methadone-maintained addicts</article-title><source>JAMA</source><year>1972</year><volume>220</volume><fpage>1733</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">5067606</pub-id></citation></ref><ref id="R305"><label>305</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>F</given-names></name><name><surname>Onofrj</surname><given-names>M</given-names></name><name><surname>Pola</surname><given-names>P</given-names></name><name><surname>Tempesta</surname><given-names>E</given-names></name><name><surname>Torrioli</surname><given-names>MG</given-names></name></person-group><article-title>Fetal addiction to methadone: postnatal abstinence syndrome and development of visual evoked potentials</article-title><source>Drug Alcohol Depend</source><year>1986</year><volume>18</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">3780406</pub-id></citation></ref><ref id="R306"><label>306</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pond</surname><given-names>SM</given-names></name><name><surname>Kreek</surname><given-names>MJ</given-names></name><name><surname>Tong</surname><given-names>TG</given-names></name><name><surname>Raghunath</surname><given-names>J</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>Altered methadone pharmacokinetics in methadone-maintained pregnant women</article-title><source>J. Pharmacol. Exp. Ther</source><year>1985</year><volume>233</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3981450</pub-id></citation></ref><ref id="R307"><label>307</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramirez-Cacho</surname><given-names>WA</given-names></name><name><surname>Flores</surname><given-names>S</given-names></name><name><surname>Schrader</surname><given-names>RM</given-names></name><name><surname>McKay</surname><given-names>J</given-names></name><name><surname>Rayburn</surname><given-names>WF</given-names></name></person-group><article-title>Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns</article-title><source>J. Soc. Gynecol. Investig</source><year>2006</year><volume>13</volume><fpage>108</fpage><lpage>111</lpage></citation></ref><ref id="R308"><label>308</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rance</surname><given-names>MJ</given-names></name></person-group><article-title>Animal and molecular pharmacology of mixed agonist-antagonist analgesic drugs</article-title><source>Br. J. Clin. Pharmacol</source><year>1979</year><volume>7</volume><issue>Suppl. 3</issue><fpage>281S</fpage><lpage>286S</lpage><pub-id pub-id-type="pmid">223616</pub-id></citation></ref><ref id="R309"><label>309</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rang</surname><given-names>HP</given-names></name><name><surname>Dale</surname><given-names>MM</given-names></name><name><surname>Ritter</surname><given-names>JM</given-names></name></person-group><source>Pharmacology</source><year>1999</year><publisher-loc>Edinburgh New York</publisher-loc><publisher-name>Churchill Livingstone</publisher-name></citation></ref><ref id="R310"><label>310</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ratanasavanh</surname><given-names>D</given-names></name><name><surname>Beaune</surname><given-names>P</given-names></name><name><surname>Morel</surname><given-names>F</given-names></name><name><surname>Flinois</surname><given-names>JP</given-names></name><name><surname>Guengerich</surname><given-names>FP</given-names></name><name><surname>Guillouzo</surname><given-names>A</given-names></name></person-group><article-title>Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age</article-title><source>Hepatology</source><year>1991</year><volume>13</volume><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">1904834</pub-id></citation></ref><ref id="R311"><label>311</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rawson</surname><given-names>RA</given-names></name><name><surname>McCann</surname><given-names>MJ</given-names></name><name><surname>Hasson</surname><given-names>AJ</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name></person-group><article-title>Addiction pharmacotherapy 2000: new options, new challenges</article-title><source>J. Psychoactive Drugs</source><year>2000</year><volume>32</volume><fpage>371</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">11210198</pub-id></citation></ref><ref id="R312"><label>312</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>AM</given-names></name><name><surname>Harper</surname><given-names>RG</given-names></name><name><surname>Stern</surname><given-names>G</given-names></name></person-group><article-title>Observations on heroin and methadone withdrawal in the newborn</article-title><source>Pediatrics</source><year>1971</year><volume>48</volume><fpage>353</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">5094335</pub-id></citation></ref><ref id="R313"><label>313</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Rementeria</surname><given-names>JL</given-names></name><name><surname>Lotongkhum</surname><given-names>L</given-names></name></person-group><source>Drug Abuse in Pregnancy and Neonatal Effects</source><year>1977</year><publisher-loc>St Louis</publisher-loc><publisher-name>C V Mosby</publisher-name></citation></ref><ref id="R314"><label>314</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ring</surname><given-names>JA</given-names></name><name><surname>Ghabrial</surname><given-names>H</given-names></name><name><surname>Ching</surname><given-names>MS</given-names></name><name><surname>Smallwood</surname><given-names>RA</given-names></name><name><surname>Morgan</surname><given-names>DJ</given-names></name></person-group><article-title>Fetal hepatic drug elimination</article-title><source>Pharmacol. Ther</source><year>1999</year><volume>84</volume><fpage>429</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">10665839</pub-id></citation></ref><ref id="R315"><label>315</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>AJ</given-names></name></person-group><article-title>Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose</article-title><source>Aust. N. Z. J. Psychiatry</source><year>2002</year><volume>36</volume><fpage>224</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">11982544</pub-id></citation></ref><ref id="R316"><label>316</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rius</surname><given-names>RA</given-names></name><name><surname>Barg</surname><given-names>J</given-names></name><name><surname>Bem</surname><given-names>WT</given-names></name><name><surname>Coscia</surname><given-names>CJ</given-names></name><name><surname>Loh</surname><given-names>YP</given-names></name></person-group><article-title>The prenatal development profile of expression of opioid peptides and receptors in the mouse brain</article-title><source>Brain Res. Dev. Brain Res</source><year>1991</year><volume>58</volume><fpage>237</fpage><lpage>241</lpage></citation></ref><ref id="R317"><label>317</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>CL</given-names></name><name><surname>Lancaster</surname><given-names>PA</given-names></name></person-group><article-title>Australian national birthweight percentiles by gestational age</article-title><source>Med. J. Aust</source><year>1999</year><volume>170</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">10065122</pub-id></citation></ref><ref id="R318"><label>318</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SE</given-names></name></person-group><article-title>Effect of prenatal opioid exposure on cholinergic development</article-title><source>J. Biomed. Sci</source><year>2000</year><volume>7</volume><fpage>253</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">10810245</pub-id></citation></ref><ref id="R319"><label>319</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SE</given-names></name></person-group><article-title>Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny</article-title><source>Neurotoxicol. Teratol</source><year>2002</year><volume>24</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">11943501</pub-id></citation></ref><ref id="R320"><label>320</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SE</given-names></name><name><surname>Wallace</surname><given-names>MJ</given-names></name></person-group><article-title>Effect of perinatal buprenorphine exposure on development in the rat</article-title><source>J. Pharmacol. Exp. Ther</source><year>2001</year><volume>298</volume><fpage>797</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">11454944</pub-id></citation></ref><ref id="R321"><label>321</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SE</given-names></name><name><surname>Wu</surname><given-names>VW</given-names></name><name><surname>Mo</surname><given-names>Q</given-names></name><name><surname>Schwartz</surname><given-names>JP</given-names></name></person-group><article-title>Perinatal opioids reduce nerve growth factor (NGF)</article-title><year>1999</year><volume>179</volume><conf-name>Proceedings of the 60th Annual Scientific Meeting of the College on Problems of Drug Dependence, NIDA Res. Monogr</conf-name><fpage>131</fpage></citation></ref><ref id="R322"><label>322</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>SR</given-names></name><name><surname>Dreher</surname><given-names>B</given-names></name></person-group><article-title>The visual pathways of eutherian mammals and marsupials develop according to a common timetable</article-title><source>Brain Behav. Evol</source><year>1990</year><volume>36</volume><fpage>177</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">2279233</pub-id></citation></ref><ref id="R323"><label>323</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>TS</given-names></name><name><surname>Johnson</surname><given-names>HL</given-names></name></person-group><article-title>Long-term effects of prenatal methadone maintenance</article-title><source>NIDA Res. Monogr</source><year>1985</year><volume>59</volume><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">3929135</pub-id></citation></ref><ref id="R324"><label>324</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosen</surname><given-names>TS</given-names></name><name><surname>Pippenger</surname><given-names>CE</given-names></name></person-group><article-title>Disposition of methadone and its relationship to severity of withdrawal in the newborn</article-title><source>Addict. Dis</source><year>1975</year><volume>2</volume><fpage>169</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">1163360</pub-id></citation></ref><ref id="R325"><label>325</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name><name><surname>Wolff</surname><given-names>K</given-names></name><name><surname>Hay</surname><given-names>AW</given-names></name><name><surname>Raistrick</surname><given-names>D</given-names></name><name><surname>Calvert</surname><given-names>R</given-names></name><name><surname>Tucker</surname><given-names>GT</given-names></name></person-group><article-title>Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes</article-title><source>Br. J. Clin. Pharmacol</source><year>1999</year><volume>48</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">10383559</pub-id></citation></ref><ref id="R326"><label>326</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rurak</surname><given-names>DW</given-names></name><name><surname>Wright</surname><given-names>MR</given-names></name><name><surname>Axelson</surname><given-names>JE</given-names></name></person-group><article-title>Drug disposition and effects in the fetus</article-title><source>J. Dev. Physiol</source><year>1991</year><volume>15</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">1678754</pub-id></citation></ref><ref id="R327"><label>327</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakellaridis</surname><given-names>N</given-names></name><name><surname>Mangoura</surname><given-names>D</given-names></name><name><surname>Vernadakis</surname><given-names>A</given-names></name></person-group><article-title>Effects of opiates on the growth of neuron-enriched cultures from chick embryonic brain</article-title><source>Int. J. Dev. Neurosci</source><year>1986</year><volume>4</volume><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">3455591</pub-id></citation></ref><ref id="R328"><label>328</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>San</surname><given-names>L</given-names></name><name><surname>Pomarol</surname><given-names>G</given-names></name><name><surname>Peri</surname><given-names>JM</given-names></name><name><surname>Olle</surname><given-names>JM</given-names></name><name><surname>Cami</surname><given-names>J</given-names></name></person-group><article-title>Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts</article-title><source>Br. J. Addict</source><year>1991</year><volume>86</volume><fpage>983</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">1912753</pub-id></citation></ref><ref id="R329"><label>329</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarman</surname><given-names>I</given-names></name></person-group><article-title>Methadone treatment during pregnancy and its effect on the child. Better than continuing drug abuse, should be monitored by a specialized antenatal care center should be monitored by a specialized antenatal care center</article-title><source>Lakartidningen</source><year>2000</year><volume>97</volume><fpage>2182-2184</fpage><lpage>2187-2188,2190</lpage><pub-id pub-id-type="pmid">10850047</pub-id></citation></ref><ref id="R330"><label>330</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sawe</surname><given-names>J</given-names></name></person-group><article-title>High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment</article-title><source>Clin. Pharmacokinet</source><year>1986</year><volume>11</volume><fpage>87</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">3514045</pub-id></citation></ref><ref id="R331"><label>331</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>SD</given-names></name><name><surname>Eder</surname><given-names>H</given-names></name><name><surname>Ortner</surname><given-names>R</given-names></name><name><surname>Rohrmeister</surname><given-names>K</given-names></name><name><surname>Langer</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name></person-group><article-title>Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy</article-title><source>Addiction</source><year>2003</year><volume>98</volume><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">12492761</pub-id></citation></ref><ref id="R332"><label>332</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schottenfeld</surname><given-names>RS</given-names></name><name><surname>Pakes</surname><given-names>J</given-names></name><name><surname>Ziedonis</surname><given-names>D</given-names></name><name><surname>Kosten</surname><given-names>TR</given-names></name></person-group><article-title>Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans</article-title><source>Biol. Psychiatry</source><year>1993</year><volume>34</volume><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">8373940</pub-id></citation></ref><ref id="R333"><label>333</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schottenfeld</surname><given-names>RS</given-names></name><name><surname>Pakes</surname><given-names>JR</given-names></name><name><surname>Oliveto</surname><given-names>A</given-names></name><name><surname>Ziedonis</surname><given-names>D</given-names></name><name><surname>Kosten</surname><given-names>TR</given-names></name></person-group><article-title>Buprenorphine <italic>vs</italic> methadone maintenance treatment for concurrent opioid dependence and cocaine abuse</article-title><source>Arch. Gen. Psychiatry</source><year>1997</year><volume>54</volume><fpage>713</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">9283506</pub-id></citation></ref><ref id="R334"><label>334</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schuh</surname><given-names>KJ</given-names></name><name><surname>Walsh</surname><given-names>SL</given-names></name><name><surname>Stitzer</surname><given-names>ML</given-names></name></person-group><article-title>Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans</article-title><source>Psychopharmacology (Berl.)</source><year>1999</year><volume>145</volume><fpage>162</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">10463317</pub-id></citation></ref><ref id="R335"><label>335</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Wuster</surname><given-names>M</given-names></name><name><surname>Herz</surname><given-names>A</given-names></name></person-group><article-title>Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone</article-title><source>Naunyn Schmiedebergs Arch. Pharmacol</source><year>1979</year><volume>306</volume><fpage>93</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">424002</pub-id></citation></ref><ref id="R336"><label>336</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seaman</surname><given-names>SR</given-names></name><name><surname>Brettle</surname><given-names>RP</given-names></name><name><surname>Gore</surname><given-names>SM</given-names></name></person-group><article-title>Mortality from overdose among injecting drug users recently released from prison: database linkage study</article-title><source>BMJ</source><year>1998</year><volume>316</volume><fpage>426</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">9492665</pub-id></citation></ref><ref id="R337"><label>337</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seatriz</surname><given-names>JV</given-names></name><name><surname>Hammer RP</surname><given-names>Jr</given-names></name></person-group><article-title>Effects of opiates on neuronal development in the rat cerebral cortex</article-title><source>Brain Res. Bull</source><year>1993</year><volume>30</volume><fpage>523</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">8384517</pub-id></citation></ref><ref id="R338"><label>338</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seidler</surname><given-names>FJ</given-names></name><name><surname>Whitmore</surname><given-names>WL</given-names></name><name><surname>Slotkin</surname><given-names>TA</given-names></name></person-group><article-title>Delays in growth and biochemical development of rat brain caused by maternal methadone administration: are the alterations in synaptogenesis and cellular maturation independent of reduced maternal food intake?</article-title><source>Dev. Neurosci</source><year>1982</year><volume>5</volume><fpage>13</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">6125371</pub-id></citation></ref><ref id="R339"><label>339</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>C</given-names></name><name><surname>Kuschel</surname><given-names>C</given-names></name></person-group><article-title>Outcomes of infants born to mothers receiving methadone for pain management in pregnancy</article-title><source>Arch. Dis. Child. Fetal Neonatal Ed</source><year>2004</year><volume>89</volume><fpage>F33</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">14711851</pub-id></citation></ref><ref id="R340"><label>340</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shayit</surname><given-names>M</given-names></name><name><surname>Nowak</surname><given-names>R</given-names></name><name><surname>Keller</surname><given-names>M</given-names></name><name><surname>Weller</surname><given-names>A</given-names></name></person-group><article-title>Establishment of a preference by the newborn lamb for its mother: the role of opioids</article-title><source>Behav. Neurosci</source><year>2003</year><volume>117</volume><fpage>446</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">12802873</pub-id></citation></ref><ref id="R341"><label>341</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherwood</surname><given-names>RA</given-names></name><name><surname>Keating</surname><given-names>J</given-names></name><name><surname>Kavvadia</surname><given-names>V</given-names></name><name><surname>Greenough</surname><given-names>A</given-names></name><name><surname>Peters</surname><given-names>TJ</given-names></name></person-group><article-title>Substance misuse in early pregnancy and relationship to fetal outcome</article-title><source>Eur. J. Pediatr</source><year>1999</year><volume>158</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">10378398</pub-id></citation></ref><ref id="R342"><label>342</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slotkin</surname><given-names>TA</given-names></name><name><surname>Lau</surname><given-names>C</given-names></name><name><surname>Bartolome</surname><given-names>M</given-names></name></person-group><article-title>Effects of neonatal or maternal methadone administration on ornithine decarboxylase activity in brain and heart of developing rats</article-title><source>J. Pharmacol. Exp. Ther</source><year>1976</year><volume>199</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">978475</pub-id></citation></ref><ref id="R343"><label>343</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slotkin</surname><given-names>TA</given-names></name><name><surname>Seidler</surname><given-names>FJ</given-names></name><name><surname>Whitmore</surname><given-names>WL</given-names></name></person-group><article-title>Effects of maternal methadone administration on ornithine decarboxylase in brain and heart of the offspring: relationships of enzyme activity to dose and to growth impairment in the rat</article-title><source>Life Sci</source><year>1980</year><volume>26</volume><fpage>861</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">7374351</pub-id></citation></ref><ref id="R344"><label>344</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Slotkin</surname><given-names>TA</given-names></name><name><surname>Whitmore</surname><given-names>WL</given-names></name><name><surname>Salvaggio</surname><given-names>M</given-names></name><name><surname>Seidler</surname><given-names>FJ</given-names></name></person-group><article-title>Perinatal methadone addiction affects brain synaptic development of biogenic amine systems in the rat</article-title><source>Life Sci</source><year>1979</year><volume>24</volume><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="pmid">571949</pub-id></citation></ref><ref id="R345"><label>345</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sobrian</surname><given-names>SK</given-names></name></person-group><article-title>Prenatal morphine administration alters behavioral development in the rat</article-title><source>Pharmacol. Biochem. Behav</source><year>1977</year><volume>7</volume><fpage>285</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">928486</pub-id></citation></ref><ref id="R346"><label>346</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soepatmi</surname><given-names>S</given-names></name></person-group><article-title>Developmental outcomes of children of mothers dependent on heroin or heroin/methadone during pregnancy</article-title><source>Acta Paediatr. Suppl</source><year>1994</year><volume>404</volume><fpage>36</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">7531041</pub-id></citation></ref><ref id="R347"><label>347</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soyka</surname><given-names>LF</given-names></name><name><surname>Peterson</surname><given-names>JM</given-names></name><name><surname>Joffe</surname><given-names>JM</given-names></name></person-group><article-title>Lethal and sublethal effects on the progeny of male rats treated with methadone</article-title><source>Toxicol. Appl. Pharmacol</source><year>1978</year><volume>45</volume><fpage>797</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">725932</pub-id></citation></ref><ref id="R348"><label>348</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spano</surname><given-names>MS</given-names></name><name><surname>Ellgren</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name></person-group><article-title>Prenatal cannabis exposure increases heroin seeking with allostatic changes in limbic enkephalin systems in adulthood</article-title><source>Biol. Psychiatry</source><year>2007</year><volume>67</volume><fpage>554</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">16876136</pub-id></citation></ref><ref id="R349"><label>349</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sporer</surname><given-names>KA</given-names></name></person-group><article-title>Acute heroin overdose</article-title><source>Ann. Intern. Med</source><year>1999</year><volume>130</volume><fpage>584</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">10189329</pub-id></citation></ref><ref id="R350"><label>350</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stimmel</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>J</given-names></name><name><surname>Reisman</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>RJ</given-names></name><name><surname>Teets</surname><given-names>K</given-names></name></person-group><article-title>Fetal outcome in narcotic-dependent women: the importance of the type of maternal narcotic used</article-title><source>Am. J. Drug Alcohol Abuse</source><year>1982</year><volume>9</volume><fpage>383</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">7188001</pub-id></citation></ref><ref id="R351"><label>351</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>ML</given-names></name><name><surname>Salerno</surname><given-names>LJ</given-names></name><name><surname>Green</surname><given-names>M</given-names></name><name><surname>Zelson</surname><given-names>C</given-names></name></person-group><article-title>Narcotic addiction in pregnancy</article-title><source>Am. J. Obstet. Gynecol</source><year>1971</year><volume>109</volume><fpage>716</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">5101601</pub-id></citation></ref><ref id="R352"><label>352</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>ME</given-names></name><name><surname>Lessen-Firestone</surname><given-names>JK</given-names></name><name><surname>Chavez</surname><given-names>CJ</given-names></name><name><surname>Stryker</surname><given-names>JC</given-names></name></person-group><article-title>Children of methadone-treated women at five years of age</article-title><source>Pharmacol. Biochem. Behav</source><year>1979</year><volume>11</volume><issue>Suppl</issue><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">550133</pub-id></citation></ref><ref id="R353"><label>353</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>ME</given-names></name><name><surname>Starr</surname><given-names>RH</given-names></name><name><surname>Ostrea</surname><given-names>EM</given-names></name><name><surname>Chavez</surname><given-names>CJ</given-names></name><name><surname>Stryker</surname><given-names>JC</given-names></name></person-group><article-title>Behavioural concomitants of prenatal addiction to narcotics</article-title><source>J. Pediatr</source><year>1976</year><volume>89</volume><fpage>842</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">978336</pub-id></citation></ref><ref id="R354"><label>354</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stulc</surname><given-names>J</given-names></name></person-group><article-title>Placental transfer of inorganic ions and water</article-title><source>Physiol. Rev</source><year>1997</year><volume>77</volume><fpage>805</fpage><lpage>836</lpage><pub-id pub-id-type="pmid">9234966</pub-id></citation></ref><ref id="R355"><label>355</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>S</given-names></name><name><surname>Conry</surname><given-names>JM</given-names></name></person-group><article-title>Role of buprenorphine in the management of heroin addiction</article-title><source>Ann. Pharmacother</source><year>2006</year><volume>40</volume><fpage>501</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">16434562</pub-id></citation></ref><ref id="R356"><label>356</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Svikis</surname><given-names>DS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Haug</surname><given-names>NA</given-names></name><name><surname>Stitzer</surname><given-names>ML</given-names></name></person-group><article-title>Attendance incentives for outpatient treatment: effects in methadone- and nonmethadone-maintained pregnant drug dependent women</article-title><source>Drug Alcohol Depend</source><year>1997</year><volume>48</volume><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">9330919</pub-id></citation></ref><ref id="R357"><label>357</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swift</surname><given-names>RM</given-names></name><name><surname>Dudley</surname><given-names>M</given-names></name><name><surname>DePetrillo</surname><given-names>P</given-names></name><name><surname>Camara</surname><given-names>P</given-names></name><name><surname>Griffiths</surname><given-names>W</given-names></name></person-group><article-title>Altered methadone pharmacokinetics in pregnancy: implications for dosing</article-title><source>J. Subst. Abuse</source><year>1989</year><volume>1</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">2485290</pub-id></citation></ref><ref id="R358"><label>358</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takata</surname><given-names>K</given-names></name><name><surname>Hirano</surname><given-names>H</given-names></name></person-group><article-title>Mechanism of glucose transport across the human and rat placental barrier: a review</article-title><source>Microsc. Res. Tech</source><year>1997</year><volume>38</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">9260845</pub-id></citation></ref><ref id="R359"><label>359</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tegeder</surname><given-names>I</given-names></name><name><surname>Geisslinger</surname><given-names>G</given-names></name></person-group><article-title>Opioids as modulators of cell death and survival: unraveling mechanisms and revealing new indications</article-title><source>Pharmacol. Rev</source><year>2004</year><volume>56</volume><fpage>351</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">15317908</pub-id></citation></ref><ref id="R360"><label>360</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tempel</surname><given-names>A</given-names></name></person-group><source>Opioid receptors and peptide system regulation in the developing nervous system</source><year>1993</year><publisher-loc>New York NY</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name></citation></ref><ref id="R361"><label>361</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tempel</surname><given-names>A</given-names></name><name><surname>Zukin</surname><given-names>RS</given-names></name><name><surname>Gardner</surname><given-names>EL</given-names></name></person-group><article-title>Supersensitivity of brain opiate receptor subtypes after chronic naltrexone treatment</article-title><source>Life Sci</source><year>1982</year><volume>31</volume><fpage>1401</fpage><lpage>1404</lpage><pub-id pub-id-type="pmid">6292636</pub-id></citation></ref><ref id="R362"><label>362</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tennant FS</surname><given-names>Jr</given-names></name><name><surname>Rawson</surname><given-names>RA</given-names></name><name><surname>Cohen</surname><given-names>AJ</given-names></name><name><surname>Mann</surname><given-names>A</given-names></name></person-group><article-title>Clinical experience with naltrexone in suburban opioid addicts</article-title><source>J. Clin. Psychiatry</source><year>1984</year><volume>45</volume><fpage>42</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">6469935</pub-id></citation></ref><ref id="R363"><label>363</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname><given-names>SK</given-names></name><name><surname>Mendelson</surname><given-names>JH</given-names></name><name><surname>Mello</surname><given-names>NK</given-names></name><name><surname>Kuehnle</surname><given-names>J</given-names></name><name><surname>Sintavanarong</surname><given-names>P</given-names></name><name><surname>Rhoades</surname><given-names>EM</given-names></name></person-group><article-title>Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation</article-title><source>J. Clin. Psychopharmacol</source><year>1993</year><volume>13</volume><fpage>87</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">8463453</pub-id></citation></ref><ref id="R364"><label>364</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theis</surname><given-names>JG</given-names></name><name><surname>Selby</surname><given-names>P</given-names></name><name><surname>Ikizler</surname><given-names>Y</given-names></name><name><surname>Koren</surname><given-names>G</given-names></name></person-group><article-title>Current management of the neonatal abstinence syndrome: a critical analysis of the evidence</article-title><source>Biol. Neonate</source><year>1997</year><volume>71</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">9197336</pub-id></citation></ref><ref id="R365"><label>365</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>R</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Berman</surname><given-names>P</given-names></name><name><surname>Finnegan</surname><given-names>LP</given-names></name></person-group><article-title>Follow-up studies of infants born to methadone-dependent mothers</article-title><source>Pediatr. Res</source><year>1974</year><volume>8</volume><fpage>346</fpage></citation></ref><ref id="R366"><label>366</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tiong</surname><given-names>GK</given-names></name><name><surname>Olley</surname><given-names>JE</given-names></name></person-group><article-title>Effects of exposure in utero to methadone and buprenorphine on enkephalin levels in the developing rat brain</article-title><source>Neurosci. Lett</source><year>1988</year><volume>93</volume><fpage>101</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">3211364</pub-id></citation></ref><ref id="R367"><label>367</label><citation citation-type="book"><collab>United Nations Office on Drugs and Crime (UNODC)</collab><source>2005 World Drug Report</source><year>2005</year><publisher-loc>Vienna</publisher-loc><publisher-name>United Nations Publications</publisher-name></citation></ref><ref id="R368"><label>368</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Ameijden</surname><given-names>EJ</given-names></name><name><surname>Langendam</surname><given-names>MW</given-names></name><name><surname>Coutinho</surname><given-names>RA</given-names></name></person-group><article-title>Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs</article-title><source>Addict. Behav</source><year>1999</year><volume>24</volume><fpage>559</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">10466851</pub-id></citation></ref><ref id="R369"><label>369</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Baar</surname><given-names>AL</given-names></name><name><surname>Soepatmi</surname><given-names>S</given-names></name><name><surname>Gunning</surname><given-names>WB</given-names></name><name><surname>Akkerhuis</surname><given-names>GW</given-names></name></person-group><article-title>Development after prenatal exposure to cocaine, heroin and methadone</article-title><source>Acta Paediatr. Suppl</source><year>1994</year><volume>404</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">7531042</pub-id></citation></ref><ref id="R370"><label>370</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van den Brink</surname><given-names>W</given-names></name><name><surname>Haasen</surname><given-names>C</given-names></name></person-group><article-title>Evidenced-based treatment of opioid-dependent patients</article-title><source>Can. J. Psychiatry</source><year>2006</year><volume>51</volume><fpage>635</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">17052031</pub-id></citation></ref><ref id="R371"><label>371</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Aa</surname><given-names>EM</given-names></name><name><surname>Peereboom-Stegeman</surname><given-names>JH</given-names></name><name><surname>Noordhoek</surname><given-names>J</given-names></name><name><surname>Gribnau</surname><given-names>FW</given-names></name><name><surname>Russel</surname><given-names>FG</given-names></name></person-group><article-title>Mechanisms of drug transfer across the human placenta</article-title><source>Pharm. World Sci</source><year>1998</year><volume>20</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">9762726</pub-id></citation></ref><ref id="R372"><label>372</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Wagoner</surname><given-names>S</given-names></name><name><surname>Risser</surname><given-names>J</given-names></name><name><surname>Moyer</surname><given-names>M</given-names></name><name><surname>Lasky</surname><given-names>D</given-names></name></person-group><article-title>Effect of maternally administered methadone on discrimination learning of rat offspring</article-title><source>Percept. Mot. Skills</source><year>1980</year><volume>50</volume><fpage>1119</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">7413386</pub-id></citation></ref><ref id="R373"><label>373</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>GC</given-names></name><name><surname>Pildes</surname><given-names>RS</given-names></name><name><surname>Vidyasagar</surname><given-names>D</given-names></name><name><surname>Keith</surname><given-names>LG</given-names></name></person-group><article-title>Effect of maternal heroin addiction on 67 liveborn neonates. Withdrawal symptoms, small body size, and small head circumference were frequent findings</article-title><source>Clin. Pediatr. (Phila)</source><year>1975</year><volume>14</volume><fpage>751</fpage><lpage>753</lpage><comment>passim</comment><pub-id pub-id-type="pmid">1167237</pub-id></citation></ref><ref id="R374"><label>374</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verebey</surname><given-names>K</given-names></name></person-group><article-title>Quantitative determination of naltrexone, 6 beta-naltrexol and 2-hydroxy-3-methoxy-6 beta-naltrexol (HMN) in human plasma, red blood cells, saliva and urine by gas liquid chromatography</article-title><source>NIDA Res. Monogr</source><year>1981</year><volume>28</volume><fpage>36</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">6791012</pub-id></citation></ref><ref id="R375"><label>375</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verebey</surname><given-names>K</given-names></name><name><surname>Mule</surname><given-names>SJ</given-names></name></person-group><article-title>Naltrexone pharmacology, pharmacokinetics, and metabolism: current status</article-title><source>Am. J. Drug Alcohol Abuse</source><year>1975</year><volume>2</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">1227297</pub-id></citation></ref><ref id="R376"><label>376</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verebey</surname><given-names>K</given-names></name><name><surname>Volavka</surname><given-names>J</given-names></name><name><surname>Mule</surname><given-names>SJ</given-names></name><name><surname>Resnick</surname><given-names>RB</given-names></name></person-group><article-title>Naltrexone: disposition, metabolism, and effects after acute and chronic dosing</article-title><source>Clin. Pharmacol. Ther</source><year>1976</year><volume>20</volume><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">954353</pub-id></citation></ref><ref id="R377"><label>377</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vinner</surname><given-names>E</given-names></name><name><surname>Vignau</surname><given-names>J</given-names></name><name><surname>Thibault</surname><given-names>D</given-names></name><name><surname>Codaccioni</surname><given-names>X</given-names></name><name><surname>Brassart</surname><given-names>C</given-names></name><name><surname>Humbert</surname><given-names>L</given-names></name><name><surname>Lhermitte</surname><given-names>M</given-names></name></person-group><article-title>Hair analysis of opiates in mothers and newborns for evaluating opiate exposure during pregnancy</article-title><source>Forensic Sci. Int</source><year>2003</year><volume>133</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">12742690</pub-id></citation></ref><ref id="R378"><label>378</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vinner</surname><given-names>E</given-names></name><name><surname>Vignau</surname><given-names>J</given-names></name><name><surname>Thibault</surname><given-names>D</given-names></name><name><surname>Codaccioni</surname><given-names>X</given-names></name><name><surname>Brassart</surname><given-names>C</given-names></name><name><surname>Humbert</surname><given-names>L</given-names></name><name><surname>Lhermitte</surname><given-names>M</given-names></name></person-group><article-title>Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome</article-title><source>Ther. Drug Monit</source><year>2003</year><volume>25</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">12883224</pub-id></citation></ref><ref id="R379"><label>379</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viveros</surname><given-names>MP</given-names></name><name><surname>de Cabo</surname><given-names>C</given-names></name><name><surname>Colado</surname><given-names>MI</given-names></name><name><surname>Martin</surname><given-names>MI</given-names></name></person-group><article-title>Naltrexone administration during the preweanling period affects striatal and hypothalamic serotonergic systems, but not midbrain serotonergic or striatal dopaminergic systems in the adult rat</article-title><source>Neurosci. Lett</source><year>1995</year><volume>201</volume><fpage>195</fpage><lpage>198</lpage><pub-id pub-id-type="pmid">8786838</pub-id></citation></ref><ref id="R380"><label>380</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>ME</given-names></name><name><surname>Brine</surname><given-names>DR</given-names></name><name><surname>Perez-Reyes</surname><given-names>M</given-names></name></person-group><article-title>Metabolism and disposition of naltrexone in man after oral and intravenous administration</article-title><source>Drug Metab. Dispos</source><year>1981</year><volume>9</volume><fpage>369</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">6114837</pub-id></citation></ref><ref id="R381"><label>381</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>ME</given-names></name><name><surname>Brine</surname><given-names>DR</given-names></name><name><surname>Perez-Reyes</surname><given-names>M</given-names></name></person-group><article-title>The metabolism of naltrexone in man</article-title><source>NIDA Res. Monogr</source><year>1981</year><volume>28</volume><fpage>105</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">6790999</pub-id></citation></ref><ref id="R382"><label>382</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>ME</given-names></name><name><surname>Perez-Reyes</surname><given-names>M</given-names></name><name><surname>Brine</surname><given-names>DR</given-names></name><name><surname>Cook</surname><given-names>CE</given-names></name></person-group><article-title>Naltrexone disposition in man after subcutaneous administration</article-title><source>Drug Metab. Dispos</source><year>1984</year><volume>12</volume><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">6150815</pub-id></citation></ref><ref id="R383"><label>383</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walz</surname><given-names>MA</given-names></name><name><surname>Davis</surname><given-names>WM</given-names></name><name><surname>Pace</surname><given-names>HB</given-names></name></person-group><article-title>Parental methadone treatment: a multigenerational study of development and behavior in offspring</article-title><source>Dev. Pharmacol. Ther</source><year>1983</year><volume>6</volume><fpage>125</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">6861597</pub-id></citation></ref><ref id="R384"><label>384</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>W</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name></person-group><article-title>Role of maintenance treatment in opioid dependence</article-title><source>Lancet</source><year>1999</year><volume>353</volume><fpage>221</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">9923893</pub-id></citation></ref><ref id="R385"><label>385</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name><name><surname>Hall</surname><given-names>W</given-names></name></person-group><article-title>The effectiveness of Methadone maintenance treatment: An overview</article-title><source>Drug Alcohol Rev</source><year>1994</year><volume>13</volume><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">16818345</pub-id></citation></ref><ref id="R386"><label>386</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>J</given-names></name><name><surname>Mattick</surname><given-names>RP</given-names></name><name><surname>Hall</surname><given-names>W</given-names></name><name><surname>Darke</surname><given-names>S</given-names></name></person-group><article-title>The effectiveness and safety of methadone maintenance</article-title><source>Addiction</source><year>1996</year><volume>91</volume><fpage>1727</fpage><lpage>1729</lpage><pub-id pub-id-type="pmid">8972930</pub-id></citation></ref><ref id="R387"><label>387</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>RM</given-names></name></person-group><article-title>Drug therapy of the fetus</article-title><source>J. Clin. Pharmacol</source><year>1993</year><volume>33</volume><fpage>780</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">8227473</pub-id></citation></ref><ref id="R388"><label>388</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warner-Smith</surname><given-names>M</given-names></name><name><surname>Lynskey</surname><given-names>M</given-names></name><name><surname>Darke</surname><given-names>S</given-names></name><name><surname>Hall</surname><given-names>W</given-names></name></person-group><article-title>Heroin overdose: prevalence, correlates, consequences and interventions</article-title><source>National Drug and Alcohol Research Centre University of New South Wales</source><year>2001</year><fpage>1</fpage><lpage>68</lpage></citation></ref><ref id="R389"><label>389</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>SL</given-names></name><name><surname>O'Neal</surname><given-names>KK</given-names></name><name><surname>Graham</surname><given-names>CW</given-names></name></person-group><article-title>A meta-analysis comparing the effectiveness of buprenorphine and methadone</article-title><source>J. Subst. Abuse</source><year>2000</year><volume>12</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">11452842</pub-id></citation></ref><ref id="R390"><label>390</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>JM</given-names></name><name><surname>Irvine</surname><given-names>RJ</given-names></name></person-group><article-title>Mechanisms of fatal opioid overdose</article-title><source>Addiction</source><year>1999</year><volume>94</volume><fpage>961</fpage><lpage>972</lpage><pub-id pub-id-type="pmid">10707430</pub-id></citation></ref><ref id="R391"><label>391</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>M</given-names></name><name><surname>Whitman</surname><given-names>S</given-names></name><name><surname>Bergner</surname><given-names>L</given-names></name><name><surname>Patrick</surname><given-names>S</given-names></name></person-group><article-title>Addiction and low birth weight: a quasi-experimental study</article-title><source>Am. J. Public Health</source><year>1978</year><volume>68</volume><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">665887</pub-id></citation></ref><ref id="R392"><label>392</label><citation citation-type="confproc"><person-group person-group-type="author"><name><surname>Whitlam</surname><given-names>J</given-names></name><name><surname>Spurrier</surname><given-names>N</given-names></name><name><surname>Sawyer</surname><given-names>M</given-names></name><name><surname>Lopatko</surname><given-names>O</given-names></name><name><surname>White</surname><given-names>J</given-names></name></person-group><article-title>Differences in Visual Evoked Potentials of 4 Month Old Infants Exposed to Buprenorphine or Methadone Maintenance Therapy During Pregnancy</article-title><year>2005</year><conf-name>Annual Scientific Conference of the Australasian Professional Society for Alcohol and Other Drugs</conf-name><conf-loc>Melbourne,Australia</conf-loc></citation></ref><ref id="R393"><label>393</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilbourne</surname><given-names>P</given-names></name><name><surname>Wallerstedt</surname><given-names>C</given-names></name><name><surname>Dorato</surname><given-names>V</given-names></name><name><surname>Curet</surname><given-names>LB</given-names></name></person-group><article-title>Clinical management of methadone dependence during pregnancy</article-title><source>J. Perinat. Neonatal. Nurs</source><year>2001</year><volume>14</volume><fpage>26</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">11930521</pub-id></citation></ref><ref id="R394"><label>394</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Willson</surname><given-names>NJ</given-names></name><name><surname>Schneider</surname><given-names>JF</given-names></name><name><surname>Roizin</surname><given-names>L</given-names></name><name><surname>Fleiss</surname><given-names>JF</given-names></name><name><surname>Rivers</surname><given-names>W</given-names></name><name><surname>Demartini</surname><given-names>JE</given-names></name></person-group><article-title>Effects of methadone hydrochloride on the growth of organotypic cerebellar cultures prepared from methadone-tolerant and control rats</article-title><source>J. Pharmacol. Exp. Ther</source><year>1976</year><volume>199</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">978491</pub-id></citation></ref><ref id="R395"><label>395</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wittmann</surname><given-names>BK</given-names></name><name><surname>Segal</surname><given-names>S</given-names></name></person-group><article-title>A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation</article-title><source>Int. J. Addict</source><year>1991</year><volume>26</volume><fpage>213</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">1889920</pub-id></citation></ref><ref id="R396"><label>396</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>K</given-names></name><name><surname>Boys</surname><given-names>A</given-names></name><name><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name><name><surname>Hay</surname><given-names>A</given-names></name><name><surname>Raistrick</surname><given-names>D</given-names></name></person-group><article-title>Changes to methadone clearance during pregnancy</article-title><source>Eur. J. Clin. Pharmacol</source><year>2005</year><volume>61</volume><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">16261362</pub-id></citation></ref><ref id="R397"><label>397</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname><given-names>K</given-names></name><name><surname>Hay</surname><given-names>AW</given-names></name><name><surname>Raistrick</surname><given-names>D</given-names></name><name><surname>Calvert</surname><given-names>R</given-names></name></person-group><article-title>Steady-state pharmacokinetics of methadone in opioid addicts</article-title><source>Eur. J. Clin. Pharmacol</source><year>1993</year><volume>44</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">8453965</pub-id></citation></ref><ref id="R398"><label>398</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wouldes</surname><given-names>TA</given-names></name><name><surname>Roberts</surname><given-names>AB</given-names></name><name><surname>Pryor</surname><given-names>JE</given-names></name><name><surname>Bagnall</surname><given-names>C</given-names></name><name><surname>Gunn</surname><given-names>TR</given-names></name></person-group><article-title>The effect of methadone treatment on the quantity and quality of human fetal movement</article-title><source>Neurotoxicol. Teratol</source><year>2004</year><volume>26</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">15001211</pub-id></citation></ref><ref id="R399"><label>399</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>VW</given-names></name><name><surname>Mo</surname><given-names>Q</given-names></name><name><surname>Yabe</surname><given-names>T</given-names></name><name><surname>Schwartz</surname><given-names>JP</given-names></name><name><surname>Robinson</surname><given-names>SE</given-names></name></person-group><article-title>Perinatal opioids reduce striatal nerve growth factor content in rat striatum</article-title><source>Eur. J. Pharmacol</source><year>2001</year><volume>414</volume><fpage>211</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">11239921</pub-id></citation></ref><ref id="R400"><label>400</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wunsch</surname><given-names>MJ</given-names></name><name><surname>Stanard</surname><given-names>V</given-names></name><name><surname>Schnoll</surname><given-names>SH</given-names></name></person-group><article-title>Treatment of pain in pregnancy</article-title><source>Clin. J. Pain</source><year>2003</year><volume>19</volume><fpage>148</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">12792553</pub-id></citation></ref><ref id="R401"><label>401</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yanai</surname><given-names>J</given-names></name><name><surname>Avraham</surname><given-names>Y</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>Maslaton</surname><given-names>J</given-names></name><name><surname>Pick</surname><given-names>CG</given-names></name><name><surname>Rogel-Fuchs</surname><given-names>Y</given-names></name><name><surname>Zahalka</surname><given-names>EA</given-names></name></person-group><article-title>Alterations in septohippocampal cholinergic innervations and related behaviors after early exposure to heroin and phencyclidine</article-title><source>Brain Res. Dev. Brain Res</source><year>1992</year><volume>69</volume><fpage>207</fpage><lpage>214</lpage></citation></ref><ref id="R402"><label>402</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoburn</surname><given-names>BC</given-names></name><name><surname>Cohen</surname><given-names>AH</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat</article-title><source>J. Pharmacol. Exp. Ther</source><year>1986</year><volume>237</volume><fpage>126</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">3958962</pub-id></citation></ref><ref id="R403"><label>403</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoburn</surname><given-names>BC</given-names></name><name><surname>Luke</surname><given-names>MC</given-names></name><name><surname>Pasternak</surname><given-names>GW</given-names></name><name><surname>Inturrisi</surname><given-names>CE</given-names></name></person-group><article-title>Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE</article-title><source>Life Sci</source><year>1988</year><volume>43</volume><fpage>1319</fpage><lpage>1324</lpage><pub-id pub-id-type="pmid">2845219</pub-id></citation></ref><ref id="R404"><label>404</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Gibo</surname><given-names>DM</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Zeta (zeta) a growth-related opioid receptor in developing rat cerebellum: identification and characterization</article-title><source>Brain Res</source><year>1991</year><volume>551</volume><fpage>28</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">1655161</pub-id></citation></ref><ref id="R405"><label>405</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Gibo</surname><given-names>DM</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Ontogeny of zeta (zeta), the opioid growth factor receptor, in the rat brain</article-title><source>Brain Res</source><year>1992</year><volume>596</volume><fpage>149</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">1334774</pub-id></citation></ref><ref id="R406"><label>406</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Hurst</surname><given-names>WJ</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Transplacental transfer of naltrexone in rats</article-title><source>Life Sci</source><year>1997</year><volume>61</volume><fpage>1261</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">9324068</pub-id></citation></ref><ref id="R407"><label>407</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Hurst</surname><given-names>WJ</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Naltrexone is not detected in preweaning rats following transplacental exposure: implications for growth modulation</article-title><source>Life Sci</source><year>1998</year><volume>62</volume><fpage>221</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">9488100</pub-id></citation></ref><ref id="R408"><label>408</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of chronic maternal methadone exposure on perinatal development</article-title><source>Biol. Neonate</source><year>1977</year><volume>31</volume><fpage>271</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">911959</pub-id></citation></ref><ref id="R409"><label>409</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>The effects of different schedules of methadone treatment on rat brain development</article-title><source>Exp. Neurol</source><year>1977</year><volume>56</volume><fpage>538</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">885202</pub-id></citation></ref><ref id="R410"><label>410</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Methadone and brain development</article-title><source>Experientia</source><year>1977</year><volume>33</volume><fpage>1486</fpage><lpage>1487</lpage><pub-id pub-id-type="pmid">923719</pub-id></citation></ref><ref id="R411"><label>411</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Perinatal methadone exposure and brain development: a biochemical study</article-title><source>J. Neurochem</source><year>1978</year><volume>31</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">671039</pub-id></citation></ref><ref id="R412"><label>412</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Perinatal methadone exposure and its influence on the behavioral ontogeny of rats</article-title><source>Pharmacol. Biochem. Behav</source><year>1978</year><volume>9</volume><fpage>665</fpage><lpage>672</lpage><pub-id pub-id-type="pmid">733856</pub-id></citation></ref><ref id="R413"><label>413</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Motor activity and learning ability in rats perinatally exposed to methadone</article-title><source>NIDA Res. Monogr</source><year>1979</year><volume>27</volume><fpage>121</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">121327</pub-id></citation></ref><ref id="R414"><label>414</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Protracted analgesia in young and adult rats maternally exposed to methadone</article-title><source>Experientia</source><year>1980</year><volume>36</volume><fpage>329</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">7371790</pub-id></citation></ref><ref id="R415"><label>415</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Enhanced sensitivity to methadone in adult rats perinatally exposed to methadone</article-title><source>Life Sci</source><year>1981</year><volume>29</volume><fpage>1137</fpage><lpage>1142</lpage><pub-id pub-id-type="pmid">7289777</pub-id></citation></ref><ref id="R416"><label>416</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Withdrawal-like symptoms in young and adult rats maternally exposed to methadone</article-title><source>Pharmacol. Biochem. Behav</source><year>1981</year><volume>15</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">7198796</pub-id></citation></ref><ref id="R417"><label>417</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Analgesia in young and adult rats perinatally exposed to methadone</article-title><source>Neurobehav. Toxicol. Teratol</source><year>1982</year><volume>4</volume><fpage>455</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">7121696</pub-id></citation></ref><ref id="R418"><label>418</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Comparative effects of postnatal undernutrition and methadone exposure on protein and nucleic acid contents of the brain and cerebellum in rats</article-title><source>Dev. Neurosci</source><year>1982</year><volume>5</volume><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">6186450</pub-id></citation></ref><ref id="R419"><label>419</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of chronic heroin exposure on pregnant rats and their offspring</article-title><source>NIDA Res. Monogr</source><year>1982</year><volume>41</volume><fpage>488</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">6811938</pub-id></citation></ref><ref id="R420"><label>420</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Neuronal cell deficits following exposure to methadone in rats</article-title><source>Experientia</source><year>1982</year><volume>38</volume><fpage>1214</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">7140924</pub-id></citation></ref><ref id="R421"><label>421</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Behavioral effects of prenatal exposure to opiates</article-title><source>Monogr. Neural Sci</source><year>1983</year><volume>9</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">6350860</pub-id></citation></ref><ref id="R422"><label>422</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Increased brain size and cellular content in infant rats treated with an opiate antagonist</article-title><source>Science</source><year>1983</year><volume>221</volume><fpage>1179</fpage><lpage>1180</lpage><pub-id pub-id-type="pmid">6612331</pub-id></citation></ref><ref id="R423"><label>423</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Naltrexone modulates growth in infant rats</article-title><source>Life Sci</source><year>1983</year><volume>33</volume><fpage>2449</fpage><lpage>2454</lpage><pub-id pub-id-type="pmid">6316064</pub-id></citation></ref><ref id="R424"><label>424</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Somatic and neurobiological alterations in the progeny of female rats treated with methadone prior to mating</article-title><source>NIDA Res. Monogr</source><year>1983</year><volume>43</volume><fpage>184</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">6410251</pub-id></citation></ref><ref id="R425"><label>425</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Naltrexone modulates body and brain development in rats: a role for endogenous opioid systems in growth</article-title><source>Life Sci</source><year>1984</year><volume>35</volume><fpage>2057</fpage><lpage>2064</lpage><pub-id pub-id-type="pmid">6092812</pub-id></citation></ref><ref id="R426"><label>426</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Perinatal exposure to methadone alters sensitivity to drugs in adult rats</article-title><source>Neurobehav. Toxicol. Teratol</source><year>1984</year><volume>6</volume><fpage>319</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">6514092</pub-id></citation></ref><ref id="R427"><label>427</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Naltrexone's influence on neurobehavioral development</article-title><source>Pharmacol. Biochem. Behav</source><year>1985</year><volume>22</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">3991759</pub-id></citation></ref><ref id="R428"><label>428</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Opioid antagonist-induced regulation of organ development</article-title><source>Physiol. Behav</source><year>1985</year><volume>34</volume><fpage>507</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">4011730</pub-id></citation></ref><ref id="R429"><label>429</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Opioid antagonist-induced modulation of cerebral and hippocampal development: histological and morphometric studies</article-title><source>Brain Res</source><year>1986</year><volume>393</volume><fpage>233</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">3017514</pub-id></citation></ref><ref id="R430"><label>430</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Opioid antagonist (naltrexone) modulation of cerebellar development: histological and morphometric studies</article-title><source>J. Neurosci</source><year>1986</year><volume>6</volume><fpage>1424</fpage><lpage>1432</lpage><pub-id pub-id-type="pmid">3711987</pub-id></citation></ref><ref id="R431"><label>431</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Endogenous opioid systems regulate cell proliferation in the developing rat brain</article-title><source>Brain Res</source><year>1987</year><volume>412</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">3607463</pub-id></citation></ref><ref id="R432"><label>432</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Maternal Exposure to Opioids and the Developing Nervous System: Laboratory Findings</article-title><source>Maternal Substance Abuse and the Developing Nervous System</source><year>1992</year><publisher-loc>San Diego CA</publisher-loc><publisher-name>Academic press,Inc</publisher-name><fpage>241</fpage><lpage>282</lpage></citation></ref><ref id="R433"><label>433</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Opioid Growth Factor Receptor in the Developing Nervous System</article-title><source>Receptors in the developing nervous system: Growth factors and hormones</source><year>1993</year><publisher-loc>New York, NY</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name><fpage>39</fpage><lpage>62</lpage></citation></ref><ref id="R434"><label>434</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><source>Receptors in the developing nervous system</source><year>1993</year><publisher-loc>New York, NY</publisher-loc><publisher-name>Chapman &#x00026; Hall</publisher-name></citation></ref><ref id="R435"><label>435</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Gene expression of OGFr in the developing and adult rat brain and cerebellum</article-title><source>Brain Res. Bull</source><year>2004</year><volume>63</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15121239</pub-id></citation></ref><ref id="R436"><label>436</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Thompson</surname><given-names>CI</given-names></name></person-group><article-title>Development of motor activity in young rats following perinatal methadone exposure</article-title><source>Pharmacol. Biochem. Behav</source><year>1979</year><volume>10</volume><fpage>743</fpage><lpage>749</lpage><pub-id pub-id-type="pmid">493289</pub-id></citation></ref><ref id="R437"><label>437</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name><name><surname>Thompson</surname><given-names>CI</given-names></name></person-group><article-title>Learning ability in adult female rats perinatally exposed to methadone</article-title><source>Pharmacol. Biochem. Behav</source><year>1979</year><volume>10</volume><fpage>889</fpage><lpage>894</lpage><pub-id pub-id-type="pmid">482309</pub-id></citation></ref><ref id="R438"><label>438</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Tobias</surname><given-names>SW</given-names></name><name><surname>Hytrek</surname><given-names>SD</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Opioid receptor blockade throughout prenatal life confers long-term insensitivity to morphine and alters mu opioid receptors</article-title><source>Pharmacol. Biochem. Behav</source><year>1998</year><volume>59</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">9443556</pub-id></citation></ref><ref id="R439"><label>439</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Tobias</surname><given-names>SW</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Endogenous opioids and prenatal determinants of neuroplasticity</article-title><source>Adv. Exp. Med. Biol</source><year>1997</year><volume>429</volume><fpage>289</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">9413582</pub-id></citation></ref><ref id="R440"><label>440</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Verderame</surname><given-names>MF</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>The biology of the opioid growth factor receptor (OGFr)</article-title><source>Brain Res. Brain Res. Rev</source><year>2002</year><volume>38</volume><fpage>351</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">11890982</pub-id></citation></ref><ref id="R441"><label>441</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Verderame</surname><given-names>MF</given-names></name><name><surname>Zimmer</surname><given-names>WE</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse</article-title><source>Brain Res. Mol. Brain Res</source><year>2000</year><volume>84</volume><fpage>106</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11113537</pub-id></citation></ref><ref id="R442"><label>442</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zagon</surname><given-names>IS</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>McLaughlin</surname><given-names>PJ</given-names></name></person-group><article-title>Opioid growth factor and organ development in rat and human embryos</article-title><source>Brain Res</source><year>1999</year><volume>839</volume><fpage>313</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">10519055</pub-id></citation></ref><ref id="R443"><label>443</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zelson</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Casalino</surname><given-names>M</given-names></name></person-group><article-title>Neonatal narcotic addiction Comparative effects of maternal intake of heroin and methadone</article-title><source>N. Engl. J. Med</source><year>1973</year><volume>289</volume><fpage>1216</fpage><lpage>1220</lpage><pub-id pub-id-type="pmid">4748595</pub-id></citation></ref><ref id="R444"><label>444</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>JH</given-names></name><name><surname>Stadlin</surname><given-names>A</given-names></name></person-group><article-title>Prenatal heroin exposure Effects on development, acoustic startle response, and locomotion in weanling rats</article-title><source>Neurotoxicol. Teratol</source><year>2000</year><volume>22</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">10758348</pub-id></citation></ref><ref id="R445"><label>445</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>MJ</given-names></name><name><surname>Bloom</surname><given-names>FE</given-names></name><name><surname>Landis</surname><given-names>SC</given-names></name><name><surname>Roberts</surname><given-names>JL</given-names></name><name><surname>Squire</surname><given-names>LR</given-names></name></person-group><source>Fundamental neuroscience</source><year>1999</year><publisher-loc>San Diego, Calif, London</publisher-loc><publisher-name>Academic</publisher-name></citation></ref><ref id="R446"><label>446</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zuckerman</surname><given-names>B</given-names></name><name><surname>Bresnahan</surname><given-names>K</given-names></name></person-group><article-title>Developmental and behavioral consequences of prenatal drug and alcohol exposure</article-title><source>Pediatr. Clin. North Am</source><year>1991</year><volume>38</volume><fpage>1387</fpage><lpage>1406</lpage><pub-id pub-id-type="pmid">1719469</pub-id></citation></ref><ref id="R447"><label>447</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zuspan</surname><given-names>FP</given-names></name><name><surname>Gumpel</surname><given-names>JA</given-names></name><name><surname>Mejia-Zelaya</surname><given-names>A</given-names></name><name><surname>Madden</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>R</given-names></name></person-group><article-title>Fetal stress from methadone withdrawal</article-title><source>Am. J. Obstet. Gynecol</source><year>1975</year><volume>122</volume><fpage>43</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">1130446</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Overview of FDA (United States) and TGA (Australia) Pregnancy Classification Relevant to Methadone, Buprenorphine and Naltrexone</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Category Definition</th><th rowspan="1" colspan="1">Drug(s) in Category</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">FDA (United States)</td><td align="center" rowspan="1" colspan="1">C: &#x0201c;&#x02026;.either studies in animals have revealed adverse effects on the fetus (teratogenic or embryocidal effects or other) and there are no controlled studies in women, or studies in women and animals are not available.&#x0201d;</td><td align="center" rowspan="1" colspan="1">Methadone, Buprenorphine, Naltrexone</td></tr><tr><td align="center" rowspan="2" colspan="1">TGA (Australia)</td><td align="center" rowspan="1" colspan="1">B3: &#x0201c;Drugs which have been taken by only a limited number of pregnant women and women of childbearing age without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.&#x0201d;</td><td align="center" rowspan="1" colspan="1">Naltrexone</td></tr><tr><td align="center" rowspan="1" colspan="1">C: &#x0201c;Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.&#x0201d;</td><td align="center" rowspan="1" colspan="1">Buprenorphine, Methadone</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Summary of the Effects of Maternally Administered Methadone on the Development of the Rat Brain</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Reference</th><th rowspan="1" colspan="1">Daily Dose (mg/kg)</th><th rowspan="1" colspan="1">Route of Admin.</th><th rowspan="1" colspan="1">Duration of Drug Exposure</th><th rowspan="1" colspan="1">Age of Offspring when Evaluated (days)</th><th rowspan="1" colspan="1">Developmental Effects (Compared to Controls)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R394">394</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Gest</td><td align="center" rowspan="1" colspan="1">1 or 3</td><td align="center" rowspan="1" colspan="1"><underline>Reduced</underline> explant outgrowth size.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R408">408</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest-lact or gest-lact + post-weaning (60 days)</td><td align="center" rowspan="1" colspan="1">0, 3, 6, 10, 15, 21 or 60</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain &#x00026; cerebellar wet weights &#x00026; <underline>reduced</underline>cerebral &#x00026; cerebellar widths.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R409">409</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest, lact or gest-lact</td><td align="center" rowspan="1" colspan="1">0, 3, 6, 10, 15, 21 or 60</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> cerebellar wet weight &#x00026; brain length.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R410">410</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest, lact or gest-lact</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain wet weights &#x00026; DNA content.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R257">257</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest, lact or gest-lact</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Reduced</underline> brain wet &#x00026; dry weights.<underline>Smaller</underline> head diameters.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R411">411</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest, lact or gest-lact</td><td align="center" rowspan="1" colspan="1">10, 21 or 60</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain &#x00026; cerebellar DNA content.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R99">99</xref>]</td><td align="center" rowspan="1" colspan="1">1-5 (twice daily)</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Gest day 13 to birth</td><td align="center" rowspan="1" colspan="1">7, 14, 21 or 28</td><td align="center" rowspan="1" colspan="1"><underline>Reduction</underline> in brain wet weight, cortical thickness &#x00026;the number of cells in the neocortex.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R256">256</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest, lact or gest-lact</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> head diameter &#x00026; brain DNA content.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R418">418</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest, lact or gest-lact</td><td align="center" rowspan="1" colspan="1">21 or 60</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain &#x00026; cerebellar wet weights.<underline>Reduced</underline> DNA, RNA &#x00026; protein concentration in brain &#x00026; cerebellum</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R420">420</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest or lact</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Reduced</underline> area in the pyramis (cerebellar lobule) &#x00026; <underline>decreases</underline> in the total number &#x00026; density of internal granule neurons.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R424">424</xref>]</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Gest-lact</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain wet weight &#x00026; length.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R318">318</xref>]</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">s.c. OMP</td><td align="center" rowspan="1" colspan="1">Gest</td><td align="center" rowspan="1" colspan="1">4,10 or 22</td><td align="center" rowspan="1" colspan="1">ACh &#x00026; NGF content <underline>reduced</underline> in striatal neurons,which are <underline>smaller</underline> in size.</td></tr></tbody></table><table-wrap-foot><fn id="TF2"><p>Gest = gestation, lact = lactation, s.c. = subcutaneous, i.p. = intraperitoneal, OMP = osmotic minipump, ACh = acetylcholine and NGF = nerve growth factor.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Summary of the Effects of Maternally Administered Buprenorphine on the Development of the Rat Brain</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Reference</th><th rowspan="1" colspan="1">Daily Dose(mg/kg)</th><th rowspan="1" colspan="1">Route of  Admin.</th><th rowspan="1" colspan="1">Duration of Drug Exposure</th><th rowspan="1" colspan="1">Age of Offspring when Evaluated (days)</th><th rowspan="1" colspan="1">Developmental Effects(Compared to Controls)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R336">336</xref>]</td><td align="center" rowspan="1" colspan="1">1 or 2</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Gest</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>No effect</underline>on met- or leu-enkephalin levels.</td></tr><tr><td align="center" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="R17">17</xref>]</td><td align="center" rowspan="3" colspan="1">0.5</td><td align="center" rowspan="3" colspan="1">i.p.</td><td align="center" rowspan="3" colspan="1">E14-22</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline>&#x000b5;-receptor Bmax in brain membranes.</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"><underline>No effect</underline>on &#x000b5;-receptor Bmax in brain membranes.</td></tr><tr><td align="center" rowspan="1" colspan="1">1 &#x00026; 7</td><td align="center" rowspan="1" colspan="1"><underline>No effect</underline> on &#x000b5;-receptor Kd.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R165">165</xref>]</td><td align="center" rowspan="1" colspan="1">0.3, 1 or 3</td><td align="center" rowspan="1" colspan="1">s.c. OMP</td><td align="center" rowspan="1" colspan="1">E8-E22</td><td align="center" rowspan="1" colspan="1">0, 22 or 30</td><td align="center" rowspan="1" colspan="1"><underline>No effect</underline> on rest-activity cycle.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R14">14</xref>]</td><td align="center" rowspan="1" colspan="1">0.15 or 0.3</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">E6-20</td><td align="center" rowspan="1" colspan="1">1, 28, 50</td><td align="center" rowspan="1" colspan="1"><underline>Impaired</underline> parental behaviour (0.6), expected sex difference for saccharine preference <underline>diminished</underline> (males consuming more in 0.6 grp).</td></tr><tr><td align="center" rowspan="2" colspan="1">[<xref ref-type="bibr" rid="R19">19</xref>]</td><td align="center" rowspan="1" colspan="1">2.5</td><td align="center" rowspan="2" colspan="1">s.c.</td><td align="center" rowspan="2" colspan="1">E6-20</td><td align="center" rowspan="2" colspan="1">1</td><td align="center" rowspan="1" colspan="1"><underline>Up-regulation</underline> of &#x003ba;-receptors.</td></tr><tr><td align="center" rowspan="1" colspan="1">0.15, 0.3 or 2.5</td><td align="center" rowspan="1" colspan="1"><underline>Down-regulation</underline> of &#x000b5;-receptor.<break/><underline>No effect</underline> on &#x000b5;- nor &#x003ba;-receptor Kd &#x00026; mRNA.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R321">321</xref>]</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">s.c. OMP</td><td align="center" rowspan="1" colspan="1">E7-22, P0-10 &#x00026; E7-P10</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> striatal NGF content by &#x0003e;40%.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R318">318</xref>]</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">Gest</td><td align="center" rowspan="1" colspan="1">10 &#x00026; 22</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> striatal choline acetyltransferase mRNA.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R320">320</xref>]</td><td align="center" rowspan="1" colspan="1">0.3, 1 or 3</td><td align="center" rowspan="1" colspan="1">s.c. OMP</td><td align="center" rowspan="1" colspan="1">E7-P13, P0-13 or E7-P13</td><td align="center" rowspan="1" colspan="1">0-21</td><td align="center" rowspan="1" colspan="1"><underline>Increase</underline> in morphine ED25 pre &#x00026;/or post (larger dose=large decrease in sensitivity).<break/><underline>Increased</underline> withdrawal score (0.3 &#x00026; 3).<break/><underline>Altered</underline> timing of behavioural characteristics.</td></tr><tr><td align="center" rowspan="2" colspan="1">[<xref ref-type="bibr" rid="R399">399</xref>]</td><td align="center" rowspan="2" colspan="1">1.5</td><td align="center" rowspan="2" colspan="1">s.c. OMP</td><td align="center" rowspan="2" colspan="1">E7-P0, P0-10 or E7-P10</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> striatal NGF.</td></tr><tr><td align="center" rowspan="1" colspan="1">4 or 10</td><td align="center" rowspan="1" colspan="1"><underline>No effect</underline> on NGF mRNA.</td></tr><tr><td align="center" rowspan="5" colspan="1">[<xref ref-type="bibr" rid="R319">319</xref>]</td><td align="center" rowspan="3" colspan="1">0.3</td><td align="center" rowspan="5" colspan="1">s.c. OMP</td><td align="center" rowspan="1" colspan="1">E7-P0</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline>striatal ACh.</td></tr><tr><td align="center" rowspan="1" colspan="1">E7-P0</td><td align="center" rowspan="2" colspan="1">21</td><td align="center" rowspan="2" colspan="1"><underline>Increased</underline>striatal ACh (males).</td></tr><tr><td align="center" rowspan="1" colspan="1">P0-21</td></tr><tr><td align="center" rowspan="2" colspan="1">3</td><td align="center" rowspan="1" colspan="1">P0-21</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="2" colspan="1"><underline>Decreased</underline>striatal ACh.</td></tr><tr><td align="center" rowspan="1" colspan="1">E7-P21</td><td align="center" rowspan="1" colspan="1">21</td></tr><tr><td align="center" rowspan="3" colspan="1">[<xref ref-type="bibr" rid="R141">141</xref>]</td><td align="center" rowspan="2" colspan="1">0.5 or 1</td><td align="center" rowspan="3" colspan="1">s.c. OMP</td><td align="center" rowspan="3" colspan="1">E10-P7</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline>&#x000b5;-receptor GTP&#x003b3;S binding in ventral tegmental area.</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1"><underline>No effect</underline> on &#x000b5;- nor N/OFQ-receptor GTP&#x003b3;S binding.</td></tr><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> N/OFQ-receptor GTP&#x003b3;S binding in nucleus accumbens &#x00026; lateral septum (males).</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>Gest = gestation, E = embryonic day, P = postnatal day, s.c. = subcutaneous, i.p. = intraperitoneal, OMP = osmotic minipump, ACh = acetylcholine, NGF = nerve growth factor and GTP&#x003b3;S = guanosine triphosphate gamma stimulatory protein.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Summary of the Effects of High/Continuous Doses of Naltrexone on Postnatal Development of the Rat Brain when Administered Directly (with One Exception of Maternal Administration)</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Reference</th><th rowspan="1" colspan="1">Daily Dose (mg/kg)</th><th rowspan="1" colspan="1">Route of Admin.</th><th rowspan="1" colspan="1">Duration of Drug Exposure</th><th rowspan="1" colspan="1">Age of Offspring when Evaluated (days)</th><th rowspan="1" colspan="1">Developmental Effects (Compared to Controls)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R422">422</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Greater</underline> brain &#x00026; cerebellar wet weights. <underline>Thicker</underline>somatosensory cortex. Cerebellum total area <underline>larger</underline>.<underline>More</underline> glial cells &#x00026; granule neurons.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R423">423</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> brain wet weight.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R425">425</xref>]</td><td align="center" rowspan="1" colspan="1">3 (3 times daily), 20, 50 or 100</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> brain wet weight.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R428">428</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days  postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> brain wet &#x00026; dry weights.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R429">429</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increase</underline> in number of granule cells of dentate gyrus. <underline>Increase</underline> in cerebral &#x00026; cortical width &#x00026; area.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R430">430</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days  postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increases</underline> in cerebellar surface dimensions, neural cell numbers, density &#x00026; size.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R431">431</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Once on postnatal day 6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> proliferation (labeling index) in cerebellum.</td></tr><tr><td align="center" rowspan="2" colspan="1">[<xref ref-type="bibr" rid="R133">133</xref>] &#x00026; [<xref ref-type="bibr" rid="R134">134</xref>]</td><td align="center" rowspan="2" colspan="1">50</td><td align="center" rowspan="2" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 10 days  postnatal</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> purkinje cell dendritic length &#x00026; spine concentration of granule cells.</td></tr><tr><td align="center" rowspan="1" colspan="1">Birth until 21 days  postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> cell dendritic length &#x00026; spine concentration in hippocampus.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R174">174</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">i.p.</td><td align="center" rowspan="1" colspan="1">Once on postnatal day 1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> proliferation (labelling index) in ganglion cell layer of the retina</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R254">254</xref>]</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">Maternal i.p.</td><td align="center" rowspan="1" colspan="1">Daily throughout  gestation</td><td align="center" rowspan="1" colspan="1">0, 10 &#x00026; 21</td><td align="center" rowspan="1" colspan="1"><underline>Increased</underline> brain dry &#x00026; wet weights.</td></tr></tbody></table><table-wrap-foot><fn id="TF4"><p>Admin. = administration, s.c. = subcutaneous, and i.p. = intraperitoneal.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float"><label>Table 5</label><caption><p>Summary of the Effects of Low/Intermittent Doses of Naltrexone on Postnatal Development of the Rat Brain when Administered Directly</p></caption><table frame="border" rules="all" width="100%"><thead><tr><th rowspan="1" colspan="1">Reference</th><th rowspan="1" colspan="1">Daily Dose (mg/kg)</th><th rowspan="1" colspan="1">Route of Admin.</th><th rowspan="1" colspan="1">Duration of Drug Exposure</th><th rowspan="1" colspan="1">Age of Offspring when Evaluated (days)</th><th rowspan="1" colspan="1">Developmental Effects (Compared to Controls)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R423">423</xref>]</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain wet weight.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R425">425</xref>]</td><td align="center" rowspan="1" colspan="1">0.1, 1 or 9</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain wet weight.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R248">428</xref>]</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> brain wet &#x00026; dry weights.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R429">429</xref>]</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Increase</underline> in cell density, with <underline>decreased</underline> macroscopic area of hippocampus.<break/><underline>Decreased</underline> cerebral area &#x00026; width.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R430">430</xref>]</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 21 days postnatal</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"><underline>Decreases</underline> in cerebellar surface dimensions &#x00026; density of internal granule cells.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R431">431</xref>]</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Once on postnatal day 6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1"><underline>Decreased</underline> proliferation (labeling index) in cerebellum.</td></tr><tr><td align="center" rowspan="1" colspan="1">[<xref ref-type="bibr" rid="R134">134</xref>]</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">s.c.</td><td align="center" rowspan="1" colspan="1">Birth until 10 or 21 days postnatal</td><td align="center" rowspan="1" colspan="1">10 or 21</td><td align="center" rowspan="1" colspan="1"><underline>Subnormal</underline> dendrite length &#x00026; spine growth, predominant by day 21.</td></tr></tbody></table><table-wrap-foot><fn id="TF5"><p>Admin. = administration, s.c. = subcutaneous, and i.p. = intraperitoneal.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>